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3Abstract
Glomerulonephritis is a common cause of end-stage renal failure and a feature of ANCA-
associated vasculitis (AAV). AAV is an example of a small vessel vasculitis, characterised by
inflammation of the endothelium and glomeruli in which the interaction between
leukocytes and endothelial cells play a crucial role. Macrophages have been demonstrated
to have a critical role during the initiation and progression of glomerulonephritis, with the
persistence of macrophages in the renal biopsy being associated with a poorer outlook.
Calprotectin (also termed S100A8/A9, mrp8/14), is a complex of 2 small calcium binding
proteins that is abundantly expressed in neutrophils and monocytes as well as early
infiltrating macrophages and is a known ligand of Toll-like receptor 4 (TLR4) and the
receptor for advanced glycation end-products (RAGE). There is growing evidence in animal
models and in patients with autoimmune diseases, of calprotectin being involved in the
inflammatory response, as well as being a marker of activation of innate immunity.
I have initially characterised the presence of calprotectin-positive cells in the renal biopsy of
patients with focal and crescentic AAV glomerulonephritis, therefore linking the presence of
these cells with renal outcome. Patients with active AAV have elevated serum calprotectin
levels, as well as significant expression on neutrophils and monocytes, which although
decrease during remission, does not normalise.
I have demonstrated that mrp14-/- mice are protected from nephrotoxic nephritis, which is
abrogated by use of LPS during disease progression. Bone-marrow derived macrophages
(BMDMs) release pro-inflammatory cytokines following stimulation with calprotectin;
mediated by TLR4. Mrp14-/- BMDMs do not respond to the pro-inflammatory stimulus of
S100A8/A9. The co-culture of endothelial cells (EC) and wild-type BMDMs is pro-
inflammatory unlike that of mrp14-/- BMDM and ECs. Mrp14-/- mesangial cells also have a
decreased pro-inflammatory response.
This work demonstrates that calprotectin has a role in experimental glomerulonephritis as
well as patients with AAV. This may improve our understanding of the inflammatory
response and identify a new novel target for treating patients in the future.
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Chapter 1 Introduction
This project explores the role of calprotectin (S100A8/A9) in the pathogenesis of ANCA
associated vasculitis (AAV) and glomerulonephritis. The first chapter explores the presence
of this protein in patients, in the circulation as assessed by measuring serum levels and
within leukocyte subsets, and within tissues, by histological assessment of renal biopsies of
patients with AAV. In addition, the effect of ANCA-IgG itself on monocyte expression of
S100A8/A9 was also investigated. The second chapter explores the role of S100A8/A9 in the
nephrotoxic nephritis animal model of immune complex glomerulonephritis. Lastly the third
chapter explores the in-vitro effect of S100A8/A9 on several primary renal cell lines which
play a role in induction of glomerulonephritis, as well as investigating the cellular responses
of cells deficient in S100A8/A9.
The terminology of S100A8/A9 can be confusing due to the numerous names given to each
of the 2 proteins that constitute the heterodimer.
As recommended, the genes should be referred to as Mrp8 and Mrp14, and the protein
S100A8 and S100A9 as internationally recognised (Roth, Goebeler et al. 2001). The
S100A8/A9 heterodimer is also termed calprotectin, and these two terms are used in the
thesis. Mice deficient in calprotectin are termed mrp14-/- mice.
1.1 Anti neutrophil cytoplasm antibody (ANCA) vasculitis
1.1.1 Epidemiology
Anti neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) is an example of a
small vessel vasculitis characterised by necrotising inflammation of blood vessel walls. It is a
multisystem disease often with kidney involvement characterised by the formation of ANCA
auto-antibodies directed against the components of neutrophil granules and monocyte
lysosomes, proteinase 3 (PR3) and myeloperoxidase (MPO). AAV consists of 3 clinical
syndromes- granulomatosis with polyangiitis (GPA formerly Wegener’s), microscopic
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polyangiitis (MPA) and Churg-Strauss syndrome (CSS), in which measurement of these auto-
antibodies has a major role in establishing the diagnosis. A 10 year study in the UK
demonstrated an overall incidence of 19.8/million, with males affected slightly more than
females (23.5/million v 16.4/million), and an increase in incidence with increasing age
(Watts, Lane et al. 2000). Clinical phenotypes can differ between different populations, for
example the overall incidence of AAV may be similar between Japan and the UK, but the
subtypes vary, with MPA predominating in a Japanese cohort, but accounting for only 41%
of cases in the UK AAV patients (Watts, Scott et al. 2008). Additionally, variations in the
clinical subtypes occur across Europe, with an increased incidence in GPA in Northern
Europe (Norway) compared to Southern Europe (Spain), and an increased incidence in MPA
in Spain (Watts, Lane et al. 2001).
A link between GPA and infection has long been observed (Pinching, Rees et al. 1980), and
treatment with the antibiotic co-trimoxazole was shown to result in a reduced incidence of
relapses in patients with GPA (Stegeman, Tervaert et al. 1996). Further evidence for a
possible role of infection is supported by the cyclical incidence of GPA, with peak incidences
observed in 2005 as well as 1990 and 1996 (Watts, Mooney et al. 2012). However, the
observation of a higher incidence in disease onset in winter rather than summer has been
inconsistent (Ntatsaki, Watts et al. 2010). In a European cohort, auto-antibodies to
lysosomal membrane protein-2 (LAMP-2) were prevalent in patients with ANCA associated
pauci-immune focal necrotising glomerulonephritis and this molecule was homologous to a
bacterial fimbrial protein, suggesting that molecular mimicry triggered by infection, may
have a role in the pathogenesis of glomerulonephritis associated with ANCA (Kain, Exner et
al. 2008). Additionally, a high incidence of preceding urinary tract infections was noted in
those patients positive for LAMP2 antibodies. The relevance of autoantibodies to human
LAMP-2 in systemic vasculitis has been debated following contradictory findings in two
separate cohorts using different assay techniques, Kain, 2012 #4093}. Possible explanations
for these different results include different patient populations and differences in the
experimental techniques and reagents used.
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1.1.2 Classification, Clinical course and biomarkers
The Chapel Hill Consensus Conference aimed to standardise the terms used to define the
systemic vasculitides and although they were not intended for use as diagnostic criteria,
they have frequently been used in this way. According to these criteria, ANCA associated
small vessel vasculitides included Wegener’s granulomatosis (now referred to as
granulomatosis with polyangiitis), Churg-Strauss syndrome and microscopic polyangiitis
(Jennette, Falk et al. 1994). These diseases are characterised by inflammation to the small
blood vessel wall and commonly result in glomerulonephritis with a typical focal segmental
necrotising and crescentic glomerular pattern of damage. Renal involvement is termed
pauci-immune due to little or no immunoglobulin deposition. Though uncommon
conditions, these diseases frequently cause end-stage renal failure (ESRF), and are a
significant cause of patient morbidity, mortality and hence result in a disproportionate
impact with respect to health economics. The renal registry report from 2010 states
glomerulonephritis accounted for 11.3 per million cases of ESRF in the UK (Gilg, Castledine
et al. 2012). These diseases follow a chronic relapsing course therefore exposing patients to
repeated courses of treatment with immunosuppression and their associated adverse
events.
A more useful classification system with respect to clinical course and prognosis is by
distinguishing these diseases by their auto-antibody profile rather than the name as defined
by the Chapel Hill Consensus conference (Lionaki, Blyth et al. 2012). It has previously been
recognised that GPA and PR3-ANCA are associated with a higher risk of relapse than
MPA/MPO-ANCA vasculitis (Booth, Almond et al. 2003). It is increasing recognised that
these diseases based on their autoantibody profile are distinct entities, with the majority of
patients with renal limited disease being positive for MPO-ANCA (81%) and those patients
with lesions of the upper respiratory tract being positive for PR3-ANCA (Lionaki, Blyth et al.
2012). Therefore, there is evidence that the autoantibody profile not only help to classify
patients but also to predict outcome. A genome wide association study demonstrated
genetic factors contributing to disease susceptibility, which differed between GPA and MPA.
These associations, including HLA, aligned with ANCA rather than the difference clinical
entities (Lyons, Rayner et al. 2012). A recent classification, has further divided AAV into
24
categories based on the presence of renal disease, ANCA specificity and
gastrointestinal/cardiovascular disease, resulting in a more homogenous groups of patients
with distinct death and relapse rates (Mahr, Katsahian et al. 2012). These 2 studies provide
evidence for distinct disease entities within the term ANCA associated vasculitis.
However, the actual ANCA titre, or changes in titre have been recognised as only being a
modest predictor of disease relapse. An increase in ANCA as well as a persistently positive
ANCA, are significantly associated with relapse (positive likelihood ratio of an increase in
ANCA on future relapse of disease was 2.84). Interestingly, measuring the ANCA in MPO-
ANCA patients was a more reliable indicator of possible relapse/disease activity than PR3-
ANCA (Tomasson, Grayson et al. 2012). Therefore, the measurement of these auto-
antibodies is of limited use in guiding individualised treatment for patients with vasculitis.
The identification of a more robust biomarker to help predict which patients will relapse is
therefore highly desirable. This could enable a more tailored treatment plan for individual
patients, allowing a reduction of unnecessary immunosuppression in a subset of patients in
a better prognostic category, and increased vigilance and/or more prolonged treatment in
those patients in a worse prognostic group with respect to relapse risk. Gene expression
profiling has emerged as a potential tool in helping to predict a patient’s response to
treatment. One successful method used the purification of lymphocyte subsets (CD4+ and
CD8+ T cells, B cells, neutrophils and monocytes) followed by the quantification of gene
expression profiles using a microarray. Separating the individual leukocyte subsets allowed
the identification of a novel CD8+ signature that defined a subgroup of patients with AAV
who were at an increased risk of relapsing disease. This same signature also predicted an
increased risk of relapse in patients with systemic lupus erythematosis (SLE). This newly
identified CD8+ T cell signature was associated with the upregulation of genes involved in
both T-cell receptor (TCR) and IL-7 receptor (IL-7R) pathways. These genes are both
important for promoting T-cell survival and memory, therefore helping to identify those
patients who may benefit from a more intensive immunosuppressive treatment regime
(McKinney, Lyons et al. 2010). However, these findings need to be reproduced in a separate
population, ideally in a prospective manner.
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Circulating markers have also been identified in order to help differentiate between active
AAV and disease remission. Matrix metalloproteinase-3 (MMP-3) has been demonstrated to
be able to differentiate active from inactive AAV better than the more traditional markers of
inflammation such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
However, this study had a few limitations, such as including a heterogeneous patient
population with respect to renal involvement, as well as a mixture of different treatment
regimes, and inter-assay variation in the measurement of MMP-3. This study requires
further investigation (Monach, Tomasson et al. 2011).
Therefore, currently routine testing of patients’ serum ANCAs titre remains the only limited
tool to help us predict a patient’s response to therapy and risk of relapse, and since it is a
poor biomarker, we are limited in our ability to tailor patient’s individual treatment.
1.1.3 Histological classification and outcome
AAV frequently affects the kidneys. A characteristic pattern of renal involvement occurs,
which is discussed further in section 1.2.3. A histopathological classification of ANCA-
associated glomerulonephritis was proposed in 2010 (Berden, Ferrario et al. 2010). The
classification validation study included 100 patients from 2 large multi-centre European
vasculitis trials (CYCAZAREM: cyclophosphamide or azathioprine as a remission therapy for
vasculitis, and MEPEX: methylprednisolone versus plasma exchange as additional therapy
for severe, ANCA associated glomerulonephritis). Renal histology from these patients
originating in 9 European countries with at least 1 year’s follow-up, and with both MPO-
ANCA and PR3-ANCA were included. The classification system was based on the glomerular
pathology assessed by light microscopy. Interestingly, tubulointerstitial parameters such as
fibrosis and tubular atrophy did not add to the classification system and resulted in
increasing the classification complexity and was thus omitted unless there was something
remarkable in this compartment. The key aspect of the classification was that the renal
biopsy could be defined by 4 separate categories: focal, crescentic, mixed and sclerosed,
and these correlated with the clinical outcome. Briefly, focal was defined by ≥50% normal
glomeruli. Crescentic included ≥50% glomeruli with cellular crescents. Importantly, the
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crescents were defined as cellular not fibrous crescents, although as long as at least 10% of
the crescent contained cellular material, they were labelled as a cellular crescent even if the
remaining material consisted of the extra-cellular matrix. Mixed referred to <50% normal,
<50% crescentic, <50% globally sclerotic glomeruli. The last category was sclerotic, which
included the biopsies with ≥50% globally sclerotic glomeruli. The biopsies included in this
classification were all pauci-immune and contained at least 10 glomeruli. The validation
study demonstrated that different classes correlated to the severity of renal impairment
during follow-up, with those patients in the focal category having the best renal outcome,
followed by crescentic, mixed and lastly, sclerotic. Additionally, those patients with a
sclerotic classification were at highest risk of death within the first year of diagnosis.
Therefore this classification could allow biopsies from different centres to be compared
within the same categories, so that patient outcome in different centres, treated in different
ways, within and without clinical trials may be analysed.
The first replication of the classification system was in a Chinese cohort, and it produced
some differences in patient outcome compared to the European cohort used in the Berden
classification. Whilst the best renal outcome remained in the focal category and the worst in
the sclerotic, surprisingly, those patients with a crescentic category had a worse outcome
than those with a mixed category (Chang, Wu et al. 2012). These differences may be due to
differences in treatment or differences in disease phenotype within different ethnic groups.
The Berden classification has been replicated in a population of patients (n=76) from the US,
with those patients with a focal class having the best outcome, and sclerotic the poorest at
1 year (Carla L. Ellis 2012). Similarly, an Australian study (n=113) has also demonstrated that
sclerotic class has the poorest patients and renal survival (Sharon Lee Ford 2012). The
Berden classification has also recently demonstrated in a European cohort of 109 patients,
to be an important predictor of renal relapse, with risk highest in those patients with the
sclerotic class (Arda Goceroglu 2012).
Although the Berden classification does provide convincing evidence for the histological
pattern of renal injury predicting long-term renal outcome, not all patients undergo renal
biopsies and a proportion do not have renal involvement. In addition, this does not inform
clinicians as to the risk of disease relapse. There remains therefore a clinical need for better
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biomarkers for predicting disease activity and risk of relapse that could be of direct clinical
applicability in this group of patients with a disease that characteristically relapses.
1.2 Pathogenesis of crescentic glomerulonephritis
Crescentic glomerulonephritis (GN) describes a histopathological pattern of glomerular
injury. The underlying cause for this pathological pattern can be divided into 3 groups of
underlying causes: Immune-complex mediated glomerulonephritis, anti-GBM associated
and pauci-immune GN. A crescent is characterised by disruption of the glomerular capillary
wall resulting in a cellular infiltration into Bowman’s space. This proliferation of infiltrating
cells is composed of macrophages, podocytes, parietal epithelial cells, fibroblasts and T-
cells(Tarzi, Cook et al. 2011; Kambham 2012). The classification of the causes of a crescentic
glomerulonephritis depends on the presence/absence of immune deposits as well as their
location within the glomerulus. Patients with a crescentic glomerulonephritis, which is a
cause of a rapidly progressive GN, present with proteinuria, haematuria, renal impairment
and if untreated may progress in end-stage renal failure in weeks to months.
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Figure 1-1 Crescentic GN has different patterns of glomerular immunoglobulin deposition.
Top figure demonstrates a crescentic glomerulus (silver stain). Bottom pictures demonstrate
the 3 patterns of IgG deposition as shown by immunofluorescence in crescentic
glomerulonephritis (Tarzi, Cook et al. 2011)
1.2.1 Immune complex crescentic glomerulonephritis
Immune complexes are composed of immunoglobulins, complement and a variety of other
proteins. Several different renal disease are characterised by the formation of immune
complexes, which can vary in size, composition and location within the glomerulus.
These complexes subsequently get trapped within the glomerulus either in the mesangium,
the subendothelial surface or the subepithelium. Large insoluble immune complexes form
when the amount of antigen increases resulting in cross-linking of these complexes. These
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immune complexes can then bind to Fc receptors with the activation of complement and
infiltration of leukocytes with the subsequent release of pro-inflammatory mediators.
When the immune complexes fail to be removed by the circulation, injury and inflammation
within the glomerulus can then be initiated (Nangaku and Couser 2005). In the animal
model, an example of this type of injury is an acute serum sickness model in the rabbit.
When crystallized bovine albumin was injected into rabbits, renal and cardiovascular lesions
were identified, which were observed in the case of renal lesions to be similar to a
glomerulonephritis in man (Germuth 1953). This is an example of a type III hypersensitivity
reaction.
SLE is an example of an immune-complex disease. A significant feature on the renal biopsy
in patients with lupus nephritis is the deposition of immunoglobulin. Patients with active
disease demonstrate high serum levels of circulating anti-dsDNA antibodies. However,
patients in disease remission may also demonstrate elevated levels of auto-antibodies as do
individuals many years before clinical disease (Arbuckle, McClain et al. 2003), suggesting a
threshold is required for development of clinical disease, with respect to the presence of
certain autoantibodies with particular specificities. Autoantibodies may lead to deposition
of immune complexes within the kidney, with two potential mechanisms which may explain
the tropism of these autoantibodies and immune complexes for the kidney. One mechanism
is the cross-reaction of anti-dsDNA antibodies to glomerular antigens such as the mesangial
cell membranes, laminin and α-actinin. The second mechanism is the binding of anti-dsDNA
antibodies to exposed chromatin fragments associated with the glomerular basement
membranes (Mortensen and Rekvig 2009). The current theory of why autoantibodies
develop initially is that apoptotic cells persist due to deficiencies in the natural clearance
mechanisms such as IgM, serum amyloid P and nucleases (such as DNase 1), which aid in
targeting and removal of dead and dying cells, and whose deficiencies are associated with
SLE, allowing chromatin release and exposure to the immune system. Following activation
of dendritic cells and chromatin-derived peptide specific T helper cells, there ensues a T cell-
B cell interaction which promotes production of anti-chromatin antibodies (Mortensen and
Rekvig 2009). This is supported by the evidence from both humans and mice, in which
nucleosome specific T cells have been identified as well as the induction of anti-nucleosome,
anti-dsDNA and anti-histone antibodies (van der Vlag and Berden 2011).
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Another renal disease which is characterised by the formation of immune deposits is
idiopathic membranous glomerulonephritis, which is a significant cause of nephrotic
syndrome in adults. These immune complexes deposit in a subepithelial location and are
mainly of the IgG4 subclass. A member of the mannose-receptor family, phospholipase A2
receptor (PLA2R), which is located on the podocyte, was recently found to the antigenic
target for the majority (70%) of patients with idiopathic membranous GN (Beck, Bonegio et
al. 2009).
1.2.2 Anti-glomerular basement membrane (GBM) or Goodpasture’s disease
The first suspected case of anti-GBM disease, in a patient with pulmonary- renal syndrome
was reported in 1919 by Ernest Goodpasture. In retrospect this may have been a case of
systemic vasculitis, but following the description of similar cases the constellation of
features was named Goodpasture’s syndrome, and Goodpasture’s disease when associated
with circulating anti-GBM antibodies. It is characterised by the formation of autoantibodies
to type IV collagen, present in the glomerular and alveolar basement membranes. Most of
the autoantibodies are of the IgG1 subtype, although in some patients the dominant
subtype may be IgG4 (Segelmark, Butkowski et al. 1990). The typical renal lesion is a florid
crescentic glomerulonephritis where most glomeruli show a similar aged lesion and have
linear deposition of IgG. The auto-antigen has been identified as the non-collagenous
domain (NC1) of α3 type IV collagen (Saus, Wieslander et al. 1988; Ryan, Mason et al. 1998),
contained within α3, α4 and α5 triple helices, making up the collagen IV complex in the
glomerular basement membrane (GBM). An early initiating process is thought to involve a
conformational change in the structure of these trimers in alveolar or glomerular basement
membrane, thus exposing neoepitopes which result in the formation of autoantibody
production and GBM deposition (Pedchenko, Bondar et al. 2010). Cigarette smoking, as well
as the organic solvents, are recognised trigger factors leading to the pathological exposure
of these neoepitopes (Donaghy and Rees 1983; Stevenson, Yaqoob et al. 1995). There are
important genetic associations with the development of this disease, with HLADRB1*1501
and *0401 being present in a significant number of patients with the disease compared to
controls (Fisher, Pusey et al. 1997). Antigen specific T-cells demonstrate an important role in
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glomerular injury. α3 (IV)NC1-specific CD4+ cells are known to be present in patients and
healthy subjects, having not been adequately deleted in the thymus despite α3 (IV)NC1
thymic expression(Wong, Phelps et al. 2001). In patients with anti-GBM disease, the
frequencies of these T-cells are higher than those in controls without disease, but undergo a
gradual decrease in the years following diagnosis (Salama, Chaudhry et al. 2001), due to the
development of antigen-specific regulatory T-cells which maintain immune tolerance and
disease remission (Salama, Chaudhry et al. 2003).
1.2.3 Pauci-immune crescentic glomerulonephritis
AAV commonly results in a pauci-immune glomerulonephritis which is characterised by little
or no deposition of immunoglobulin within the glomerulus. It is associated with the
presence of anti-neutrophil cytoplasmic antibodies (ANCA) directed against components of
neutrophil granules and monocyte lysosomes, proteinase-3 and myeloperoxidase. However,
approximately 10% of patients with pauci-immune GN will be ANCA negative.
1.2.3.1 Pathogenicity of ANCA
ANCA were detected and demonstrated to be associated with vasculitic disease activity in
1985 (van der Woude, Rasmussen et al. 1985). There is now evidence that these
autoantibodies are additionally involved in the disease pathogenesis. However, there is
conflicting human evidence whether the presence of the autoantibodies alone can cause
disease as demonstrated by 2 cases of maternal transfer of MPO-ANCA. In 1 case, the child
was born with a renal-pulmonary syndrome and required immunosuppression, and in the
other case the newborn was healthy with no clinical disease despite placental transfer of
MPO-ANCA in both cases (Schlieben, Korbet et al. 2005; Silva, Specks et al. 2009).
After being primed by cytokines such as TNFα, both neutrophils and monocytes express PR3
and MPO on the cell surface. ANCA can then bind to the antigen with several pro-
inflammatory results. Neutrophils have been shown to subsequently release reactive oxygen
species (ROS) and to undergo degranulation (Falk, Terrell et al. 1990). Binding of ANCA to
the cell can occur through both F(ab) and FcR engagement with crosslinking of the antigens
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and activation of the cell (Kettritz, Jennette et al. 1997) leading to release of pro-
inflammatory cytokines such as IL-1 and IL-8 (Harper, Cockwell et al. 2001). The interaction
of ANCA-primed neutrophils with the endothelium is an important part of disease
pathogenesis. MPO-ANCA has been demonstrated in a murine model to increase leukocyte
adhesion and transmigration within the endothelium, with mice deficient in FcRγ chain 
protected from this action (Nolan, Kalia et al. 2008). Additionally, neutrophil degranulation
with subsequent release of elastase and proteinase-3 has been shown to induce endothelial
cell apoptosis (Yang, Kettritz et al. 1996). Further evidence of the importance of the role of
ANCA in leukocyte-endothelial interactions is provided by animal models which will be
discussed further.
1.2.3.2 Genetic factors
Like other complex auto-immune diseases, susceptibility depends on predisposing genetic
factors and particular environmental factors. The relative risk of GPA in first degree relatives
of patients with the disease is 1.56 (Knight, Sandin et al. 2008). Additionally, relatives are at
a slightly increased risk of other autoimmune/inflammatory diseases (Knight, Sandin et al.
2010). Recently, a genome wide association study in a European cohort, demonstrated both
MHC and non-MHC associations with AAV. There were significant differences in the genetics
between PR3-ANCA and MPO-ANCA, with associations of PR3-ANCA with HLA-DP and genes
coding for α1-antitypsin and proteinase 3, while MPO-ANCA was associated with HLA-DQ,
confirming that the syndromes associated with these 2 different auto-antibodies are
genetically distinct (Lyons, Rayner et al. 2012).
Other genetic associations of AAV which emerged from smaller cohort studies suggested
polymorphisms in CTLA-4 (Lee, Choi et al. 2012), and PTPN22 gene (tyrosine phosphatase
enzyme present in lymphocytes) may play a role (Carr, Niederer et al. 2009) as well as
associations with the IL-2RA (IL-2 receptor) locus (Carr, Clatworthy et al. 2009). Fc-receptor
genotypes have also been identified as a factor influencing the development of severe renal
disease in GPA (Kelley, Monach et al. 2011), while The Z allele of the polymorphic α1 anti-
trypsin, an inhibitor of PR3, has been shown to be associated with GPA (Morris, Morgan et
al. 2011) in smaller cohort studies and in the GWAS.
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1.2.4 Immune mediators in glomerulonephritis
Both the innate and adaptive immune responses play important roles in the pathogenesis of
glomerulonephritis. There is a complex interplay between different immune cells, with
evidence acquired from animal models of disease.
Figure 1-2 Demonstrates the interplay between both the innate and the adaptive immune
mechanisms in causing glomerular injury.
Receptors, such as toll-like receptors (TLRs) additionally play an important role, with both
infiltrating immune cells as well as the resident intrinsic cells playing a role (Couser 2012).
1.2.4.1 Macrophages
Macrophages have a central role in both the initiation and the progression of experimental
glomerulonephritis as well as roles in healing and repair. A study of the renal biopsies of
patients with lupus nephritis demonstrated the presence of glomerular monocytes and
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tubular macrophages correlated the best with outcome parameters, with the persistent
presence of macrophages on repeat biopsies in those treated patients correlating with poor
renal survival (Hill, Delahousse et al. 2001).
1.2.4.1.1 Macrophage phenotype
There is increasing evidence that macrophages are able to alter their phenotype depending
on the local environment and the cytokine milieu. Analogous to the Th1/Th2 subset,
macrophages can be divided into the classically activated M1, and the alternatively
activated M2 (with further subdivisions) depending on various cell surface markers as well
as their functional behaviour. Macrophages originate from a progenitor myeloid cell within
the bone marrow, the precursor of many different cell types. These myeloid progenitor cells
eventually develop into monocytes under the influence of macrophage colony-stimulating
factor, which are then subsequently released into the circulation from the bone marrow and
into tissues where there is further differentiation into macrophages. Both the innate and
the adaptive immune response can then influence the behaviour and the phenotype of the
infiltrating macrophages.
35
Figure 1-3 Diagram to demonstrate the generation of different macrop
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Classically activated macrophages (M1a) are produced under the influence of INFγ, which 
can be produced by both adaptive and innate cells such as antigen specific Th1 CD4+ cells,
CD8+ cytotoxic T cells and NK cells. They have several particular functions such as increased
phagocytosis and endocytosis and therefore increased uptake of bacteria; they mediate
activation of Th1 cells through increased expression of major histocompatibility (MHC)
complex class II and molecules such as CD40, CD80 and CD86 which function as critical co-
stimulatory molecules. They also release several pro-inflammatory cytokines (IL-1, IL-12,
TNF-α). M1b subsets, stimulated by LPS-TLR4 activation, are similar to M1a with respect to
many of the pro-inflammatory properties but they are characterised by not secreting IL-12.
Other endogenous stimulants of M1b include pathogen-associated molecular patterns that
through interaction with pattern recognition receptors are able to activate M1b (Rees
2010). Additionally, the cytokine profile secreted by classically activated macrophages (IL-1,
IL-6, IL-23) are associated with development of Th17 cells which appear to have an
important role in autoimmunity (Langrish, Chen et al. 2005).
Alternatively activated macrophages (M2a) have been identified in culture following
stimulation with IL-4 or IL-13. This macrophage subset is associated with very different
actions to that of the classically activated macrophage, with less pro-inflammatory cytokine
production, but production of IL-10. M2a cells are also characterised by decreased nitric
oxide production and reactive oxygen species, recruitment of Th2 cells and expression of
the cell surface mannose receptor. A further sub-type of alternatively activated
macrophages is the M2b cell, macrophages formed under the influence of LPS and in the
presence of IgG immune complexes. Although this subtype produces cytokines such as IL-1β,
IL-6 and TNFα, the production of IL-10 results in an anti-inflammatory phenotype. The
response supports a Th2 effect with IgG class switching by B cells (Rees 2010). They are
associated with tissue remodelling as well as response to parasites. Apoptotic cells affect
monocyte activation resulting in increased secretion of IL-10, with decreased secretion of
pro-inflammatory cytokines. Therefore having an anti-inflammatory effect (Voll, Herrmann
et al. 1997).
It has been suggested using rat bone marrow derived macrophages (BMDMs), following
exposure to numerous cytokines, the phenotype of the macrophage is determined by the
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first cytokine to which it was exposed to, following which the macrophage is then
unresponsive to an alternative activating signal (Erwig, Kluth et al. 1998). In an extension of
this finding, macrophages from inflamed, nephritic rat glomeruli responded differently to
macrophages from normal glomeruli with respect to the amount of nitric oxide production
following treatment with IL-4, therefore supporting the hypothesis that once the
macrophages have a determined phenotype, they become unresponsive to alternative
stimuli, as previously demonstrated with BMDMs (Erwig, Stewart et al. 2000).
However, there is experimental evidence to demonstrate that the functional phenotype of
mouse macrophages can be changed, and this plasticity occurs as the microenvironment
changes, and therefore polarized macrophages have an element of reversibility (Stout, Jiang
et al. 2005). Whether, this in-vitro work in which macrophages are exposed to a limited
number of cytokines can then be translated into the in-vivo setting is unclear. In the mouse
model of ischaemia-reperfusion, pro-inflammatory M1 macrophages are the early
infiltrating cells which are recruited into the kidney, followed by a predominance of M2-type
macrophages a few days later. Labelled M1 macrophages were demonstrated to switch to
an M2 phenotype and to change their function from a pro-inflammatory macrophage to a
macrophage involved with repair of the injured kidney. Depletion studies demonstrated a
protective effect on the kidney when depletion occurred early on, however, recovery was
delayed when depletion occurred at a later stage (Lee, Huen et al. 2011).
1.2.4.1.2 Macrophages in animal models of disease
Macrophages have been demonstrated to play an important role in experimental
glomerulonephritis. Macrophages have crucial roles in causing disease in both the initiation
and the progression of inflammation. Treatment with anti-macrophage serum in an animal
model of anti-GBM disease, resulted in a decrease in macrophage accumulation within the
kidney and reduced renal injury (Holdsworth, Neale et al. 1981). T cell dependent
macrophage recruitment has been shown to be the crucial effector response in anti-GBM
disease in rats, with macrophage depletion using clodronate resulting in decreased
proteinuria (Huang, Tipping et al. 1997). Additionally, macrophages have an important role
in the progression of experimental glomerulonephritis. By selectively ablating tissue
macrophages at days 15-20 after the initiation of a crescentic glomerulonephritis, disease
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progression was terminated as demonstrated by a reduction in crescents, improved renal
function and decreased proteinuria (Duffield, Tipping et al. 2005).
Supporting the importance of macrophage phenotype, several experiments have
demonstrated that it’s not just the mere presence of macrophages that causes disease, but
it’s their particular phenotype. This is clearly seen when murine macrophages were
modulated ex-vivo (LPS to generate M1, IL-4/IL-13 to generate M2) then injected into a
mouse with severe combined immunodeficiency (SCID- in which there is an absence of
lymphocytes), in which adriamycin nephropathy was induced. Injection of M1 macrophages
resulted in increased renal injury compared to M2 macrophages (Wang, Wang et al. 2007).
In a similar model, treatment with M1 macrophages also resulted in more severe injury
compared to treatment with resting macrophages, even when significantly more resting
macrophages were injected (Wang, Cao et al. 2008). Additionally, IL-10/TGF-β modified
macrophages attenuated renal injury (Cao, Wang et al. 2010). In a crescentic GN rat model,
early treatment with IL-4 resulted in a decrease in glomerular inflammation and reduced
macrophage activation (Cook, Singh et al. 1999). Additionally, transfer of IL-10 macrophages
to ischemic rat kidneys protected against ischemic injury (Jung, Sola et al. 2012)
Further evidence to support the presence of a protective macrophage phenotype has been
recently reported using the ischaemia/reperfusion model of renal injury with 2 different
macrophage depleting strategies. These strategies included administration of diphtheria
toxin in a mouse transgenic for the human diphtheria toxin receptor under the control of
the CD11b promoter, or the administration of liposomal clodronate to deplete
macrophages. These different techniques resulted in very different outcomes, with respect
to renal function and renal damage, with clodronate mediated macrophage depletion
resulting in less renal injury. Clodronate did not deplete all the macrophages, leaving CD206
(mannose receptor)-positive renal macrophages intact as well as some resident CD11c
positive cells, suggesting that these cell populations are renoprotective. These cells may
survive clodronate administration due to a decrease in phagocytic properties, or by not
being accessible to the liposomal clodronate (Ferenbach, Sheldrake et al. 2012).
Additionally, particular macrophage pattern recognition receptors may influence the
outcome of crescentic glomerulonephritis. Mice deficient in mannose-receptor are
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protected from nephrotoxic nephritis, in part due to decreased macrophage phagocytosis,
and due to an interaction between macrophages and mesangial cells resulting in a less-
inflammatory phenotype of macrophage and therefore disease protection (Chavele,
Martinez-Pomares et al. 2010).
The Wistar Kyoto (WKY) rat is very susceptible to induction of crescentic glomerulonephritis,
unlike the resistant Lewis (LEW) strain of rat. Genetic studies from congenic WKY-LEW strain
combinations have demonstrated the importance of macrophage activation in determining
glomerular damage in this model of immune-mediated passive nephrotoxic
nephritis(Behmoaras, Smith et al. 2010). Using the same susceptible rat strain, but another
model of GN, experimental autoimmune glomerulonephritis, EAG, induced by immunisation
with glomerular basement membrane extract or purified alpha3 chain of type IV collagen,
macrophage activation, partly through Fc receptor mediated activation, was found to be an
important factor in disease susceptibility. This was demonstrated by Lewis and WKY BMDMs
having significant differences in Fc receptor mediated oxidation, as well as WKY BMDMs
demonstrating increased phagocytosis as well as increased MCP-1 secretion in response to
LPS compared to the resistant Lewis strain. Additionally, the susceptibility to a crescentic GN
in this model seemed to be independent of the levels of antibody to alpha3 chain type IV
collagen (Reynolds, Cook et al. 2012).
1.2.4.2 T cells
T cells are commonly found within glomerular lesions in several different types of immune-
mediated glomerulonephritis. In renal biopsies of patients with rapidly progressive
glomerulonephritis, including AAV, there is prominent T cell and macrophage infiltration,
which is absent in less inflammatory renal diseases (Cunningham, Huang et al. 1999), while
T-cells in proliferative lupus nephritis are correlated with the number of cellular crescents
and a poor outcome following induction therapy (Couzi, Merville et al. 2007). In addition,
there is extensive experimental evidence to demonstrate their critical role in mediating
disease, often as part of a delayed-type hypersensitivity (DTH) response, characterised by
activated T cells and macrophages.
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1.2.4.2.1 CD4+ T cells
CD4+ T cells appear to be the most important subtype of T cell involved in mediating renal
injury in experimental glomerulonephritis, with the Th1 cytokine response dominating.
Figure 1-4 Diagram to demonstrate the differentiation of CD4+ T cells
CD4+ T cells differentiate intoTh1 and Th2 T cells under the influence of different cytokines
with resulting effector responses. The Th1 response is important in a crescentic
glomerulonephritis (Tipping and Holdsworth 2006).
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The role of the Th1 response has been demonstrated by comparing 2 different mouse
strains which demonstrate either a Th1 polarised response (C57BL/6) or a Th2 response
(BALB/c) when injected with sheep anti-mouse nephrotoxic serum. Following induction of
disease, C57BL/6 mice demonstrate a severe crescentic GN with both T-cell and
macrophage infiltration, and cytokine profiles consistent with a Th1 response. Depletion of
CD4 cells in this model using a monoclonal antibody attenuated disease, demonstrating the
critical role for T cells. In the Th2 prone BALB/c mice, renal injury was significantly
diminished, and was not dependent on T cells (Huang, Tipping et al. 1997). Th1 responses
also predominate in murine anti-GBM disease, induced by immunisation with GBM in
adjuvant, with increased production of INF-γ and diminished IL-10 production, typical of a 
Th1 response (Hopfer, Maron et al. 2003). Further evidence to support the importance of
IFN-γ in mediating disease, and the protective effect of Th-2 cytokines is demonstrated by 
attenuated disease in IFN-γ deficient animals and  increased disease in IL-4 or IL-10 deficient 
mice (Kitching, Tipping et al. 1998; Kitching, Holdsworth et al. 1999). Interestingly, to
confirm the importance of cellular immunity, mice with a deletion in the mu-
immunoglobulin heavy chain, which are unable to develop mature B cells, or produce any
immunoglobulin, but retain an intact cell-mediated immune response, were used for
induction of nephrotoxic nephritis. These mice still developed crescents and renal disease
with similar severity of renal injury as wild-type mice (Li, Holdsworth et al. 1997). Regulatory
T cells (CD4+CD25+ [Treg]) have an important role in the maintenance of tolerance. T regs
have been transferred into mice prior to the administration of NTS during NTN, with the
resultant reduction in renal injury and proteinuria. The transferred T regs were located in
the secondary lymphoid organs and exerted potent immunosuppressive effects with the
resultant decrease in kidney expression of pro-inflammatory cytokines as well as isolated
splenocytes demonstrating a decreased production of Th-1 associated cytokines. The mice
that received T regs had a similar humoral response to the control mice. This demonstrates
that regulatory T cells counterbalance the actions of autoreactive T cells (Wolf, Hochegger
et al. 2005).
In vasculitis the importance of T cells has also been demonstrated. GPA patients in
remission, demonstrate differences in the homeostasis of CD4+ T cells compared to healthy
controls. These patients demonstrate a lower proportion of naive T cells with an increase in
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effector memory T cells, suggesting a persistent antigenic signal. Additionally in remission
patients, the effector memory cells demonstrate a Th2 phenotype (Abdulahad, van der Geld
et al. 2006). There are also abnormalities in both the number and function of regulatory T
cells in patients with GPA, with patients demonstrating an increase in effector T cells, with a
relative imbalance of effector and regulatory T cells. Regulatory T cells in this study were
shown to play an important role in controlling the autoantigen-specific effector T cell
response to PR3, with ANCA positive patients showing an increased T cell proliferation
compared to ANCA negative patients and healthy controls, therefore illustrating the
important role of regulatory T cells to prevent relapse during disease remission (Morgan,
Day et al. 2010). The antigens in AAV, MPO and PR3, have been demonstrated to stimulate
proliferation of CD4+ cells from patients, but also from healthy controls (Popa, Franssen et
al. 2002). Work in our group has demonstrated that patients with MPO-AAV have
diminished MPO-specific Th1 cell responses during remission compared to acute disease,
but this attenuated response is not due to suppression by antigen specific regulatory T cells
(Chavele, Shukla et al. 2010). A further study demonstrating the functional and phenotypic
differences of T cells in AAV patients further confirms a persistently activated T cell
population in patients, with impaired IL-10. (Marinaki, Neumann et al. 2005)
1.2.4.2.2 CD8 cells
There is less evidence exploring the role of CD8+ T cells in either human glomerular disease
or experimental GN. Early work demonstrated that development of a crescentic
glomerulonephritis in the murine nephrotoxic nephritis model was dependent on CD4 cells,
with the absence of CD8 cells accelerating disease (Tipping, Huang et al. 1998). By contrast,
in experimental autoimmune glomerulonephritis in the susceptible WKY rat, administration
of an anti-CD8 monoclonal antibody either at the time of disease induction or during disease
progression, resulted in a significant reduction in renal injury, suggesting an important role
for CD8 cells in disease pathogenesis in this particular model (Reynolds, Norgan et al. 2002).
1.2.4.2.3 Th17 cells
IL-17A is a relatively newly described cytokine that has been implicated in autoimmunity. IL-
17A belongs to a family of several cytokines. IL-17 is now known not just to be produced by
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T cells (Th17 cells), but also by many cells on the innate immune system such as
macrophages, dendritic cells and natural killer cells amongst others. CD4+ cells differentiate
to Th17 subtype under the influence of the cytokines IL-1, IL-6 and TGF-β. Once
differentiated, IL-23- a member of the IL-12 family, is required for the cells to proliferate and
maintain their phenotype (Korn, Bettelli et al. 2009). Additionally, the steroid receptor-type
nuclear receptor RORγt has a critical role in the differentiation of Th17 cells as well as IL-17 
production (Ivanov, McKenzie et al. 2006). The IL-17 receptor is expressed ubiquitously (Yao,
Spriggs et al. 1997).
Work done in our laboratory by Dr Sally Hamour, has demonstrated that in patients with
acute AAV, serum levels of IL-17 and IL-23 are significantly increased compared to controls,
and remain increased in a proportion of patients during disease remission. Additionally,
increased frequencies of autoantigen-specific IL-17 producing cells were found in patients
compared to healthy controls therefore demonstrating a potential role in contributing to
disease (Nogueira, Hamour et al. 2010). Kidney biopsies of patients with AAV demonstrate
the presence of IL-17 cells within the glomeruli and interstitium, with a suggestion that
neutrophils may be the source of IL-17 in acute disease (Velden, Paust et al. 2012). IL-17 has
been shown to have a role in experimental glomerulonephritis. IL-17 increases the
production of proinflammatory cytokines, such as MCP-1, which plays an important role in
the recruitment of both T-cells and monocytes to mesangial cells. Mice deficient in IL-23 p19
and IL-17 demonstrated less T-cell infiltration and less severe disease compared to wild-type
mice (Paust, Turner et al. 2009). Γδ T cells have also been shown to produce IL-17 in
experimental glomerulonephritis within the kidney and to contribute to disease by
enhancing neutrophil recruitment into the kidney (Turner, Krebs et al. 2012). In a mouse
model of autoimmunity to MPO, mice deficient in IL-17 were protected against renal
disease, with less neutrophil infiltration and a decrease in macrophage recruitment, perhaps
as a result of decreased delayed type hypersensitivity responses to the planted neutrophil
autoantigens (Gan, Steinmetz et al. 2010). Interestingly, IL-17 seems to play different roles
at different times during the course of experimental GN. In NTN, IL 17-/- mice developed
less disease early in the model at day 6 compared to WT animals. This protection becomes
less prominent by day 14, with similar infiltration of neutrophils and macrophages in both
animal groups. However, by day 21, both WT and IL-17-/- mice had established crescentic
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GN with the IL-17-/- mice demonstrating more severe disease, with a profound upregulation
of the Th1 associated cytokine INF-γ (Odobasic, Gan et al. 2011). 
1.2.4.3 B cells
B cells are known to contribute to both humoral and cellular immunity by acting as
precursors to antibody producing cells, and through antigen presentation and expansion of
the population of regulatory T cells mediated through expression of co-stimulatory
molecules that are required for T cell activation, such as CD80, CD86 and CD40 (Sfikakis,
Souliotis et al. 2007). In patients with AAV, treatment with B-cell depleting agents such as
rituximab has generated very promising results (Jones, Tervaert et al. 2010; Stone, Merkel et
al. 2010) suggesting that B cells have an important role in disease pathogenesis. In an
experimental model of auto-immune MPO associated crescentic GN, mice deficient in B cells
(μMT-/-) still develop renal injury with infiltration of CD4+ T cells, macrophages and
neutrophils demonstrating that the presence of B cells is not a critical requirement in
causing disease in this particular model (Ruth, Kitching et al. 2006). This is supported by
another study using nephrotoxic nephritis in which mu-chain deficient mice had the same
response as wild-type mice, with respect to renal injury, despite a lack of B cells and
absence of immunoglobulin (Li, Holdsworth et al. 1997).
B cells have a complicated role in relation to autoimmunity, with infrequently reported
cases of increased autoimmunity following B cell depletion therapies with rituximab (Dass,
Vital et al. 2007; El Fassi, Nielsen et al. 2008). Additionally, a subset of B cells called
regulatory B cells, are thought to play an important role in immune tolerance, mediated
through their IL-10 production (Xiao, Brooks et al. 2012). In patients with vasculitis, a
population of CD25+ B cells have been identified that are present in patients in remission.
Although this study suggested that this population of cells may have ‘immunoregulatory’
properties, there was a lack of functional data to support this claim (Eriksson, Sandell et al.
2010). A population of IL-10 secreting B cells in humans does exist, which are able to
influence cytokine secretion of monocytes in-vitro (Iwata, Matsushita et al. 2011). However,
the role of this subset of IL-10 secreting regulatory B cells in AAV is yet to be fully
determined.
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1.2.4.4 Neutrophils
In the nephrotoxic nephritis animal model, the infiltration of neutrophils is an early
response, occurring 2 hours after injection of nephrotoxic serum, and has a crucial role in
mediating glomerular injury (Cochrane, Unanue et al. 1965). Early experiments
demonstrated this by depleting neutrophils with nitrogen mustard (cyclophosphamide
precursor), which resulted in attenuation of renal injury (Naish, Thomson et al. 1975).
Neutrophils have been shown to have a crucial role in mediating vasculitis and glomerular
injury in humans. The interaction of ANCAs with neutrophils results in the production of
reactive oxygen species (ROS) and neutrophil degranulation, a process further enhanced by
priming with TNF (Falk, Terrell et al. 1990).
Additionally, recent work has demonstrated further mechanisms by which neutrophils play
an important role in disease pathogenesis. Cellular microparticles are membrane vesicles
released from several cell types, including neutrophils and endothelial cells, following cell
activation or apoptosis and are pro-inflammatory. Primed neutrophils release microparticles
in response to ANCA, which express PR3 and MPO, and are able to bind to the endothelium
where they have several effects including increased release of endothelial IL-6 and IL-8 as
well as upregulation of ICAM-1. The overall result is induction of an inflamed and
thrombogenic endothelium (Hong, Eleftheriou et al. 2012).
Neutrophil extracellular traps (NETs) formation constitutes a newly described process of
extracellular microbe killing by the release of chromatin fibres by neutrophils (Brinkmann,
Reichard et al. 2004). NET formation can be triggered by incubation of neutrophils with
ANCA, but not by incubation with control IgG, and there is evidence of deposition of NETs
within areas of inflamed kidney including the glomeruli (Kessenbrock, Krumbholz et al.
2009). Recent work has demonstrated that myeloid dendritic cells (mDC) co-cultured with
NETotic PMN and subsequently used to immunise mice, resulted in induction of murine
auto-antibody production including the production of ANCA and development of
glomerulonephritis (Sangaletti, Tripodo et al. 2012).
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1.2.4.5 Mast cells
Mast cells are present throughout extravascular tissues where they have several roles, such
as the hypersensitivity reactions found in asthma involving the IgE-mediated release of
inflammatory mediators. There are additional IgE-independent mechanisms of
inflammation, involving proteases such as histamine, tryptase and chymase, stored in
cytoplasmic granules and released from mast cells (Caughey 1991). It is increasingly
recognised that mast cells may have a role in human glomerulonephritis, with the
accumulation of mast cells in the interstitium in rapidly progressive glomerulonephritis
correlating with the frequency of glomerular crescents, as well as co-localising with α-SMA
(smooth muscle actin) positive myofibroblasts, with mast cell products such as tryptase and
chymase having fibroblast mitogenic activity and increasing collagen synthesis (Toth, Toth-
Jakatics et al. 1999). Mice deficient in mast cells (KitWWv) have less crescent formation,
decreased infiltration of macrophages and T cells and decreased glomerular expression of
adhesion molecules, such as P-selectin, in a non-accelerated anti-GBM mouse model.
Reconstitution by WT mast cells, in deficient mice, restores disease to levels found in WT
mice (Timoshanko, Kitching et al. 2006). Additionally, mice that are deficient in the mouse
mast cell protease-4 (mMCP-4) (a homolog of human chymase- demonstrated to have pro-
inflammatory properties) have less severe kidney disease with respect to less proteinuria
and improved renal function as measured by serum urea as well as less glomerular
hypercellularity, tubular necrosis and a decreased mononuclear cell infiltrate in the later
stages of the accelerated anti-GBM model. mMCP-4 was demonstrated to play a role in type
1 collagen deposition within the kidney, a process associated with fibrosis (Scandiuzzi,
Beghdadi et al. 2010).
However, the evidence that mast cells promote disease in experimental glomerulonephritis
is conflicted with reports of mast cells having a protective role in disease pathogenesis. In
accelerated nephrotoxic nephritis, Kit WWv mice deficient in mast cells, had greater
glomerular injury and mortality that their WT counterparts, with increased macrophage and
T cell infiltration. (Hochegger, Siebenhaar et al. 2005). In a model of NTN in which Tregs
were adoptively transferred, Treg derived IL-9 was implicated to have a role in mast cell
recruitment to the local inflammatory lymph node which results in a immunosuppressant
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effect. However, the exact mechanisms by which mast cells have this immunosuppressive
effect in the local lymph node were not elucidated to (Eller, Wolf et al. 2011). A recent study
explores the relationship between mast cells and Treg in autoimmunity. Mast cell deficient
mice (Kit(W-sh/W-sh)) immunized with myeloperoxidase resulted in a greater production of
myeloperoxidase specific CD4+ T cells and more severe glomerular injury compared to WT
mice. Mast cell deficient mice also had a decrease in Tregs and reduced IL-10 production.
This was reversed by reconstitution of WT bone marrow. The role of mast cell enhancement
of IL-10 production was confirmed by in-vitro experiments (Gan, Summers et al. 2012).
1.2.4.6 Dendritic cells
Dendritic cells are important antigen presenting cells (APC). First identified as skin
Langerhans cells in 1868, they are now increasingly recognised as having a role in both
innate and adaptive immunity, with different phenotypes of cell now being identified
according to various cell surface markers, and different DC subsets having the ability to skew
cytokine production towards Th1 or Th2. Additionally, DC may originate from either
monocyte-derived myeloid DCs or plasmacytoid-derived DCs. Dendritic cells are present in
most tissues promoting the immune response to foreign antigens as well as tolerance to
self-antigens. They have the ability to take up and process antigens, then migrate to
lymphoid organs and present to antigen specific T-cells through extensive MHC complexes
at the cell surface with up-regulation of co-stimulatory molecules. Dendritic cells are also
able to stimulate the production of antibodies and B cell proliferation (Banchereau and
Steinman 1998). In the kidney, there is an extensive network of resident dendritic cells.
In patients with AAV, there is a decrease in circulating plasmacytoid Dc (pDC) and myeloid
DC during both active and inactive disease, with increased CD62L expression, which has a
role in DC migration to lymph nodes. This decrease in DCs may subsequently impact on
Tregs, resulting in a DC-mediated decrease in Treg suppressive function (Rimbert, Hamidou
et al. 2011). In the kidney biopsies of patients with ANCA associated glomerulonephritis,
aggregates of DCs are seen around the glomeruli and the peri-tubular interstitial
compartment, with immature DCs co-localising with T cells, although it is unknown whether
DCs here are having a pro-inflammatory effect or dampening down the immune response
(Wilde, van Paassen et al. 2009). In addition, PR3 itself has been demonstrated to induce
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dendritic cell maturation, similar to that seen with TNFα. PR3-treated dendritic cells were
also able to stimulate auto-antigen specific CD4+ T cells, which were subsequently able to
produce IFNγ, therefore influencing Th1 polarisation of CD4+ T cells (Csernok, Ai et al. 2006). 
In experimental glomerulonephritis, the role of DCs is unclear with DCs having both
protective and detrimental effects during disease. DC depletion during NTN using the
diphtheria toxin mouse model, resulted in worse disease possibly due to a reduction in
regulatory T cells (Scholz, Lukacs-Kornek et al. 2008). However, when DC are depleted in the
later stages of NTN (day 7), macrophage and T cell infiltration is decreased and there is a
reduction in crescent number. Co-culture of kidney DC, isolated from normal control kidneys
and also from nephritic mice during NTN (day 10), with CD4+T cells, DCs stimulate the
production of proinflammatory cytokines (TNF-α, IFN-γ, IL-17, IL-6) as well as IL-10 
(Hochheiser, Engel et al. 2011).
1.2.4.7 Complement
The complement system is a crucial constituent of the innate immune system. It is activated
by 3 different pathways: classical, lectin and alternative, leading to cleavage of C3 and the
generation of C3a and C3b. Their deposition on the surface of a pathogen results in its
removal by the phagocytic system or damage by the membrane attach complex. It is a
system tightly regulated by both circulating factors as well as membrane bound inhibitors.
Activation of the classical pathway is due to C1q binding to antibody- antigen complexes
while the lectin pathway is stimulated in response to carbohydrate ligands on the surface of
organisms, recognised by soluble mannose-binding lectin. Alternative pathway activation in
the plasma occurs continuously; with the hydrolysis of C3 resulting in an amplification of a
loop with the generation of more C3b. It is regulated by inhibitory molecules such as factor
H and factor I, which allow for controlled turnover of the pathway. Activation of the
complement system has long been recognised to play an important role in diseases such as
SLE. Additionally, mutations in the regulatory components are now recognised causes of
atypical haemolytic uraemic syndrome which commonly affects the kidney.
In AAV, complement was initially thought not to play a role, due to the pauci-immune
nature of the pathologic lesions. However, there is now evidence from both human and
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animal work which challenges this idea. In patients, complement activation during active
AAV may be found, with elevated levels of numerous complement components including
C3a, C5a and membrane attack complex. In addition, alternative pathway activation was
shown to be important by elevated plasma Bb levels which correlated with disease activity,
as assessed by Birmingham vasculitis activity score- (BVAS) and the number of glomerular
crescents (Gou, Yuan et al. 2012).
The role of complement was demonstrated in animal models, using the MPO-model of
vasculitis. Depletion of complement using cobra venom factor protects WT mice from
disease, despite the formation of circulating antibodies against MPO. Additionally, mice
deficient in complement C5 are also protected from disease, as are factor B deficient mice,
confirming the role of the alternative pathway in disease induction. Human TNF-α primed
neutrophils, when stimulated with MPO-ANCA or PR3-ANCA, generated C3a, which did not
occur following stimulation with control IgG (Xiao, Schreiber et al. 2007). In support of C5a
being a potential therapeutic target, inhibition of C5a, both prior to disease induction and,
more relevantly, following induction of disease, resulted in attenuation of the renal lesions
(Huugen, van Esch et al. 2007). C5a generation has been demonstrated following neutrophil
incubation with MPO-ANCA or PR3-ANCA, and animals deficient in C5a-receptor are
protected from disease in the same MPO-ANCA animal model, with C5a-receptor on
neutrophils playing an important role (Schreiber, Xiao et al. 2009).
1.2.4.8 Fc receptors
Fc-receptors (Fc-R) are present on many cells of the immune system and appear critical to
the generation of glomerulonephritis. In mice, there are several different Fc-receptors with
varying affinities for IgG; the high affinity activatory FcγRI (interacting with IgG2a) and the 
lower affinity receptors FcγRII (inhibitory) and FcγRIII (activatory and interacting with IgG1, 
IgG2a, IgG2b). Although mice deficient in FcRγ have antibody bound to the glomerular 
basement membrane in the nephrotoxic nephritis model, they are protected from nephritis
(Park, Ueda et al. 1998). To assess whether circulating or resident renal cell Fcγ expression 
contributed to the pathogenesis of nephrotoxic nephritis, bone marrow chimeras were
created which demonstrated the importance of Fcγ expression on bone marrow derived 
cells in mediating disease, with no role for Fcγ expression on resident cells (Tarzi, Davies et 
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al. 2002). To further elucidate the roles of the different activatory receptors, mice deficient
in FcγRIII or FcγRI/III were subjected to NTN, and it appeared that both FcγRI and FcγRIII play 
a role, with absence of both of these receptors necessary for significant protection from
disease (Tarzi, Davies et al. 2003).
FcγRII is a low affinity inhibitory IgG receptor. Mice that are deficient in this receptor 
demonstrate an increased incidence of glomerulonephritis compared to wild-type mice in
an anti-GBM model of renal disease. This receptor needs to be absent on a combination of
cells for an increased incidence of disease, with deletion in B cells or myeloid cells alone not
being sufficient (Sharp, Martin-Ramirez et al. 2012).
The Wistar Kyoto (WKY) rat is highly susceptible to a crescentic glomerulonephritis following
passive nephrotoxic serum transfer, unlike the Lewis strain. Genomic screening identified 2
loci which were associated with crescentic glomerulonephritis, with the activatory Fc
receptor, Fcgr3, identified as a likely candidate within one of the loci. WKY macrophages
additionally showed enhanced antibody-dependent cellular cytotoxicity, explained by the
absence of an inhibitory Fcgr3-related sequence, found in the less susceptible Lewis strain,
which allows FcR-mediated macrophage over activity. In keeping with this finding, human
studies demonstrated that reduced copy number of FCGR3B, the human orthologue of rat
Fcgr3 is a risk factor for development of lupus nephritis (Aitman, Dong et al. 2006). Another
study in humans confirmed an association between low FcgRIIIB copy number and a risk of
developing both SLE and AAV, with the impaired clearance of immune complexes implicated
in SLE and enhanced neutrophil activation in AAV suggested as proposed mechanisms
(Fanciulli, Norsworthy et al. 2007). Additionally, FcR genotypes that affect disease
phenotype have been identified, with the NA1 allele of FCGR3B having an effect on the
severity of renal disease in patients with GPA (Kelley, Monach et al. 2011).
1.2.4.9 Toll-like receptors
Toll like receptors (TLRs) are expressed on a variety of leucocytes as well as parenchymal
cells. They recognise pathogen-associated molecular patterns (PAMPs) as well as danger-
associated molecular patterns (DAMPs). TLRs can be divided into receptors on the cell
surface (TLR4, TLR2, TLR1, TLR6, TLR5), and intracellular receptors (TLR3, TLR7, TLR8, TLR9).
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Once stimulated, a signal transduction pathway is initiated with myeloid differentiation
factor 88 (MyD88) playing an important role in the subsequent transcription of several key
cytokines which have a role in the inflammatory response. TLRs have been demonstrated to
be expressed within renal tissue (Robson 2009). Mouse renal tubular cells in vitro have been
demonstrated to express TLR1,-2,-3,-4 and -6, with the upregulation of TLR2,-3 and -4 in
response to LPS. Human and murine mesangial cells have been demonstrated to express
TLR1 and TLR4, with TLR3 expression in intracellular endosomes, TLR2, TLR4 and TLR6 have
been demonstrated to be induced in mesangial cells following stimulation with TNF-α and
IFN-γ (Anders and Schlondorff 2007) 
Figure 1-5 Diagram to demonstrate the site and signalling pathways of the TLRs.
The cell surface receptors signal through MyD88 resulting in the activation of nuclear factor
κB (NKκB) as well as a MyD88 independent pathway (TRAF- TNF receptor- associated factor; 
IRAK- IL-1R-associated kinase; IRF- IRN regulatory factor, DC- dendritic cell) (Robson 2009).
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The link between infection and glomerulonephritis is well known. Components of pathogens
are able to bind to TLRs and therefore may contribute to disease by stimulating the
production of pro-inflammatory cytokines. TLR2 recognises molecular patterns associated
with both gram positive and gram negative bacteria and a synthetic TLR2 agonist
administered at the time of nephrotoxic nephritis induction , results in more severe disease
compared to mice not immunised with the TLR2 agonist (Brown, Sacks et al. 2006). In a
murine MPO model, mice were injected with MPO plus a TLR2 or TLR9 ligand, followed by a
sub-nephritic dose of sheep anti-mouse GBM 14 days later. The addition of the TLR ligands
resulted in enhanced autoimmunity and greater renal injury. A TLR9 ligand resulted in an
enhanced Th1 response with increased glomerular macrophage infiltration, and the addition
of a TLR2 ligand resulted in greater neutrophil recruitment and increased IL-17 production
(Summers, Steinmetz et al. 2011).
TLR4, the LPS receptor, is of particular interest as it has been demonstrated that
calprotectin (S100A8/A9) is one of its endogenous ligands (Vogl, Tenbrock et al. 2007)
(discussed further in section 1.4). TLR4 plays an important role in experimental
glomerulonephritis demonstrated using both the heterologous and accelerated nephrotoxic
nephritis models, the former which is characterised by early neutrophil influx following
administration of the sheep anti-mouse GBM antibody. TLR4 has been shown using in-situ
hybridization to be expressed in normal kidney on mesangial cells parietal and visceral
glomerular epithelial cells. Lipid A is a pure TLR4 agonist and was administered at the same
time as nephrotoxic serum to both WT and TLR4 deficient mice. TLR4-/- mice were
protected from neutrophil influx, despite similar glomerular sheep IgG deposition. Since
TLRs are present on both bone marrow and non-bone marrow derived cells, bone marrow
chimeras were generated and demonstrated that both these cell types contributed to
disease. Mesangial cells stimulated with LPS produce chemokines which have an important
role in neutrophil chemotaxis through TLR4 (Brown, Lock et al. 2007). Further studies have
shown that TLR4 stimulation in the autologous accelerated NTN model (pre-immunised with
sheep IgG and Complete Freund’s Adjuvant) resulted in disease exacerbation. Bone marrow
chimeras demonstrated that it is renal cell TLR4 stimulation which promotes glomerular
crescent formation and thrombosis following LPS and NTS administration (Giorgini, Brown et
al. 2010).
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In the experimental anti-MPO glomerulonephritis animal model, administration of a highly
purified LPS with MPO resulted in a synergistic effect on glomerular neutrophil influx, an
effect mediated through TLR4 (Summers, van der Veen et al. 2010). Confocal microscopy
demonstrated that TLR4 co-localised with glomerular endothelial cells, while other renal
cells types such as podocytes and possibly mesangial cells, also expressed this receptor.
Bone marrow chimeras demonstrated bone marrow derived TLR4 had a more prominent
role with respect to glomerular neutrophil recruitment, but TLR4 expression was required
on both bone marrow and tissue derived cells for maximal neutrophil recruitment. Mice
administered LPS and anti-MPO antibodies demonstrated that the increased expression of
chemokines important for neutrophil recruitment (CXCL1 and CXCL2) was partly dependent
on TLR4. (Summers, van der Veen et al. 2010).
In patients with AAV, there is increased expression of TLR2 in monocytes, and an increase in
monocyte TLR4 expression in a subset of patients. Additionally, NK cells express several TLRs
(TLR2, 4 and 9), with an increased proportion of TLR-expressing NK cells in patients
compared to healthy controls (Tadema, Abdulahad et al. 2011).
1.2.4.10Mesangial cells
Mesangial cells, along with endothelial cells and podocytes, form a network of closely
interacting cells within the glomerulus. Mesangial cells are considered to be a modified
smooth muscle cell. The cells are present within their matrix therefore providing structural
support to the glomerular tuft. Components of the matrix are able to influence mesangial
cell proliferation and activation (Schlondorff and Banas 2009). Mesangial cells have several
important roles. They have been demonstrated to play a role in the regulation of glomerular
ultrafiltration as well as efferent arteriolar resistance (Blantz, Gabbai et al. 1993). Mesangial
cells are able to sense and subsequently respond to capillary stretch and therefore to
glomerular pressure, and respond by the release of vasoactive substances, for example TGF-
β1 (Riser, Cortes et al. 1996). Finally, mesangial cells play an important role during
glomerular inflammation. They secrete MCP-1 and IL-8, as well as the monocyte attractant,
RANTES (regulated upon activation, normal T cell expressed and secreted), and express the
chemokine receptor CCR1 (Banas, Luckow et al. 1999). Mesangial cells demonstrate
increased levels of RANTES and ICAM-1 mRNA after stimulation with TNF-α or aggregated
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IgG, both of which have a role in leukocyte recruitment (Satriano, Banas et al. 1997). In-vitro
studies have demonstrated that mesangial cells are able to secrete and respond to several
cytokines, such as IL-1β, TNF-α, PDGF (Cove-Smith and Hendry 2008). Further studies have
demonstrated the importance of leukocyte derived IL-1β in crescentic glomerulonephritis in
the mouse NTN model, with the intrinsic renal cells (which are composed of mesangial cells
amongst others), being the primary target, as a lack of IL-1RI on intrinsic renal cells offers a
degree of protection against renal disease (Timoshanko, Kitching et al. 2004). Another
cytokine produced by intrinsic renal cells which plays an important role in nephrotoxic
nephritis is IL-12. IL-12 has several important effects on T cells including priming CD4 cells to
produce high quantities of IFN-γ as well as polarising T cells to a Th1 phenotype. Again, bone 
marrow chimeric mice have demonstrated the importance of intrinsic renal cell production
of IL-12 in the development of a crescentic glomerulonephritis (Timoshanko, Kitching et al.
2001), with in-vitro work demonstrating that mesangial cells are able to produce this
cytokine (Bussolati, Mariano et al. 1999).
Mesangial cells also express Fc receptors and can bind immune complexes with the
resultant production of reactive oxygen species (ROS) (Santiago, Satriano et al. 1989). MCP-
1, a mediator of monocyte/macrophage recruitment and accumulation, is also synthesised
and released in response to FcR engagement on mesangial cells (Hora, Satriano et al. 1992).
Mesangial cell lines derived from the susceptible WKY rat produce increased amounts of
MCP-1 basally and following IgG or TNF-α stimulation, when compared to the Lewis rat,
which is resistant to renal injury (Smith, Lai et al. 2007).
There is an interesting interaction between macrophages and mesangial cells during
inflammation, which is clearly of importance due to significant macrophage infiltration
during glomerulonephritis. In the rat, autocrine and macrophage-derived production of
nitric oxide has a detrimental cytotoxic effect on mesangial cells (Hruby and Beck 1997).
Additionally, activated rat macrophages isolated from either bone marrow or from inflamed
glomeruli, express inducible nitric oxide synthase, and following co-culture with mesangial
cells, result in mesangial cell apoptosis and inhibition of mitosis (Duffield, Erwig et al. 2000).
Mesangial cells also play an important role in antigen presentation to CD4 T cells. IFN-γ 
induces expression of MHC class II in rat mesangial cells, and synergises with IL-1β and
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TNFα, to induce a higher frequency of mesangial cells expressing MHC class II in a time and
concentration dependent manner (Martin, Schwinzer et al. 1989). The importance of
expression of MHC class II on intrinsic renal cells has been further demonstrated in the
mouse using MHC II deficient mice. These experiments demonstrated that crescentic
nephritis (in murine NTN) was an MHC II dependent process, with bone marrow chimeras,
showing that the absence of MHC II on intrinsic radioresistant cells, with normal levels of
MHC II on bone marrow derived cells, prevented renal injury (Li, Kurts et al. 1998).
Additionally, glomerular CD40 expression during NTN has been shown to be important in
disease, with mice deficient in non-bone marrow derived CD40 showing less T cell
glomerular infiltration, less renal injury and decreased production of cytokines such as MCP-
1 (Ruth, Kitching et al. 2003).
1.3 Animal Models
The experimental work in this thesis utilises the murine nephrotoxic nephritis (NTN) animal
model. This has the advantage of being reproducible in genetically modified mice. This has
greatly advanced the knowledge and understanding of the pathogenesis of immune-
mediated glomerulonephritis. NTN is not an animal model of vasculitis, but it is a model of
crescentic glomerulonephritis, characterised by T cell and macrophage infiltration,
glomerular thrombosis and crescent formation, similar to many forms of immune mediated
glomerulonephritis seen in humans. There is a reproducible MPO- ANCA and, more recently,
a single report of a PR3-ANCA model of vasculitis and glomerulonephritis described,
however these were not yet established in our laboratory.
1.3.1 Nephrotoxic nephritis
In 1900 W. Lindemann at the Pasteur Institute, developed a model of immune mediated
glomerulonephritis by the injection of rabbits with anti-serum which had been developed in
guinea pigs immunised with rabbit kidneys. NTN can be divided into 2 phases, the
heterologous and autologous phases. The first heterologous phase is the early phase
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occurring after injection of the nephrotoxic serum when the sheep or rabbit antibody is
‘planted’ on the glomerular basement membrane. This early response causes neutrophil
infiltration, and proteinuria, and occurs within the first few hours (Cochrane, Unanue et al.
1965). The second autologous phase is characterised by an antibody response by the host to
the heterologous globulin and occurs 5 to 6 days after the injection of nephrotoxic serum. It
was noted that if animals were immunised with serum from the species in which the
nephrotoxic serum was generated, prior to the injection with the NTS (pre-immunisation),
then the appearance of nephritis was more rapid (Kay 1940).
1.3.2 Experimental autoimmune glomerulonephritis
The injection of human or animal GBM mixed with Complete Freud’s adjuvant (CFA) into
sheep consistently results in uraemia and death of the sheep with the characteristic finding
of a severe progressive crescentic glomerulonephritis (Steblay 1962). This model has
subsequently been refined in order to model the human disease more closely by the
administration of homologous or isologous GBM antigens using the Brown-Norway strain of
rat known to be susceptible to renal disease (Pusey, Holland et al. 1991). Experimental
autoimmune glomerulonephritis (EAG) has also been replicated in several other stains of rat
demonstrating that genetic differences are an important factor in inter-strain variability of
disease, with the WKY rat demonstrating greatest susceptibility to this model with a severe
GN, pulmonary haemorrhage and renal failure 4 weeks after disease induction (Sado, Naito
et al. 1986). As with NTN, Lewis rats are resistant to disease induction. Following the
identification of the target antigen in human Goodpasture syndrome (anti-GBM disease) as
the non-collagenase domain of α3 chain of type IV collagen [α3(IV)NC1], the EAG model has
been refined further using recombinant rat [α3(IV)NC1] or synthetic peptides derived from
it. Immunisation of WKY rats with α3(IV)NC1 peptides induces glomerulonephritis and
pulmonary haemorrhage, resembling human disease (Abbate, Kalluri et al. 1998). T cells
have been demonstrated to play an important role in this model, as treatment with an anti-
CD8 antibody either during initiation of disease, or more importantly, once disease was
established, resulted in a significant reduction in disease severity demonstrated by an
improvement in renal histology (Reynolds, Norgan et al. 2002). Similarly, treatment with an
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anti-CD4 monoclonal antibody has been shown to inhibit the development of EAG in the rat
(Reynolds and Pusey 1994).
1.3.3 Vasculitis animal models
In the past 10 years there have been numerous advances in the study of ANCA associated
vasculitis due to the development of animal models which mimic the pauci-immune nature
of human disease more closely and are dependent on ANCA, in contrast with models of
crescentic GN which are mediated by immune-complex deposition. There are differences
between human and murine PR3, which in part explains the difficulties in generating a
model of PR3 vasculitis. However, there are now several models of MPO-ANCA vasculitis,
which have provided evidence for the pathogenicity of ANCA.
Xiao et al described a MPO-ANCA model in 2002. Mouse MPO was purified and
subsequently injected into mpo-/- mice at several time points, and was shown to induce
anti-MPO antibodies. Transfer of isolated splenocytes into rag2-/- (recombinase-activating
gene-2-deficient) mice lacking T and B cells, or of anti-MPO IgG isolated from the serum,
into WT or rag2-/- recipients, induced vasculitis, necrotising crescentic GN and pulmonary
haemorrhage (Xiao, Heeringa et al. 2002). To demonstrate the significance of neutrophils in
this model, a monoclonal antibody to mouse neutrophils was administered which resulted
in profound neutrophil depletion for up to 5 days. Neutrophil depletion prevented anti-MPO
induced GN. These experiments demonstrated that glomerular neutrophil influx occurred at
the areas of necrotising glomerular injury (Xiao, Heeringa et al. 2005). Another important
factor in the pathogenesis in this model is complement activation with the generation of
C5a and the subsequent priming of neutrophils (Schreiber, Xiao et al. 2009).
This model was subsequently refined by the same group. Similar to the previously described
model in which mpo-/- mice were immunised with MPO, the mice with high titres of anti-
MPO antibodies subsequently underwent lethal irradiation, but were rescued by bone
marrow transplantation with WT bone marrow, creating a chimera that produced anti-MPO
IgG and expressed MPO on its leukocytes. Mice with MPO positive bone marrow cells
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(unlike the mice transplanted with MPO-/- bone marrow) went on to develop disease,
(Schreiber, Xiao et al. 2006)
A further murine model has been described which explores the roles of both the humoral
and effector arms of the autoimmune response in the pathogenesis of AAV. WT mice were
immunised with human MPO in CFA, which resulted in the formation of anti-human MPO
antibodies, and were subsequently injected with a sub-nephritogenic dose of NTS. Using
mpo-/- mice, there was a reduction in CD4+ T cell, macrophages and neutrophil infiltration
as well as significantly less crescent formation in the glomeruli despite these mice still
generating an anti-MPO antibody response. CD4+ T cell depletion in WT mice also resulted
in less glomerular injury despite an equivalent antibody response to MPO. In this model, B-
cell deficient mice (μMT-/-) do not produce MPO-ANCA yet still develop a crescentic GN
with a similar infiltration of CD4+ T cells, macrophages and neutrophils within the
glomerulus. In this model, glomerular MPO is thought to act as a planted antigen which is
then able to recruit effector cells (Ruth, Kitching et al. 2006). This model has not yet been
replicated by other groups.
Rat models have also been described. The experimental autoimmune vasculitis model
described a reliable, reproducible model of MPO-ANCA vasculitis in the susceptible WKY rat.
Rats were immunised with human MPO in CFA, with development of anti-MPO antibodies.
With increasing concentrations of human MPO, there was greater amount of pauci-immune
renal injury as well as lung haemorrhage. The addition of further adjuvants, such as LPS or
pertussis, resulted in a more consistent disease phenotype, although other rat strains still
remained resistant to disease induction despite the generation of an antibody response to
human MPO (Little, Smyth et al. 2009). These models do have their limitations. The murine
model replies on the immunisation of mpo-/- mice with MPO, an alloantigen for mice which
are naive to MPO. Additionally, the rat model relies on the use of adjuvants to reproduce a
consistent crescentic glomerulonephritis. Therefore these models do not replicate the
spontaneous breaking of tolerance, and induction of autoimmunity, which occurs in the
human disease.
Until recently, there was no model of PR3-ANCA vasculitis due to numerous differences
between both PR3 and anti-PR3 IgG in the mouse and human, and therefore there was a
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lack of experimental evidence confirming the pathogenicity of PR3-ANCA. A PR3-ANCA
model has now been developed which is based on generating mice with a humanised
immune system. This used NOD-scid-IL2Rγ-/- mice which lack native T, B and NK cells and
the IL2 receptor. Following irradiation the mice were transplanted with human stem cells.
The mice were then injected with LPS to mobilise mature neutrophils and monocytes from
the bone marrow and injected with human PR3-ANCA, while a subset of mice were injected
with control human IgG. Mice that had been injected with human PR3-ANCA subsequently
showed evidence of a pauci-immune GN, as well as evidence of pulmonary haemorrhage
with patchy areas of haemorrhage and leucocyte recruitment. Although the extent of renal
involvement in this model was mild, this model was the first to describe the pathogenicity of
human PR3-ANCA in an animal model (Little, Al-Ani et al. 2012). However, an animal model
replicating the human granulomatous disease seen in AAV has yet to be developed.
1.4 Calprotectin, mrp8/14, S100A8/A9
My thesis concentrates on a protein complex called calprotectin. This is a heterodimer
composed of S100A8, also known as myeloid-related protein (mrp)-8 or calgranulin A, and
S100A9, also known as mrp-14 or calgranulin B. The heterodimer is known as calprotectin as
well as S100A8/A9 and mrp8/14. S100A8 and S100A9 preferentially form a heterodimer.
1.4.1 Introduction
The S100 proteins represent a family of proteins which obtained its name following isolation
from bovine brain upon fractionation with 100% ammonium sulphate (Moore 1965). In
humans, 25 members of the S100 family have been identified of which most form
homodimers or heterodimers (Manolakis, Kapsoritakis et al. 2011). This family of S100
proteins are only found in vertebrates. S100A8 and S100A9, like the majority of S100 family
of proteins, are EF-hand calcium binding proteins. The EF-hand motif is a helix-loop-helix
structure, which typically undergoes a conformational change upon the central loop binding
to Ca2+ (Yap, Ames et al. 1999). S100A8 and S100A9, form non-covalently associated
complexes and, in the human, calcium induced tetramer formation (Vogl, Roth et al. 1999).
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As well as the ability to bind calcium, this heterodimeric complex can also bind zinc, with
anti-microbial activity (Sohnle, Hunter et al. 2000).
These proteins are expressed in cells of myeloid origin, such as neutrophils, monocytes and
early differentiated macrophages (Lagasse and Clerc 1988). They are absent from normal
tissue macrophages (Odink, Cerletti et al. 1987). They have been termed damage (or
danger) associated molecular patterns (DAMPs) and are released from phagocytes at the
site of inflammation and in response to cell damage. Recognition of damage associated
molecular patterns (DAMPs) by pattern recognition receptors (PRR) is a crucial part of
innate immunity providing host defence against invading microorganisms. The heterodimer
constitutes 45% of neutrophil cytosolic proteins and about 1% in monocytes. Both S100A8
and S100A9 are similar to many of the other S100 proteins with respect to their coding
pattern. The genes consist of 3 exons with 1 intron on chromosome 1q12-q21. Within the
human bone marrow, the neutrophil precursor, the metamyelocyte, as well as early
monocytes express the heterodimer. Since resident tissue macrophages do not express this
complex, the complex is lost as monocytes differentiate into more mature macrophages
except under inflammatory conditions (Hessian, Edgeworth et al. 1993). In human cells,
S100A9 gets upregulated during monocyte maturation, expression of which correlated with
expression of CD11b and CD14. In the development of neutrophils, S100A9 is detected in
CD15+ cells (Goebeler, Roth et al. 1993). Both S100A8 and S100A9 mRNA in human
monocytes is upregulated by TNF-α and IL-1β (Kido, Hayashi et al. 2005). Additionally, cell
surface expression on monocytes has been shown to be increased by LPS and IFN-γ (Zwadlo, 
Schlegel et al. 1986). Monocytes which are positive for S100A8/A9 release substantial
amounts of IL-1 and TNF-α (Bhardwaj, Zotz et al. 1992). In a study of human monocytes and
the Th2 cytokines, the addition of IL-4 and IL-10 to stimulated monocytes resulted in
decreased secretion of S100A8/A9, as detected by ELISA (Lugering, Kucharzik et al. 1997).
A study investigated the expression of these 2 proteins during murine haematopoiesis using
a cloning technique. Cloning demonstrated a protein homology of 59% with the human
counterpart, with the greatest homology between mouse and human located in the calcium
binding regions, which is known to be conserved across species. In the murine spleen, the
expression of mrp-positive cells correlates with markers of myeloid cells and are
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predominantly located in the red pulp and marginal areas of the spleen, with the mrp-
positive cells in the spleen and peripheral blood being myelomonocytic, monocytes and
neutrophils. This study also demonstrated that the majority of non-activated tissue
macrophages do not express this complex. During an animal model of peritoneal
inflammation, high levels of S100A8 and S100A9 proteins in peritoneal neutrophils and
monocytes were observed, which disappeared 4 days later despite the presence of
macrophages (Lagasse and Weissman 1992). There are no differences between murine
S100A9 and human S100A9 with respect to cellular localisation, quantity expression or its
interaction with S100A8 (Nacken, Sopalla et al. 2000). Targeted disruption of the mrp8
(S100A8) gene results in embryo resorption by day 9.5 of development with infiltration of
maternal leucocytes and resorption, and is therefore an embryologically lethal mutation
(Passey, Williams et al. 1999). However, mrp-14-/- mice live a normal life span with no
obvious abnormalities. The neutrophils in mrp-14 null mice express mrp-8 mRNA but lack
the mrp-8 protein, agreeing with the human data that mrp-8 is unstable in the absence of
mrp-14. The loss of these mrp proteins results in a decrease in neutrophil density but not in
adhesion molecules, cell size or granularity. Additionally, there were no differences in
apoptosis or cell death in neutrophils and monocytes of WT and mrp-14 null mice in
response to calcium mobilisers, or to cytokines known to induce apoptosis and cell death.
Lastly, there was no difference between WT and mrp-14 null mice in response to
thioglycolate-induced peritonitis (Hobbs, May et al. 2003).
This complex of S100A8/A9 has additionally been demonstrated to be induced in wound
keratinocytes and to be expressed during the hyperproliferative phase of cutaneous wound
repair (Thorey, Roth et al. 2001). Human and murine S100A8 and S100A9 have also been
detected in osteoclasts by immunohistochemistry (Zreiqat, Howlett et al. 2007).
Additionally, S100A8 has been demonstrated to be induced in response to pro-inflammatory
cytokines in murine microvascular cells, but there is no evidence of its binding partner
S100A9 (mrp14) being induced (Yen, Harrison et al. 1997). Similarly, S100A8 mRNA is
induced in murine fibroblasts following stimulation with fibroblast growth factor-2 (FGF-2),
without detection of S100A9 mRNA. IL-1β also had the capacity to induce S100A8 in a
primary fibroblast cell line (3T3) either alone or in conjunction with FGF-2 (Rahimi, Hsu et al.
2005). Additionally, an epithelial cell line has been demonstrated to be able to express this
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complex of S100A8/A9, which was able to bind to keratin intermediate filaments in a
calcium dependent manner (Goebeler, Roth et al. 1995). Dendritic cells are discussed in
section 1.4.4 Isolated murine endothelial cells following treatment with TNF-α, upregulated
S100A8 mRNA. However, secreted S100A8/A9 was not detectable, suggesting that the
secretion must be significantly less than that of myeloid cells (Averill, Barnhart et al. 2011).
Recent data demonstrated that a transcription factor, Kruppel-like factor-5 (KLF5) mainly
expressed in renal collecting duct epithelial cells, upregulated S100A8 and S100A9 and
induced monocyte recruitment in the unilateral ureteral obstruction (UUO) model. Direct
injection of these proteins into the kidney, resulted in recruitment of inflammatory
monocytes which subsequently developed into an M1 type of macrophage with the
promotion of renal injury and inflammation (Fujiu, Manabe et al. 2011).
1.4.1.1 Intracellular roles of S100A8/A9
S100A8/A9 has a significant role in the transendothelial migration of phagocytes. In human
monocytes, S100A8/A9 translocates from the cytoplasm to the cytoskeleton and the
membrane in the presence of calcium, and co-localises with vimentin and microtubules and
resulting in tubulin polymerisation and stabilisation (Roth, Burwinkel et al. 1993). Activation
of p38 MAPK causes phosphorylation of S100A9 at site threonine 113 and in the presence of
an elevation in intracellular calcium a conformational change in S100A9 occurs. As a result
of this phosphorylation of S100A9, the complex no longer stabilises the microtubules and
results in an inhibition of tubulin polymerisation. Small GTPases are activated and
transmigration is facilitated. Mrp14-/- granulocytes demonstrate a decreased activation of
small GTPases (Rac1 and Cdc42) which have an important role in cellular migration
processes and actin metabolism. In a chamber assay, activation of p38 MAPK results in an
increase in granulocyte transmigration whereas mrp14-/- granulocytes do not demonstrate
an acceleration of migration compared to WT granulocytes (Vogl, Ludwig et al. 2004).
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Figure 1-6 Effect of mrp14 on transmigration
The complex of mrp8/14 binds to and promotes the stabilisation of microtubules in
phagocytes at rest. In the presence of 2 independent signals (activation of p38 MAKP and
increase in intracellular calcium) there is a conformational change in the complex which
allows phosphorylation of mrp14 (S100A9) and the resultant dissociation of the
microtubules (Vogl, Ludwig et al. 2004)
S100A8/A9 may also have a role in phagocyte NADPH oxidase activity, an enzyme complex
which results in the production of the superoxide anion. S100A8/A9 binds neutrophil
arachidonoic (AA) acid in a calcium dependent manner and facilitates NADPH oxidase
activation, potentially by transferring AA to the NADPH complex (Kerkhoff, Nacken et al.
2005).
1.4.1.2 Extracellular roles of S100A8/A9
The identification of elevated plasma levels of S00A8/A9 (mrp8/14) lead to the conclusion
that this complex may have a role in the inflammatory process (Roth, Teigelkamp et al.
1992). The mechanism by which this complex is secreted and released by phagocytes has
been investigated. Human monocytes release this complex in an energy dependent manner
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involving protein kinase C activation. The secretory pathway is independent of the
endoplasmic reticulum and Golgi apparatus and is dependent upon an intact microtubule
network as secretion was inhibited by microtubule-depolymerisation agents (Rammes, Roth
et al. 1997).
1.4.1.2.1 Phagocyte chemoattraction and activation
Murine S100A8 is a potent chemoattractant for neutrophils (Lackmann, Cornish et al. 1992).
Human in-vitro work has demonstrated that S100A9 can induce neutrophil adhesion to
fibrinogen by increasing the affinity of the integrin, Mac-1 (CD11b), on neutrophils.
However, the human heterodimer of S100A8/A9 was unable to induce a similar effect to
that of S100A9 (Newton and Hogg 1998), suggesting that differences in effector function
exist between the individual proteins of the heterodimer as well as differences between
species. However, these differences may be attributed to improper folding of the proteins
or inactivation during the purification process. In a separate study, recombinant human
S100A8, S100A9 and S100A8/A9, were all chemotactic for neutrophils and induced
upregulation of Mac-1 (CD11b) and stimulated neutrophil adhesion to fibrinogen. Injection
of these proteins into the murine air pouch, resulted in leukocyte accumulation and a rapid
collection of neutrophils confirming that all these proteins are potent inducers of neutrophil
chemotaxis, adhesion and migration (Ryckman, Vandal et al. 2003). Corroborating these
findings, murine mrp14-/- neutrophils exhibit a reduction in IL-8 mediated upregulation of
CD11b, and demonstrate a decreased ability to migrate through an endothelial cell
monolayer in response to the chemotactic stimuli of IL-8. However, this did not translate to
the in vivo setting as mrp14-/- and wild-type leukocytes showed similar responses following
induction of thioglycolate peritonitis (Manitz, Horst et al. 2003). With regards to leukocyte
activation, recombinant human S100A9 is able to induce neutrophil degranulation and
induce the release of granule proteins such as MMP-9, contributing to tissue damage
following neutrophil degranulation (Simard, Girard et al. 2010). Additionally, S100A8/A9
secretion, following neutrophil programmed cell death (PCD), partially protects surrounding
neutrophils from PCD by having an anti-apoptotic effect. Blocking TLR4 partially abrogated
the S100A8/A9 survival effect, as well as blocking CD11b/CD18 (Atallah, Krispin et al. 2012).
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1.4.1.2.2 Effect on the endothelium
S100A8/A9 has an important role mediating the interaction between the myeloid cells and
the endothelium in addition to its role described previously in which it facilitates migration
of the myeloid cells. The heterodimer has the capacity to be rapidly released from
monocytes as they move from the circulation into tissues without being re-synthesised.
Indeed, maximal secretion of S100A8/A9 follows an interaction between monocytes and
endothelial cells and facilitates monocyte transmigration through both microvascular and
macrovascular endothelial cells, mediated by CD11b (Mac-1) expression and activation, as
well as an increase in monocyte surface ICAM-1 (Eue, Pietz et al. 2000). Endothelium may
stain positive for the S100A8/A9 complex, in association with the presence of a myeloid cell
or following myeloid cell traffic, despite lacking the capacity to induce expression of the
complex (Hogg, Allen et al. 1989). Despite a murine endothelial cell line expressing S100A8
(mrp-8) under certain conditions (Yen, Harrison et al. 1997), the human endothelial cell line
(HMEC-1) has been shown not to produce this complex, but is able to bind S100A8/A9 via a
heparin sulphate moiety (Robinson, Tessier et al. 2002), and via carboxylated glycans
expressed on endothelial cells (Srikrishna, Panneerselvam et al. 2001). The secretion of the
heterodimer, once myeloid cells comes into contact with endothelial cells, is tightly
controlled, requiring TNF priming of the endothelium allowing the release of S100A8/A9 to
occur when myeloid cells adhere to inflamed endothelium (Frosch, Strey et al. 2000).
Peripheral blood monocytes are known to consist of a heterogeneous population of cells.
Those monocytes positive for intracellular S100A8/A9 demonstrated increased spontaneous
migration rates through a monolayer of both micro- and macrovascular human endothelial
cells compared to monocytes that were negative for S100A8/A9. The migration of
monocytes positive for the heterodimer was dependent on ICAM-1 expression on the
endothelial cells (Eue, Pietz et al. 2000).
Experiments incubating S100A8/A9, isolated from human granulocytes, with HMEC-1
further delineated the response of the endothelium to binding of the heterodimer. Genes
involved with platelet aggregation (Thombospondin-1), pro-inflammatory cytokines and cell
adhesion molecules were upregulated while genes involved with growth, differentiation and
endothelial cell monolayer integrity were down-regulated. Specifically, S100A8/A9
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treatment of HMEC monolayers resulted in secretion of IL-8, as well as up-regulation of
ICAM-1 and disrupted intracellular endothelial cell boundaries (Viemann, Strey et al. 2005).
Additionally, S100A8/A9 was able to induce apoptosis and necrosis of endothelial cells, with
induction of caspase-3 and caspase -9 as well as inducing caspase-independent cell death
(Viemann, Barczyk et al. 2007).
In an experimental mechanical arterial injury model, mice deficient in mrp14-/-
demonstrated decreased macrophage and neutrophil infiltration, as well as reduced vessel
proliferation and neointimal formation. There were additionally fewer vasculitic lesions
following the local Scwartzman-like reaction induced by injection of LPS and cytokines. In-
vitro experiments demonstrated important differences between WT and mrp14-/-
macrophages in response to LPS, with mrp14-/- macrophages producing less TNF-α, MCP-1,
IL-1β and IL-12 by ELISA. Lastly, human evidence was provided by demonstrating abundant
expression of mrp8/14 associated with CD68 positive macrophages within human carotid
atheroma, unlike normal arteries without detectable expression of mrp8/14 (Croce, Gao et
al. 2009).
Therefore, S100A8/A9 results in several pro-inflammatory and thrombogenic effects on the
endothelium, and induces endothelial cell apoptosis and necrosis; Features which are
characteristic of small vessel vasculitis and which may implicate a role for S100A8/A9 in the
pathogenesis of vasculitis.
1.4.1.2.3 Other paracrine effects
In-vitro experiments have shown that S100A8/A9 (isolated from rat) is able to inhibit growth
of both mouse embryonic as well as human dermal fibroblasts and had the ability to induce
their apoptosis. The apoptosis effect was observed to occur very slowly. This data therefore
suggests that S100A8/A9 may suppress the proliferation of fibroblasts (Yui, Mikami et al.
1997).
1.4.2 Endogenous TLR4 ligand and RAGE
Bone marrow cells isolated from mrp14-/- mice, demonstrate a reduced response to LPS
stimulation despite similar expression levels of the LPS receptor, TLR4, with reduced
activation of the transcription factor NF-κB and decreased induction of TNF-α, an effect 
reversed by the extracellular administration of S100A8/A9. Phagocytes from a mouse
expressing a non-functional TLR4 demonstrate a similar lack of response to both LPS and
S100A8, demonstrating that S100A8 is an endogenous ligand of TLR4, and its binding results
in activation of NF-κB and subsequent gene expression. S100A8/A9 acts as an amplification 
signal during the inflammatory response through its actions on TLR4, as demonstrated by
the LPS induced septic shock model in which mrp14-/- mice, were found to have a
significantly longer survival than WT mice (Vogl, Tenbrock et al. 2007).
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In-vitro work using human CD14 cells has demonstrated that S100A9 (mrp-14) is able to
stimulate the transcription factor NF-κB in a dose dependent manner with the resultant 
production of pro-inflammatory cytokines such as IL-1β, TNF-α, IL-6, IL-8 and IL-10, though
the effect was less potent than that of LPS. This pro-inflammatory effect was then
demonstrated in murine TLR4-/- bone marrow derived dendritic cells to be dependent on
TLR4 (Riva, Kallberg et al. 2012). In addition, S100A8/A9, acting through TLR4, can
upregulate transcription factors associated with IL-17 production, as demonstrated in a
CD40L-overexpressing murine model of autoimmunity which is characterised by CD8 T cell-
activation and IL-17 production (Loser, Vogl et al. 2010).
RAGE (receptor for advanced glycation end-products) is a multi-ligand cell surface receptor
that belongs to the immunoglobulin superfamily. Known ligands include advanced glycation
end-products as well as some members of the S100 family such as S100A12 and S100B (Yan,
Ramasamy et al. 2003), while recent evidence confirmed that the heterodimer, S100A8/A9
is another RAGE ligand. In an animal model of post-ischaemic heart failure, hypoxia results
in the stimulation of fibroblasts and macrophages with S100A8/A9 induction and the
stimulation of pro-inflammatory cytokines. This effect was abrogated after knock-down of
either the heterodimer or RAGE. Administration of recombinant S100A8/A9 resulted in
reduced cardiac function, and this effect was mediated through RAGE (Volz, Laohachewin et
al. 2012). This is supported by work using a prostate cancer cell line, in which recombinant
S100A8/A9 co-localised with RAGE (Hermani, De Servi et al. 2006), and over-expression of
S100A8/A9 in cardiac tissue resulted in RAGE dependent effects (Boyd, Kan et al. 2008).
Finally, human umbilical vein endothelial cells (HUVEC) incubated with advanced glycation
end-products (AGE) followed by stimulation with S100A8/A9; increased production of IL-6,
ICAM-1 and s-VCAM-1. This increase was not seen in cells that were not pre-incubated with
AGE prior to stimulation with S100A8/A9 (Ehlermann, Eggers et al. 2006).
Human S100A9 has been identified as the target of quinoline-3-carboxamides (referred to as
Q compounds), which have been used in the treatment of autoimmune diseases, such as
multiple sclerosis. S100A9 binding to RAGE, is dependent on both calcium ions and zinc, and
was competed for by the Q compounds. Similarly, a dose-dependent inhibition of S100A9
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interaction with TLR4 occurred in the presence of the Q compound, however, Q compound
binding to the heterodimer was poor compared to that of S100A9 (Bjork, Bjork et al. 2009).
1.4.3 Anti-inflammatory action of S100A8 and S100A9
There are data demonstrating the anti-inflammatory and protective effects of these S100
proteins with their role in leukocyte recruitment and chemotaxis being vital in the host
defence to infection (Lim, Raftery et al. 2011). Murine S100A8 in macrophages, and human
S100A8 and S100A9 in monocytes and macrophages have been shown to be dependent on
IL-10- an important anti-inflammatory cytokine, although murine S100A8 has also shown to
be upregulated by LPS, IFN-γ and TNF-α (Hu, Harrison et al. 1996; Xu and Geczy 2000; Xu, 
Yen et al. 2001). Additionally, murine S100A8 was upregulated by a combination of LPS and
glucocorticoids, while glucocorticoids alone had no effect with the authors noting that
S100A8 may demonstrate additional anti-inflammatory roles independent of the roles of the
heterodimer, S100A8/A9. (Hsu, Passey et al. 2005).
Dendritic cells have been demonstrated to express S100A8/A9 under inflammatory
conditions in-vitro when stimulated with LPS and IFN-γ, to an even greater degree than that 
seen in macrophages. However, S100A9-/- DC when stimulated with LPS and IFNγ 
demonstrate increased secretion of the pro-inflammatory cytokine IL12p40 and
upregulation of iNOS mRNA, in contrast to LPS stimulated S100A9-/- macrophages. DCs from
S100A9-/- demonstrate this increased pro-inflammatory response as well as an increased
ability to induce T-cell proliferation. S100A9 deficiency in DC resulted in an increase in
inflammation, therefore demonstrating that in diseases in which DCs play an important role,
a deficiency of S100A9 may actually increase inflammation (Averill, Barnhart et al. 2011).
Interestingly, it has been demonstrated that the anti-inflammatory cytokine, IL-10, up-
regulates S100A8 and S100A9 in human dendritic cells, as demonstrated using real-time PCR
(Kumar, Steinkasserer et al. 2003). Additionally, S100A9 has a role in the inhibition of the
important co-stimulatory molecules, CD80 and CD86, and its deficiency results in
augmented CD80/86 expression on dendritic cells, with a resultant increase in IFN-γ 
production and T-cell proliferation (Shimizu, Libby et al. 2011). This effect resulted in
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diminished cardiac allograft survival in mrp14-/- mice with augmented infiltration and
accumulation of an inflammatory cell infiltrate consisting of CD8, CD4 T cells and
macrophages, compared to wild-type counterparts. Finally, both S100A8 and S100A9 are
known to undergo oxidative modifications, which may then inhibit certain (pro-
inflammatory) activities of these proteins. S-glutathionylation of S100A8 suppresses
neutrophil adhesion to fibronectin, and thus modulation of their transmigration. S-
glutathionylation did not have a similar effect on S100A9 and the effect on the more
physiologically relevant heterodimer was not tested (Lim, Raftery et al. 2011). S100A8 can
additionally undergo S-nitrosylation, which results in inhibition of mast cell activation (Lim,
Raftery et al. 2008).
1.4.4 Calprotectin and infection
Targeting S100A9 may result in decreased protection to infection. Calprotectin has been
identified to be a major component of NETS (neutrophil extracellular traps). NETs are
composed of chromatin and granule proteins, and are released from the neutrophil during a
novel cell death mechanism (NETosis). In response to fungal infection (C.albicans,
C.neoformans), S100A8/A9 has been demonstrated to be a major component of NETs. Loss
of calprotectin in NETs resulted in a loss of the anti-fungal activity of NETs (Urban, Ermert et
al. 2009). During murine Klebsiella pneumonia infection, levels of mrp8/14 increase in the
bronchoalveolar lavage fluid, and mice deficient in mrp14-/- demonstrated a greater degree
of bacterial dissemination than WT animals. However, mrp14 deficient mice did not
demonstrate a difference in neutrophil lung recruitment during Klebsiella infection.
Neutrophils and macrophages isolated from mrp14-/- mice had a reduction in the ability to
phagocytose Klebsiella. The addition of the heterodimer to a bacterial Klebsiella culture
resulted in growth inhibition, and confirmed the function of NETS in controlling infection
was partly dependent on the heterodimer (Achouiti, Vogl et al. 2012). Similarly, a further in-
vitro study demonstrated S100A9 stimulated neutrophil phagocytosis (Simard, Simon et al.
2011).
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1.4.5 Calprotectin in disease
There is now evidence from both clinical studies and animal models that the heterodimer
has a role both as a marker of disease and also disease pathogenesis.
1.4.5.1 Juvenile Idiopathic arthritis
S100A8/A9 serum levels in juvenile idiopathic arthritis (JIA) were measured during a trial of
methotrexate (MTX) therapy and investigated as a potential predictor of disease relapse. In
this trial patients were treated with MTX for either 6 or 12 months and S100A8/A9 levels
were obtained during disease remission. Those patients who subsequently had a disease
flare, (defined by active arthritis/ active systemic symptoms), demonstrated a significantly
higher level of S100A8/A9 without other more traditional markers of disease activity (Foell,
Wulffraat et al. 2010). S100A8/A9 levels have been shown to correlate with response to
treatment and disease activity in JIA, with significant increases during disease flares, and a
level of >740ng/ml during remission having a high sensitivity and specificity at predicting
future disease flares (Holzinger, Frosch et al. 2012), suggesting that the heterodimer may
have some value in indicating subclinical inflammation.
In a small subset of patients, treatment with anakinra (IL-1Ra) resulted in a significant
decrease in S100A8/A9 serum levels; with in-vitro work demonstrating S100A9 had the
ability to induce IL-1β secretion in human monocytes in a dose dependent manner. Patients’
serum had the ability to induce monocyte IL-1β secretion, an effect which was blocked by
the addition of anti-S100A9 antibodies. This suggests that S100A8/A9 and IL-1β are in a
positive amplifying feedback loop (Frosch, Ahlmann et al. 2009).
Patients with cryopyrin-associated periodic syndromes (CAPS) have significantly elevated
levels of S100A8/A9. Treatment with anti-IL-1 therapies resulted in a decrease in levels
although they did not all normalise, suggesting subclinical phagocyte activation in some,
with the exception being those patients treated with canakinumab (Wittkowski,
Kuemmerle-Deschner et al. 2011).
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1.4.5.2 Renal Inflammation
The presence of glomerular macrophages containing S100A8/A9 has previously been
described, in a range of renal pathologies, including a small number of patients with
proliferative glomerulonephritis. Overall, those patients with more severe renal injury, such
as with SLE or endocapillary glomerulonephritis (including 4 patients with GPA)
demonstrated a greater population of S100A8/A9 positive glomerular macrophages
compared with patients with a diagnosis of focal segmental glomerulosclerosis or minimal
change disease suggesting that CD68+ S100A8/A9+ glomerular macrophages represent a
pro-inflammatory macrophage, which the authors presume had been recruited from blood
monocytes (Frosch, Vogl et al. 2004).
S100A8/A9+ macrophages have also been noted in ANCA associated GN, with almost all
glomerular macrophages expressing this complex as well as markers of proliferation,
whereas far fewer macrophages expressed this complex in cryoglobulinemic vasculitis
despite macrophage infiltration in the kidney (Rastaldi, Ferrario et al. 2000). Urinary
calprotectin (S100A8/A9) has been used to differentiate between pre-renal and intrinsic
renal failure with significantly higher levels found in the urine of cases with intrinsic acute
kidney injury (Heller, Frischmann et al. 2011).
Similar to GN, acute renal allograft rejection was associated with the presence of S100A8/A9
positive macrophages. However, chronic allograft rejection was characterised by
macrophages generally being negative for the heterodimer (Goebeler, Roth et al. 1994). In a
study of patients with biopsy proven allograft rejection, the presence of S100A8 and S100A9
(mRNA, as well as protein expression) was increased in patients who went on to have stable
graft function compared to those patient whose graft dysfunction progressed and a
diagnosis of chronic allograft nephropathy was made (Eikmans, Roos-van Groningen et al.
2005).
As well as being a histological marker, serum levels of S100A8/A9 have also been
investigated during episodes of acute renal transplant rejection. S100A8/A9 levels were
significantly elevated in a group of patients with rejection, in a pilot and a validation study,
while treatment with pulsed intravenous methylprednisolone resulted in a decrease in
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serum levels. In patients who experienced graft rejection within the first 4 weeks, a cut-off
level of 4.2µg/mL was sensitive and specific with a high predictive value for graft rejection.
Factors such as delayed graft function and ischemic time did not affect serum levels,
however, there was a correlation between HLA mismatches and S100A8/A9 levels
(Burkhardt, Radespiel-Troger et al. 2001).
1.4.5.3 Arthritis
Several studies, both clinical and experimental, have elucidated a role for the heterodimer
in disease pathogenesis, in which macrophages have been shown to play an important role
in joint inflammation. Patients with rheumatoid arthritis (RA) have higher serum and
synovial fluid levels of S100A8/A9 than healthy controls and patients with osteoarthritis
(OA)(mean values in the serum RA 38900µg/ml, synovial fluid 54.8µg/ml), with high
expression of the heterodimer in CD68 positive macrophages infiltrating the synovial tissue
(Sunahori, Yamamura et al. 2006). In addition, serum levels of S100A8/A9 strongly
correlated with musculoskeletal ultrasound appearances in patients with RA, with sensitive
decreases in the serum levels after the initiation of treatment (Hammer, Fagerhol et al.
2011).
In the antigen induced arthritis murine model, there is abundant expression of the complex.
Mice deficient in mrp14-/- demonstrated the same cellular and humoral response as WT
mice in this model; however, there was decreased joint inflammation in the mrp14-/- mice.
Injection of S100A8 resulted in upregulation of pro-inflammatory cytokines, such as IL-1, IL-6
and TNF-α. S100A8/A9 had a role in cartilage destruction by mediating induction of different
matrix metalloproteinases (MMPs)(particularly MMP 3,9 and 13), enzymes known to
mediate cartilage destruction (van Lent, Grevers et al. 2008). Furthermore, following intra-
articular injection of S100A8 into the normal knee joint of mice, there is upregulation of
activating FcγR (FcγRI, FcγRIV). Similar, although less potent effects were observed following 
injection of S100A8/A9. This effect was abrogated in TLR4-/- macrophages (van Lent,
Grevers et al. 2010), again demonstrating the importance of the interaction between S100
proteins and TLR4.
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In addition, S100A8 has been shown to mediate osteoclast formation and increase bone
resorption. Osteoclasts derived from TLR4-/- bone marrow show a significantly reduced
bone resorption capacity after stimulation with S100A8 compared to wild-type osteoclasts
(Grevers, de Vries et al. 2011).
S100A8/A9 is also released by neutrophils following incubation with monosodium urate
monohydrate (MSUM) crystals. This effect was blocked by antibodies directed against
CD11b and CD16, as well as by a src-kinase inhibitor, and a combination of syk and PI-3-
kinase-inhibitors, demonstrating that src, syk as well as PI-3K are involved in the release of
S100A8/A9 following neutrophil stimulation with MSUM crystals (Ryckman, Gilbert et al.
2004).
The murine LPS-collagen-induced arthritis model (LPS-CIA) has also been utilised to
investigate a role of S100A9 and S100A8/A9 in the pathogenesis of joint destruction. Mice
treated with an antibody to S100A9 demonstrated lower serum levels of S100A8/A9 as well
as decreased severity of arthritis, decreased bone destruction and a reduction in
monocyte/granulocyte infiltration. The histological results were similar to those seen in
mice treated with anti-TNF-α antibody therapy at the time of disease induction. Treatment
with an antibody to S100A9 also resulted in decreased IL-6 and TNF-α detected by western
blotting at the site of inflammation (Cesaro, Anceriz et al. 2012).
Similar results have been obtained in human and animal studies into osteoarthritis. In the
murine collagenase-induced OA model, synovial S100A8 and S100A9 mRNA is strongly
upregulated with similar results in synovial biopsy samples from patients with early OA.
Patients who subsequently progressed with respect to joint destruction, had higher serum
levels of S100A8/A9 that those patients who did not progress (487ng/ml v 581ng/ml), again
suggesting that the complex may be of use in predicting which patients may progress (van
Lent, Blom et al. 2012). A possible mechanism for the increased chondrocyte damage in
patients was further explored and, agreeing with previous studies, S100A8 and S100A9
upregulated pro-inflammatory mediators (MMP1, MMP3, MMP9, MMP13, IL-6, IL-8 and
MCP-1 mRNA measured by quantitative PCR). These effects were abrogated by TLR4
blockade (Schelbergen, Blom et al. 2012).
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1.4.5.4 Cardiovascular disease
There is now some evidence from both human and animal data that S100A8/A9 may also
have a role in cardiovascular disease and cardiac dysfunction. LPS has been demonstrated to
induce expression of S100A8/A9 in a cardiomyocyte cell line (HL-1). Following transfection
with plasmids encoding S100A8, S100A9 and S100A8/A9, the cardiomyocyte cell line
demonstrated a decrease in calcium flux. In mice, there is a decrease in cardiac contractility
following delivery of the S100 proteins, an effect abrogated by the addition of blocking
antibodies to RAGE (Boyd, Kan et al. 2008). However, there are conflicting reports, with a rat
model of ischaemia showing no induction of S100A8 or S100A9 in cardiac myocytes, and
data suggesting that infiltrating neutrophils are the source of the heterodimer (Du, Yang et
al. 2012).
A patient study demonstrated that S100A8/A9 plasma concentration was independently
associated with the risk of recurrent cardiovascular events in a population of patients
presenting with an acute coronary syndrome (Morrow, Wang et al. 2008). However, a study
confirmed that in patients presenting with chest pain, measuring this heterodimer did not
aid diagnosing a cardiac event due to its low sensitivity and poor positive predictive value
(Vora, Bonaca et al. 2012). However, a higher level of S100A8/A9 was observed in non-
survivors compared to survivors of acute myocardial infarction (Schaub, Reichlin et al.
2012). Elevated S100A8/A9 levels are also observed in diabetic patients with confirmed
coronary artery disease, and were higher than those non-diabetic patients with coronary
heart disease (Peng, Jian et al. 2011).
1.4.5.5 Systemic lupus erythematosus
Patients with SLE have significantly higher serum levels of S100A8/A9 than healthy controls
(mean value 1412ng/ml versus 339ng/ml), with higher levels in those patients with disease
flares compared to those patients in disease remission (Soyfoo, Roth et al. 2009).
S100A8/A9 has also been detected on the cell surface of several different populations of cell
subsets in patients with SLE. In patients with active disease, there was increased cell surface
expression detected on CD+16 monocytes, myeloid dendritic cells (mDC), plasmacytoid
dendritic cells (pDC) and neutrophils compared to patients with inactive disease. There was
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no difference between those patients with inactive disease and healthy controls, unlike
serum levels in which a significant difference was detected. Not all of these cell types
actually produced S100A8/A9, as confirmed by intracellular detection in PMNs, monocytes
and pDCs, suggesting that detection may have been due to external deposition of this
complex. Of interest to this thesis is that SLE patients with renal involvement and arthritis
demonstrated the highest serum levels of S100A8/A9. This study was also able to
demonstrate the upregulation of S100A8/A9 on pDCs, which may be significant, due to the
central role pDCs are believed to play in the pathogenesis of SLE (Lood, Stenstrom et al.
2011). S100A9 expression has been demonstrated to be increased in the PBMCs of patients
with SLE compared to healthy controls at both protein and mRNA level (Pavon, Garcia-
Rodriguez et al. 2012)
1.4.5.6 Diabetic nephropathy
A murine model of diabetes can be generated by intra-peritoneal injection of streptozotocin
(STZ) followed by a high fat diet which results in hyperglycaemia, increased triglycerides
and albuminuria with evidence of damage to podocytes, macrophage infiltration, mesangial
expansion and upregulation of S100A9 gene expression in the kidney.
Immunohistochemistry demonstrates S100A8 staining in both human and murine
glomerular lesions, while mice deficient in TLR4 develop less severe renal injury than WT
counterparts following administration of STZ and a high fat diet. Similar mild renal changes
were observed in both mouse groups after STZ and a normal diet suggesting that TLR4 may
have a role in the propagation of diabetic nephropathy rather than influencing the initial
onset (Kuwabara, Mori et al. 2012).
In patients with type II diabetes, serum levels of S100A8/A9 were associated with
microvascular complications of diabetic retinopathy and nephropathy as assessed by digital
measurements of retinal vessels and proteinuria (Burkhardt, Schwarz et al. 2009).
1.4.5.7 Kawasaki disease
Kawasaki disease is a medium vessel vasculitis particularly affecting the coronary arteries in
children. The initial levels of S100A8/A9 in the serum are elevated in this cohort of
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paediatric patients as are the RNA expression levels of mrp8 and mrp14 in granulocytes
compared with healthy controls. Following treatment with intravenous immunoglobulin
(IVIG), those children who fail to respond to treatment demonstrate higher serum levels
than the responders. Similarly, those patients who develop complications of coronary artery
lesions have higher levels than those patients without coronary artery lesions. Patients also
demonstrate increased numbers of circulating endothelial cells, with the majority of
circulating cells positive for S100A8/A9. These data suggest that S100A8/A9 could be used
to aid diagnosis and predict response to treatment (Hirono, Foell et al. 2006).
1.4.5.8 Inflammatory bowel disease
There is evidence that measuring faecal calprotectin in both ulcerative colitis and Crohn’s
disease is a reliable reflection of bowel inflammation (Ricanek, Brackmann et al. 2011).
Measurement of faecal calprotectin is now used by the physician in the investigation and
diagnosis of patients, with increasing evidence that this test may correlate with mucosal
disease activity therefore helping diagnose active disease/relapse as well as monitoring the
response to treatment (Smith and Gaya 2012)
Table 1 Demonstrates the serum levels of S100A8/A9 (calprotectin) in various diseases.
Values above demonstrate the mean +/- 95% confidence interval for the serum levels of
S100A8/A9 (calprotectin, mrp18/14) in a selection of diseases.
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1.5 Project hypothesis
As described above, S100A8/A9 has been implicated in the pathogenesis of several
autoimmune and inflammatory conditions. There is evidence from both human and animal
studies that this heterodimer is a biomarker of disease severity and experimental evidence
suggesting that it also plays a part in disease pathogenesis. However, other evidence
suggests that the S100 proteins may additionally have anti-inflammatory effects which could
possibly be independent of the heterodimer and be a property of the individual proteins.
Currently our treatment options in AAV are limited with significant adverse effects
contributing to the early disease mortality (Little, Nightingale et al. 2010). As our
understanding of the pathogenesis of AAV improves, newer therapies develop which aim to
have more of a targeted immunomodulatory action as opposed to a generalised
immunosuppressive effect, such as rituximab (Jones, Tervaert et al. 2010).
This project aims to explore S100A8/A9 in the pathogenesis of AAV. I hypothesis that
patients with AAV demonstrate increased calprotectin expression both in the serum and in
acute glomerular lesions associated with monocyte/macrophage infiltration. Additionally, I
hypothesise that mice deficient in mrp14-/-, and therefore deficient in the heterodimer,
may demonstrate disease protection in nephrotoxic nephritis, which may mostly be due to
S100A8/A9 deficient phagocytes but with non-bone marrow derived cells additionally
contributing.
79
The aims of the work in this thesis are:-
 Investigation of serum levels of S100A8/A9 in patients with AAV with both active
disease and in disease remission compared to healthy controls- Chapter 3
 The measurement of cell surface S100A8/A9 expression on monocytes and
neutrophils, with the investigation of patients’ renal biopsies and correlation with the
presence of S100A8/A9 glomerular lesions with the new Berden classification of ANCA
associated glomerulonephritis- Chapter 3.
 Investigation of disease protection of mice deficient in S100A8/A9 in the nephrotoxic
nephritis animal model- Chapter 4
 Investigation of the in-vitro the effect of S100A8/A9 on bone marrow derived
macrophages extracted from WT, TLR4 and mrp14-/- deficient animals. The effect of
S100A8/A9 on mesangial cells will be explored- Chapter 5.
 Investigation of the interaction between microvascular endothelial cells and either WT
or mrp14-/- bone-marrow derived macrophages. The comparison of the phagocytic
ability of WT and mrp14-/- macrophages. This chapter aims to delineate the
mechanisms by which mice deficient in mrp14-/- may be protected from renal
disease- Chapter 5.
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Chapter 2 Materials and methods
2.1 Materials
2.1.1 Animals
Mrp14-/- mice were kindly provided by Professor F Ivars, University of Lund, Sweden.
Mrp14-/- mice were generated by the replacement of 760bp of genomic DNA containing
exon 2 resulting in the deletion of the initial start codon. The resulting construct was
subsequently inserted into an embryonic stem cell line and microinjected into blastocysts of
C57BL/6 mice (Manitz, Horst et al. 2003). Homozygous mice aged 8-12 weeks were used for
experiments and were bred at the Central Biological Services Unit, Hammersmith Hospital
Campus, Imperial College London. TLR4-/- mice (The Jackson Laboratory) were kindly
provided by Dr. Nathan Davis, Royal Free Hospital Campus, UCL. Control mice were aged
and sex matched. C57BL/6 control mice used at the Hammersmith Hospital were obtained
from Charles River laboratories. Control mice at UCL were bred within the animal house.
The mice were located in a pathogen-free environment with access to food and water.
Experiments were performed in accordance with Home Office guidelines.
2.2 Methods
2.2.1 Human Studies
Written consent was obtained from patients and controls included in the following
experiments. Clinical sample collection and use and received ethical approval from the
hospitals involved (Hammersmith Hospital and the Royal Free hospital, London and
Addenbrooke’s Hospital, Cambridge).
2.2.1.1 Immunohistochemistry on renal biopsies
Immunohistochemistry (IHC) was performed on formalin fixed paraffin embedded sections
using standard techniques staining for macrophages (anti-CD68) and S100A8/A9
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(calprotectin) using the Dako Envision system-HRP (DAB). Antigen retrieval was performed
using a 0.1% calcium chloride solution in 0.5 mM TBS with 1% trypsin to pH 7.8 for 10
minutes at 37°C. Primary antibodies used were mouse anti-human CD68 (Dako)(dilution
1:25) or mouse anti-human S100A8/A9 (calprotectin)(Bachem)(dilution 1:50). Isotype
control antibody was used as a negative control at the same dilution as the primary
antibody. The primary antibodies were incubated at room temperature in a humidified
chamber for 1 hour. Peroxidase activity was detected with 3,3-diaminobenzidine (DAB). The
slides were then rinsed in water and counterstained with filtered Harris’ haematoxylin (Cell
Path plc, Powys, UK), then dehydrated and mounted with DePeX Gurr mounting medium
and coverslips where then placed. The slides were categorized according to the recently
described Berden classification for AAV (Berden, Ferrario et al. 2010) and the quantification
of S100A8/A9 staining in both the glomerulus and the interstitium was graded 0 (no
staining) to 3 (extensive staining) by blinded observers. The Trio (Caliper life sciences)
multispectral imaging system was used to assess the sections.
2.2.1.2 Patients included for measurement of serum and cell surface levels.
AAV patients were identified through the vasculitis clinics at hospitals in London (Royal Free
and Hammersmith Hospitals) and Cambridge (Addenbrooke’s hospital). All fulfilled the
Chapel Hill Consensus criteria for diagnosis of either Granulomatosis with polyangiitis (GPA,
formerly Wegener’s granulomatosis) or microscopic polyangiitis (MPA). Disease activity was
assessed clinically, biochemically and histologically. Active disease at presentation was
defined by symptoms consistent with vasculitis, an elevated Birmingham vasculitis activity
(BVAS) score and biochemical findings demonstrating an acute inflammatory response,
without evidence of infection. Acute patients were either newly diagnosed, with positive
autoantibody serology, or in the case of ANCA negative patients, histological evidence of a
pauci-immune glomerulonephritis, or were known patients undergoing disease relapse
which was defined clinically as requiring an escalation in immunosuppression in order to
control disease activity. Acute blood samples were obtained where possible before
induction therapy initiation or shortly thereafter. Remission patients were assessed by
experienced clinicians and had no symptoms related to active vasculitis, and had a BVAS
score of 0. Healthy controls were volunteers from the individual units. Additionally, serum
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stored from a cohort of patients with limited systemic AAV, from the NORAM trial
conducted by the European Vasculitis Society (EUVAS) were also investigated, in
collaboration with the EUVAS serum biobank.
2.2.1.3 Measurement of serum calprotectin levels
Serum was isolated from blood samples obtained from patients with active disease, as well
as patients in disease remission and healthy controls. The serum from the patients in the
NORAM trial was obtained from the EUVAS serum bank and consisted of samples from
patients at between 0-2 months from entry into the study and commencement of
immunosuppressive treatment with initial active disease, at 5-7 months from entry when in
remission on immunosuppressive treatment, and at 12-14 months from entry when a
number of patients had relapsed. Serum was stored at -20°C until analysis. Calprotectin
levels were assessed by sandwich ELISA (BMA Biomedicals) according to manufacturers’
instructions. Sample dilution was optimized and incubated overnight at 4°C before analysis
the following day.
2.2.1.4 Leukocyte cell surface expression
Whole blood was collected from patients in ethylenediaminetetraacetic acid (EDTA) and
processed shortly following collection. The sample was centrifuged at 2400 rpm for 5
minutes to remove plasma. Red cell lysis was carried out for 10 minutes at room
temperature followed by 2 washing steps. Extracellular staining was performed with CD14
PE (BD biosciences), CD3 PE (eBioscience) and calprotectin FITC (Santa-Cruz biotechnology),
as well as isotype control antibodies. The cells were incubated with the antibodies on ice for
30 mins followed by 2 washing steps. Cells were fixed in 2% paraformaldehyde prior to flow
cytometry.
2.2.1.5 Purification of human IgG
Total human ANCA containing-IgG was purified using a protein G column (GE Healthcare Life
Sciences) from the plasma exchange fluid from patients with AAV receiving plasma
exchange as a treatment during active disease. The 5ml protein G column was connected to
a 20ml syringe via a suitable adapter and was washed with 50mls binding buffer (20mM
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sodium phosphate pH 7.0). 7.5mls of filtered plasma exchange fluid was applied to the
column with the same volume of binding buffer. The column was then washed with a
further 50mls of binding buffer. 10mls elution buffer (0.1M glycine-HCl, pH 2.7) was then
added to the column and the eluted IgG was collected in 1.5ml reaction tubes containing
120µl 1M Tris-HCl. The amount of IgG eluted was determined using a spectrophotometer,
measuring absorbance at 280nm. The sample was dialysed over night using a dialysis
membrane in sterile PBS. After dialysis, the samples were quantified again using a
spectrophotometer at 280nm and then stored at -20°C until used. The same method was
used to isolate IgG from the serum of healthy controls.
2.2.1.6 Endotoxin removal and detection assay
In order to ensure there was no LPS contamination of the isolated IgG, the preparations
were applied to a polymyxin B column (Detoxi-Gel Endotoxin Removing Gel, Thermo
Scientific). The column was regenerated by adding 5mls of 1% sodium deoxycholate (Sigma)
and then washed with pyrogen-free water. Each individual sample was added to the column
and incubated in the column for 1 hour before being collected and frozen at -20°C. To test
for the presence of LPS, the limulus amebocyte lysate assay (Lonza) was used. Standard LPS
concentrations were obtained by following manufactures’ instructions and diluting E.coli
endotoxin into the following concentrations: 1.0, 0.5, 0.25 and 0.1EU/mL. The assay was
performed in a water bath at 37°C. The Limulus amebocyte lysate was added to 50µl of
sample or standard and following 10 minutes incubation, a chromogenic substrate supplied
in the kit was added. The absorbance was then read at 405nm. The final concentration of
the LPS-free IgG was determined using a spectrophotometer at 280nm.
2.2.1.7 Isolation of human polymorphonuclear cells (PBMCs) and stimulation with
IgG-ANCA.
Buffy coat was obtained from NHS blood and transplant from healthy donors. PBMCs were
isolated by Lymphoprep density centrifugation. CD14 positive cells were subsequently
selected by incubation of the PBMCs with CD14 microbeads (Miltenyl biotec Ltd). One
million CD14 cells were plated in 12-well plates (Costar) in 1ml of RPMI/10% FCS solution.
Each well was subjected to various conditions: unstimulated, IgG from healthy control,
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MPO-ANCA IgG, PR3-ANCA IgG, (IgG concentrations 250µl/ml) TNFα (10ng/ml) and LPS
(1µg/ml). The samples were incubated at 37°C overnight. Cells were then assessed for
intracellular S100A8/A9 expression by flow cytometry (section 2.3.1.9)
2.2.1.8 Human umbilical vein endothelial cells
Human umbilical vein endothelial cells were a kind gift from Professor Justin Mason,
Imperial College London. They were obtained at passage 3, and used between passage 3-4.
The cells were supplemented with M199 culture media (Sigma-Aldrich), with 20% foetal calf
serum (FCS) and 30µg/ml endothelial cell growth supplement (ECGS)(Sigma-Aldrich). 10
units/ml of heparin (CP Pharmaceuticals Ltd) was added and 100U/ml penicillin and
100µg/ml streptomycin. Tissue culture flasks were coated with 2% sterile gelatine (Sigma-
Aldrich) for 10 minutes at 37°C. Excess liquid was aspirated prior to use of the tissue culture
flasks. For experiments once the HUVECs have been plated out: 2.5 units/ml of heparin with
7.5µg/ml of ECGF was added to M199 culture media. 1ml of 300,000/ml HUVECs were
added to each well. TNF 10ng/ml and LPS 1µg/ml were added to the cells in triplicate
overnight, before trypsinising the following day
2.2.1.9 Flow cytometry
Following incubation, adherent PBMCs and HUVECs were obtained by trypsinisation. For
extracellular staining, cells were washed in 1% FCS/PBS and re-suspended in 200µl 1%
FCS/PBS in a 96 well V-shaped plate (Nunc, Denmark). Cells were stained with 20µl mouse
anti-human S100A8/A9 FITC antibody (Santa-Cruz) or mouse isotype control IgG antibody
(Santa-Cruz) on ice in the dark for 30 minutes. Cells were then washed in 1% FCS/PBS twice
and subsequently fixed in 2% paraformaldehyde and stored in the dark at 4°C before
analysis by flow cytometry. For the PBMC experiments, surface staining for CD14 was
performed on the same day as CD14 isolation. 20µl mouse anti-human CD14 PE antibody
(BD Pharmingen) was added to cells in a 96 well V-shaped plate, followed by cell fixation in
2% paraformaldehyde.
For intracellular staining, following trypsinisation of adherent cells, cells were fixed in 4%
paraformaldehyde for 10 minutes at room temperature, followed by 2 washing steps with
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PBS/1% FCS/ 0.1% saponin (Sigma-Aldrich). Cells were stained with either 20µl mouse anti-
human S100A8/A9 FITC antibody, or 20µl mouse isotype control IgG FITC antibody. Cells
were incubated for 30 mins on ice in the dark and then washed with PBS/1% FCS/ 0.1%
saponin. 200µl of paraformaldehyde was added to all the wells and the plates were covered
in the dark at 4°C until analysis by flow cytometry using a FACS Calibur machine running Cell
Quest software (BD Biosciences) within 1 week.
2.2.1.10 Measurement of ANCA titres
ANCA positivity was analysed by indirect immunofluorescence. To measure ANCA antigenic
specificity and titre, Luminex-based technology, using the FIDIS vasculitis kit (Technoclone,
Vienna, Austria), in the Hammersmith Hospital Immunology Laboratory was performed.
2.2.2 Animal studies- in vivo
2.2.2.1 Genotyping of mrp14-/- mice by polymerase chain reaction
Genomic DNA was isolated from an ear clipping. The samples were lysed overnight in 100µl
of DNA lysis buffer (100mM Tris-HCl pH 8.5, 5mM EDTA, 0.2% sodium dodecyl sulphate
(SDS), 200mM NaCl) at 55°C with 100µg/ml proteinase K (Sigma-Aldrich). The DNA was then
diluted with 3 volumes distilled water and heat inactivated for 15 minutes at 75°C. A 25µl
PCR was then performed using the following primer sequences kindly provided by Professor
Ivars.
1. S100A9 AS: 5’-CACCTTCATAAAGGTTGCCAACTG-3’
2. S100A9-S 5’-TACCAACATCTGTGACTCTTTAGC-3’
3. S100A9AS-Neo 5’-TGCACATTGGGTGGAAACATTCCA-3’
The first 2 primers are used to detect a 565bp product of the wildtype allele and primers 2
and 3 are used to detect a shorter product from the knock-out allele (230 bp). A total
volume of 25µl PCR reaction was carried out (GeneAmp 9700, Applied Biosystems). Each
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reaction tube consisted of Illustra puReTaq PCR beads (GE Healthcare). Each bead contained
the following:- 2.5 units PuReTaq DNA polymerase, 10mM Tris-HCl, 50mM KCl, 1.5mM
MgCl2, 200µM each dNTP. To each reaction tube, the following was added: 1µl DNA, 1µl
WT/mutant primers, 22µl water. A final volume of 25µl was obtained. PCR cycling conditions
were kindly provided by Prof. Ivars.
PCR conditions
Denaturation 94°C 2 mins
Amplification 94°C 30 sec
60°C 30 sec
72°C 30 sec
x30 cycles
Extension 72°C 10 mins
Following PCR, the products were then analysed by gel electrophoresis. 2g agarose (Sigma-
Aldrich) was diluted in 100ml Tris acetate EDTA (TAE), microwaved for 2 mins. 2µl of
ethidium bromide (Sigma) was then added. The gel was left for 40 mins at room
temperature to set. 10µl of each sample was mixed with 2µl of loading dye (New England
BioLabs inc) and loaded onto the gel. 10µl of 100bp DNA ladder (New England BioLabs inc)
was used. The samples underwent electrophoresis in TAE buffer for 60 mins at 80V. DNA
was then visualized using a transilluminator under ultra-violet light.
2.2.2.2 Induction of nephrotoxic nephritis
To induce accelerated nephrotoxic nephritis, mice were initially pre-immunised
subcutaneously or intra-peritoneally, with 0.2mg of sheep IgG (Sigma-Aldrich) made up in
0.9% sterile saline, mixed in a ratio of 1:1 with Complete Freunds Adjuvant (CFA) (Sigma
Aldrich). This combination was prepared by the continuous mixing of this solution between
two glass syringes joined by a double-luer lock (Sigma Aldrich). To assess if the mixing was
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adequate, a drop of the solution was placed on water and observed to ensure it retained its
form. Five days following the immunisation, the mice were injected with 200µl sheep
nephrotoxic globulin (NTS) diluted 1:1 in 0.9% NaCl, via the tail vein. Mice were placed in
metabolic cages for 24 hours one day before they were humanely killed 7-9 days after NTS
injection. The kidneys were harvested, and urine and blood collected. Blood was allowed to
clot at room temperature followed by the separation of serum by centrifugation, which was
then stored at -80°C.
For the non-accelerated model of nephrotoxic nephritis, mice were not pre-immunized with
sheep IgG. Instead, mice were injected with 200µl of nephrotoxic serum diluted 1:1 with
sterile saline (0.9%) into the tail vein and killed 2 hours later.
2.2.2.3 Bone marrow transplantation
To obtain donor bone marrow, the femur and tibia were dissected followed by flushing
through the bone using a 21G needle with sterile PBS and bone marrow cells collected. The
cells were subsequently spun down at 2000 rpm for 10 minutes at 4°C. The cells were re-
suspended and washed again. The re-suspended cells were counted, followed by another
centrifugation step. Finally, the cells were re-suspended in RPMI media at a concentration of
5x107cells/ml and kept on ice. Ten million cells (0.2ml) were injected per mouse
intravenously into the tail vein.
The female recipients of the bone marrow were irradiated in an IBL 637 irradiator at CBS
Hammersmith Hospital. A radiation dose of 8Gy was used- established from previous bone
marrow transplantation experiments. Within an hour of receiving this dose of radiation, the
mice were injected with donor bone marrow cells. Following transplantation the mice were
housed in cages in the CBS, Hammersmith Hospital with access to food and water for 8
weeks prior to undergoing nephrotoxic nephritis.
2.2.2.4 PCR of circulating DNA
Genetic reconstitution of leucocytes following bone marrow transplantation was analysed at
the end of the experiments once mice had been sacrificed. Blood was collected after
sacrifice and the clotted portion of blood was used for DNA extraction and analysis to
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confirm reconstitution of the donor bone marrow. 100µl of clotted blood was placed into an
autoclaved Eppendorf tube. 0.5ml of DNA lysis buffer containing proteinase K (100µg/ml)
was added to each blood sample, followed by incubation while rotating at 56°C overnight.
300µl of saturated NaCl was added to each lysed sample, followed by vortexing of the
sample. 200µl of chloroform was added, and the sample briefly vortexed again. The samples
were spun at 13000rpm for 10 minutes at room temperature. The supernatant (0.5mls)
subsequently contained the DNA for analysis and was carefully removed and transferred
into another tube. 50µl of 3M sodium acetate was added to the tube containing the
supernatant, followed by 550µl of isopropanol to precipitate the DNA. After careful
inversion of the tube, the samples were centrifuged at 13000rpm for 10 minutes. 70%
ethanol was used to wash the DNA pellet a total of 2 times, and allowed to air dry. 20µl Tris-
EDTA was used to dissolve the washed DNA pellet. DNA concentration was measured using
a NanoDrop spectrophotometer and diluted to 100ng/ml.
1µl of the DNA was added to the 24µl of the PCR reaction mixture, containing primers for
WT and mrp14-/- DNA. To compare the reconstitution, DNA from WT and mrp14-/- mice
was also included at varying mixtures. Although this was not a quantitative PCR, by
comparing the intensities of the bands obtained with DNA from WT and mrp14-/- mice, it
was possible to estimate the relative reconstitution.
2.2.2.5 Measurement of proteinuria and serum urea.
Serum urea and creatinine were measured in the department of clinical chemistry,
Hammersmith Hospital, by Mr. John Meek and Dr. John Morris.
Twenty-four hours prior to sacrifice, the mice were placed in individual metabolic cages and
urine collected. Mice had access to food and water. Proteinuria was quantified using the
sulphosalicylic acid assay. Standards were obtained using several concentrations of bovine
serum albumin (BSA)(Sigma-Aldrich). The following dilutions prepared: 1, 0.8, 0.6, 0.4, 0.2,
0.1, 0.05, 0.02 and 0mg/ml. Urine from individual animals was plated into a 96 well plate in
triplicate at either a dilution of 1:10 (or 1:100 if significant proteinuria on urine dipstick
analysis (Multistix 8 SG, Siemens)). 10µl per well of 25% sulphosalicylic acid was added to 2
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wells, with water added to the third well. The optical density was then analysed using an
ELISA plate reader (Lab Tech International, UK) at 450nm and proteinuria concentration
calculated from the standard curve generated by BSA.
2.2.2.6 Measurement of murine serum S100A8/A9
Serum levels of calprotectin in WT mice following NTN were measured by Prof. Thomas
Vogl, Germany. Measurement was by ELISA developed by Prof. Vogl.
2.2.2.7 Processing of histological specimens
Half of a kidney was used for light microscopy. These specimens were initially fixed in
neutral buffered formalin overnight before then being transferred to 70% ethanol and
subsequently processed into paraffin blocks. Sections were stained with periodic acid Schiff
(PAS) and haemotoxylin-eosin (H+E) (Leucocyte biology, biological sciences, Imperial College
London, South Kensington). Sections to be used for immunofluorescence and
immunoperoxidase were initially fixed in paraformaldehyde-lysine-periodate (PLP) fixative
at 4°C for 4 hours before being transferred to a 10% sucrose solution overnight and then
snap frozen and embedded in OCT (Cellpath, Powys, UK) with isopentane cooled with liquid
nitrogen. Sections of 5µm were then cut using a cryostat and were left to air dry for 24
hours before being transferred to -80°C until used.
2.2.2.8 Immunofluorescence staining
Direct immunofluorescence was performed on PLP fixed- frozen kidney sections to detect
mouse and sheep IgG. 20% goat serum (Sigma) was applied to block non-specific binding,
followed by either goat anti-mouse IgG FITC (Sigma) 1:200 or monoclonal anti goat/sheep
IgG FITC (Sigma) 1:200 for 1 hour in a humidified chamber. Antibodies were diluted in PBS.
After washing the sections, they were mounted in AF1 solution (Citiflor).
2.2.2.9 Immunoperoxidase staining
Immunoperoxidase staining was performed to detect macrophages, T cells and calprotectin
(S100A8/A9) positive cells using the Polink-2 HRP Plus kit (Newmarket scientific). 5µm
sections of PLP fixed tissue were used. Endogenous peroxidase activity was blocked with 3%
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hydrogen peroxide for 10 minutes. Subsequently, after rinsing the sections in distilled water,
sections were blocked with skimmed milk (Marvel) for 30 minutes. The sections were then
incubated with the primary antibody: rat anti-mouse CD68 (Serotec), rat anti-mouse CD4
(BD Pharmingen) both at a dilution of 1:100, and rat anti-mouse S100A8/A9 antibody (kind
gift from Dr. N. Hogg)(1:120 dilution). The antibodies were diluted in PBS. Negative controls
were also included in which the primary antibody was replaced with PBS. The sections were
incubated with the primary antibody for 1 hour in a humified chamber at room
temperature. Following incubation, sections were washed in PBS followed by 2 drops of
Antibody Enhancer was then added to each section for 10 minutes. Slides were washed 3
times again and 2 drops of the Polymer-HRP incubated with the sections for a further 10
minutes. Slides were washed 3 times in PBS, followed by adding the detection antibody
made up by adding 2 drops of the DAB chromagen (3,3’diaminobenzidine chromagen
solution) to 1ml of DAB substrate. Once a brown colour development was obtained, slides
were rinsed in distilled water and counterstained in filtered Harris’ haematoxylin (Cell Path
PLC) for 30 seconds. Followed by a rinsing step in distilled water, the slides were briefly
placed in acid alcohol, followed by a washing step for 5 minutes until the sections turned
blue. Sections were dehydrated by serial immersions for 3 minutes each in 100% ethanol
twice and xylene twice, before mounting with DePeX Gurr mounting medium (BDH) and
coverslip placement.
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Antibody specificity
Source Host/Clone Concentration
(mg/ml)
Dilution
Immunofluorescence
Sheep IgG FITC-
Fc specific
Sigma Mouse IgG1
Clone GT34
1.7 1:200
Mouse IgG FITC-
Fc specific
Sigma Goat
polyclonal
5.2 1:200
Primary antibodies
CD68 Serotec Rat
FA11
0.1 1:100
CD4 BD Pharmingen Rat
GK1.5 (L3T4)
0.5 1:100
S100A8/A9 Gift Dr. N Hogg Rat
2B10
1.2 1:120
Table 2 Antibodies used for immunofluorescence and immunohistochemistry on mouse
sections.
2.2.2.10 Histological analysis
Sections were blinded so the animal identity was unknown.
2.2.2.10.1 Thrombosis
To calculate a score for glomerular thrombosis, PAS kidney sections were used to grade the
amount of PAS positive material occupying the glomeruli. A score of 0 indicated no PAS
material, 1= 0-25%, 2= 25-50%, 3=50-75% and 4=75-100%.
2.2.2.10.2 Macrophages and CD4+ T cells
Macrophages and T cells inside the glomeruli on immunoperoxidase were also counted. 25
glomeruli were counted and the mean score then calculated for each mouse.
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2.2.2.10.3 Immunofluorescence
Immunofluorescent sections were scored using Image Pro Plus software (Media
Cybernetics). To quantitate using Image Pro Plus, images of glomeruli were captured using a
QImaging Retiga 2000R Fast 1396 camera (QImaging). Glomeruli were outlined manually on
the computer screen and the mean fluorescence intensity over each glomerulus was
measured electronically. For each section 10 glomeruli were examined and the mean
fluorescence intensity recorded. Where Image Pro Plus software was used results are
expressed in arbitrary fluorescence units (AFU).
2.2.2.11 Systemic immune response to sheep IgG analysis
Serum mouse anti-sheep IgG and IgG sub-classes levels were measured by ELISA. For total
IgG, ELISA plates (Nunc Maxisorb, Life Technologies, Paisley, UK) were coated overnight at
4°C with 100µg/ml of sheep IgG (Sigma-Aldrich) diluted in 100mM boric acid (BBS). Plates
were washed and blocked with 3% BSA (Sigma-Aldrich). Serum was diluted 1:1000 in 1%
BSA. Alkaline phosphatase conjugated goat anti-mouse IgG (Southern Biotechnology,
Birmingham, Alabama) at 1:1000 in 1% BSA was used as the secondary antibody. All
incubations were for 1 hour at 37°C. Plates were developed using p-nitrophenyl phosphate
(Sigma-Aldrich) and measured on an ELISA plate reader at 405nm. For IgG subclasses, the
same protocol was performed. For IgG1 serum was added at a dilution of 1:1000, for IgG2a,
IgG2b, IgG3 1:500. The secondary antibodies were used at a dilution of 1:1000 for IgG1 and
IgG2b and 1:500 for IgG2a and IgG3 (all Southern Biotechnology).
2.2.3 Animal Studies- in-vitro
2.2.3.1 T cell proliferation assay
Mice were pre-immunised as previously described, followed by injection of nephrotoxic
serum 5 days later. After sacrifice of the mice at day 7, the spleens were harvested for the T-
cell proliferation assay. Each mouse spleen was passed through a 100µM cell strainer
followed by re-suspension in HL-1 serum free media (Lonza Group Ltd., Basel, Switzerland)
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including 100U/ml penicillin, 100µg/ml streptomycin and L-glutamine (Gibco Life
Technologies). The isolated splenocytes were spun down for 10 minutes at 2000rpm
followed by re-suspension in 1ml RBC lysis buffer (4.17g NH4Cl, 0.00185g EDTA, 0.5g
NaHCO3, 500ml sterile water). Red blood cells were lysed on ice for 5 minutes, followed by
the addition of media to a final volume of 15mls. Splenocytes were then spun down at
1800rpm for 10 minutes and re-suspended in 20mls of media. After counting the cells, a
final suspension of 5x106 cells per ml/media.
500,000 splenocytes in 100µl were plated out per well in a 96-well plate. Splenocytes were
plated alone in triplicate, or with CD28/CD3 beads (Invitrogen)(5µl of beads- 1µl
beads/40,000 T cells), or 10µg/ml of aggregated (heated to 60°C for 5 minutes to aggregate)
sheep IgG, or 50µg/ml of aggregated sheep IgG. The cells were stimulated at 37°C, 5% CO2
for 72 hours. Following the stimulation, 1µCu of 3H thymidine was added to each well,
followed by incubation for a further 24 hours at 37°C, 5% CO2. The radioactivity uptake was
then counted after 24 hours using a 1450 MicroBeta TriLux liquid scintillation and
luminescence counter (PerkinElmer, Waltham, Massachusetts).
2.2.3.2 Bone marrow derived macrophages
Following sacrifice of the animals, the femurs and tibias with the attached tissues were
cleaned in the tissue culture hood in an aseptic manner. The tissues attached to the bones
were excised using a sterile scalpel. The bones were washed in sterile PBS and Hanks media
(Sigma-Aldrich). In a clean Petri dish, the ends of the femurs and tibias were cut off and the
bone marrow was flushed through using a 25G needle and Hanks medium. The collected
bone marrow was washed with Hanks media and spun at 1,500 rpm for 5 minutes. The cells
were re-suspended in sterile culture medium of DMEM (Invitrogen) supplemented with 20%
FCS (Biosera), 100U/ml penicillin (Gibco Life technologies), 100µg/ml streptomycin and 25%
L929 cells (European collection of cell cultures) conditioned media containing M-CSF. The
cells were cultured at 37°C, 5% CO2. After 3 days, the media was replaced with the removal
of the non-adherent cells. Fresh media was added. The macrophages were harvested day 7
by washing with Hanks solution (Sigma-Aldrich), followed by 2mls of trypsin. The cells were
subsequently spun at 1500 rpm for 5 mins and re-suspended with DMEM media. For
stimulation experiments, 1x106 cells were used per condition.
94
2.2.3.3 Mesangial cell purification and culture
Kidneys were removed from WT, TLR4-/- and mrp14-/- mice and placed in RPMI media
(Invitrogen) with penicillin/streptomycin. The kidneys were blended using a 5ml syringe
plunger followed by being forced through sieves of initially size 70µm then size 40µm.
Glomeruli were collected on the smaller sieve and collected into a falcon tube with sterile
PBS. The glomeruli were spun down at 1000 rpm for 5 minutes followed by a digestion step.
Collagenase (Sigma-Aldrich) was added (380U/ml) for 30 minutes at 37°C, followed by a
centrifuge step and re-suspension in RPMI media, supplemented with glutamine, 20% FCS,
100U/ml penicillin, 100µg/ml streptomycin, 1% ITS (Sigma-Aldrich) and 20mM Hepes
(Invitrogen). The cells were cultured in tissue culture flasks and incubated at 37°C with 5%
CO2 .Media was replaced every 2-3 days.
When the cells became confluent, the media was aspirated and cells washed with sterile
PBS. Trypsin-EDTA (Invitrogen) was added to each flask and incubated for 5 minutes at 37°C.
The effect of trypsin was neutralised by the addition of media with 20% FCS and the cells
were split into 2 culture flasks. Mesangial cells were used between passage 6-12.
2.2.3.4 Isolation of WT kidney endothelial cells
Kidneys from WT mice were harvested and placed in DMEM media on ice. The kidneys were
blended using a syringe plunger and passed through a 70µm sieve. The kidney was then
digested using collagenase (Sigma-Aldrich) 3mg/ml in an agitated water bath at 37°C for 30
minutes. The digested cells were collected and washed twice in DMEM/0.5% FCS and re-
suspended in media. 10µg rat-anti-mouse CD31 (BD Pharmingen) and 5µg rat anti-mouse
CD105 (BD Pharmingen) was added to the cells and incubated at 4°C for 30minutes. The
cells were then washed twice in 0.5% FCS/DMEM and re-suspended in 80µl 0.5%
FCS/DMEM and 20µl of goat anti-rat microbeads (Miltenyi Biotec) and incubated for 15
minutes at 4°C. A column (Miltenyi Biotec) was washed with 0.5% FCS/DMEM, and after the
cells were washed, they were added to the column which was attached to a magnet. The
cells were pushed out the column and placed into a 25 cm flask which had been pre-coated
with 2% gelatine (Sigma-Aldrich). The cells were cultured in glutamax DMEM (Gibco), 20%
FCS, endothelial growth supplement (Sigma-Aldrich), 100U/ml penicillin and 100µg/ml
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streptomycin. Media was changed every 3 days. When confluence was achieved, cells were
split into different culture flasks. The cells were used for experiments at passage 8-12.
2.2.3.5 Stimulation of BMDM and mesangial cells
The primary cell lines were used for stimulation experiments. Between 0.5-1x106 cells were
used per well depending on cell availability. The number of cells used for each condition in a
given experiment was constant, as were the number of cells when more than 1 cell line was
being compared. When the cell number differed between 2 cell lines, this is stated in the
results. The BMDMs or the mesangial cells were left overnight in serum free media prior to
the addition of fresh media the following day. S100A8 and S100A8/A9 (kind gift from T.Vogl)
was used at a concentration of 1µg/ml for stimulation experiments, as this dose has been
consistently used in the published literature. TNF-α was used at a concentration of 10ng/ml
and LPS 1µg/ml. Cells were stimulated overnight and supernatants collected for ELISAs the
following day.
2.2.3.6 Phenotyping of cells
Mesangial cells and endothelial cells were characterised by immunohistochemistry.
2.2.3.6.1 Mesangial cells
Mesangial cells were plated onto an 8-well culture slide. They were fixed the following day
by immersion in cold acetone for 10 mins. Mesangial cells were phenotyped using 2
different antibodies: anti-pancytokeratin FITC (Sigma-Aldrich)(1:50) and rabbit anti-mouse
myosin antibody (Sigma-Aldrich)(1:10) followed by a secondary goat anti-rabbit (Dylight
488,Vector labs)(1:100). Cell nuclei were counterstained using DAPI (4’,6’ diamino-2-
phenylindole). The cells were mounted and viewed with a fluorescent microscope.
2.2.3.6.2 Endothelial cells
100,000 cells per well were plated out into an 8-well chamber slide before being fixed in
cold acetone the following day. The cells were stained with pancytokeratin FITC antibody
(Sigma-Aldrich)(1:50), rabbit anti-mouse mysoin antibody (Sigma-Aldrich)(1:10) and anti-
mouse CD31 antibody (Abcam)(1:100). Secondary antibodies were used following the anti-
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myosin antibody: goat anti-rabbit Dylight 488 (Vector labs)(1:100), and following the anti-
CD31 antibody: horse anti-mouse FITC (Vector labs)(1:75). After 1 hour’s incubation, cells
were washed in PBS and mounted prior to being viewed by a fluorescent microscope.
2.2.3.7 Co-culture of endothelial cells and macrophages
Cultured endothelial cells were plated into a 6 well plate (Corning). 320,000 cells per well
were plated out and left to grow in DMEM/10% FCS for 48 hours. The media was the
aspirated. BMDM from WT and from mrp14-/- mice were grown and were isolated day 7.
1x106 BMDMs were added to the endothelial cells in DMEM. The following groups of cells
were co-cultured together:
 Endothelial cells alone
 Endothelial cells + WT BMDMs
 Endothelial cells + mrp14-/- BMDMs
 WT BMDMs
 Mrp14-/- BMDMs
Each group of cells were co-cultured in triplicate. The cells were incubated at 37°C with 5%
CO2 for 24 hours. The supernatants were then collected and kept at -20°C prior to cytokine
analysis.
2.2.3.8 Phagocytosis assay
WT and mrp14-/- BMDMs were cultured for 7 days as previously described. 100,000
BMDMs were plated out into an 8-well chamber slide in media before being used the
following day in the assay.
2μm microspheres latex polystyrene microspheres (Polysciences Inc) were incubated with
BSA (Sigma-Aldrich) in PBS (10 mg/ml) at 4°C overnight while rotating. The beads were
subsequently washed in PBS before being re-suspended in 100μl of PBS. The IgG fraction of
a rabbit anti-bovine albumin antibody (Sigma-Aldrich) was added to the suspension of
microsphere beads, to obtain a final dilution of 1:2. After incubation for 1 hour at 4°C, the
beads/antibody were then washed and re-suspended in PBS. 20µl of opsonized beads and
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20µl of unopsonised beads were added to the wells in triplicate and incubated for 30
minutes at 37°C in 5% CO2. The media was aspirated and the cells washed with PBS before
being stained with Diff-Quick fix (Dade Behring). The beads ingested by 50 macrophages per
well were counted.
2.2.3.9  Measurement of Fcγ-receptors at baseline 
The expression of Fcγ-receptors of WT and mrp14-/- BMDMs at baseline was compared. 
BMDMs were cultured as described above. At day 7, BMDMs were plated into a 96 well V-
shaped plate and stained with 10µl rat anti-mouse CD16/32 PE conjugated antibody (BD
Pharmingen) in triplicate or with an isotype control IgG2bκ antibody (BD Pharmingen). The 
cells were incubated with antibodies on ice for 30 mins in the dark before 2 washing steps
and cell fixation in 2% paraformaldehyde. The cells were analysed by flow cytometry using a
FACS Calibur machine running Cell Quest software (BD Biosciences).
2.2.3.10 RNA extraction
RNA was extracted from mouse kidney endothelial cells. Endothelial cells were plated into 6
well plates and stimulated for 4 hours with LPS 1µg/ml. Media was then aspirated and 1ml
Trizol (Invitrogen) was added, and the cells homogenised before being placed into sterile
eppendorfs. The sample was left at room temperature for 5 minutes. 0.2ml of chloroform
(Sigma-Aldrich) was then added followed by shaking the tube for 15 seconds and then
incubating at room temperature for 2-3 minutes. The eppendorf tube was then centrifuged
at 12,000g for 15 minutes at 4°C which separated the mixture into a lower phenol-
chloroform DNA phase, and an upper clear aqueous phase containing RNA. The upper clear
aqueous phase was subsequently transferred into a new eppendorf tube and 0.5ml of
isopropanol (VWR International) was added at room temperature for 10 minutes. The tube
was centrifuged at 12000g for 10 minutes at 4°C which resulted in the RNA forming a gel-
like pellet at the tube bottom. The supernatant was removed and the pellet washed with
1ml of 75% ethanol. The sample was briefly vortexed, followed by centrifugation at 7500g
for 5 minutes at 4°C. The supernatant was removed and the pellet allowed to air-dry, with
care taken to avoid the pellet drying out. 20µl of RNAse-free water (Sigma-Aldrich) was the
added to dissolve the pellet. RNA concentration was measured by UV absorption using a
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NanoDrop spectrophotometer and quality assessed using the absorption ratio at 260/280
nm.
2.2.3.11 Reverse-transcription polymerase chain reaction
Reverse transcription was used to synthesis complementary DNA (cDNA) from RNA. 1µl
Oligo(dT)12-18, 1µl 10mM dNTP mix (Invitrogen), 1µg RNA and up to 10µl RNAse-free water
(to make a total volume of 11µl) was heated in a thermal cycler for 5 minutes in a sterile
PCR tube at 65°C, followed by spinning down briefly and a 1 minute incubation on ice. 4µl
5x1st strand buffer, 1µl 0.1M Dithiothreitol and 1µl RNAse out (all Invitrogen) were added,
the contents spun down and incubated on ice. To assess for genomic DNA contamination,
3µl was removed from the tube and placed into a separate PCR tube not to undergo reverse
transcription but instead to be used as a control to exclude DNA contamination. 1µl of
SuperScript III Reverse Transcriptase (Invitrogen) was then added to the 1st reaction tube,
followed by careful pipetting. After 5 minutes incubating at room temperature, the reaction
tube underwent a heating step of 50°C for 50 minutes to allow reverse transcription to take
place. The sample was subsequently heated at 70°C for 15 minutes to complete reverse
transcription.
2.2.3.12 Detection of TLR4 mRNA
PCR was performed to detect TLR4 cDNA following the reverse transcription step. RT-PCR
was performed to analyse the presence or absence of TLR4 as opposed to the relative gene
expression under different conditions. The following TLR4 primers were used, as used in the
following reference (Peng, Sigua et al. 2008)
Forward: 5’ACCTGGCTGGTTTACACGTC’3
Reverse: 5’CAGGCTGTTTGTTCCCAAAT’3
Similar to the genotyping experiments, PCR was performed using a reaction tube consisting
of Illustra puReTaq PCR beads (GE Healthcare). To each reaction tube, the following was
added: 1µl DNA, 1µl of forward and reverse primers, 22µl water. A final volume of 25µl was
obtained. A negative control was also included.
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PCR conditions
Denaturation 94°C 2 mins
Amplification 94°C 30 sec
60°C 30 sec
72°C 30 sec
x30 cycles
Extension 72°C 4 mins
The product was analysed by gel electrophoresis as previously described.
2.2.3.13 Supernatant ELISAs
Several cytokine ELISAs were used to analyse cytokine production stimulated by S100A8,
S100A8/A9 and TNF-α. Following overnight stimulation, supernatants were collected and
kept at -20°C until use. The dilutions for each individual cytokines were optimised and varied
accordingly.
2.2.3.13.1 MCP-1 and IL-6
MCP-1 and IL-6 were measured using mouse CCL2 (MCP-1) ELISA Ready-SET-Go and IL-6
ELISA Ready-SET-Go kit (eBiosciences, Insight Biotechnology Ltd, UK) according to the
manufacturer‘s instructions. ELISA plates were coated overnight with the capture antibody
in the Coating Buffer included in the ELISA kit, at 4°C. Plates were washed 5 times with
0.05% Tween 20/PBS, followed by blocking with assay diluent (included in the ELSIA kit) for
1 hour at room temperature. After a further 5 washes, the samples and standards were
incubated for 2 hours at room temperature. After 5 washing steps, the detection antibody
was diluted according to instructions in the provided assay diluent, and was incubated at
room temperature for 1 hour. Plates were washed 5 times, followed by adding avidin-HRP
diluted in assay diluent for 30 minutes. After 7 further washes, substrate solution (TMB) was
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added until a colour change was observed, and the reaction terminated with stop solution.
Plates were read at 450nm, with correction set to 570nm.
2.2.3.13.2 TNF-α and IL-8
TNF-α and IL-8 were analysed using Duoset ELISA Development System (R&D systems,
Abingdon, UK). MaxiSorp-Immuno plates (Nunc, Denmark) were coated with goat anti-
mouse TNF-α (concentration 0.8µg/ml) and rat anti-mouse IL-8 (2µg/ml) and left overnight
at room temperature. The ELISA plates were washed 3 times, followed by a blocking step of
at least 1 hour at room temperature. The samples and the standards were incubated (TNF-
α: 2000- 31.2pg/ml)(IL-8: 1000-15.6pg/ml). Each sample/standard was added in duplicate.
The samples were not diluted to measure TNF-α. For IL-8, the dilutions were optimised. The
samples incubated for 2 hours before 3 further washes and the addition of the detection
antibody (biotinylated goat anti-mouse for TNF-α (400ng/ml) and IL-8 (200ng/ml)) for 2
hours). Streptavidin-HRP was added for 20 minutes followed by TMB substrate (colour
reagent A (H2O2) and colour reagent B (tetramethylbenzidine) until colour development.
Optical density readings were taken at 450 nm, with correction at 570nm.
2.2.4 Statistical analysis
The animal studies results are expressed as median (range); patient studies are expressed as
median (range). All statistics were performed using GraphPad prism 4.0 (GraphPad
Software, San Diego California, USA). Non-parametric tests of significance were applied. For
comparing 2 groups, Mann-Whitney U test was used. In chapter 5, unpaired-t-test was used
to compare 2 groups. One way analysis of variance (ANOVA) was carried out using non-
parametric Kruskal-Wallis test and Dunn’s multiple comparison post test for groups of three
or more. Two-way ANOVA was used to analyse differences between groups from more than
one experiment to analyse if experimental data could be combined. Correlations were
assessed using the non-parametric Spearman rank correlation analysis. A significant value
was defined p<0.05 with 95% confidence.
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2.3 Buffers and solutions
2.3.1 Polymerase chain reaction
Lysis buffer for tail lysis
100mM Tris-HCL (pH 8.5), 5mM EDTA, 0.2% SDS, 200mM NaCl and 100µg/ml-added
immediately before use.
Tris/EDTA (TE) buffer
1M Tris-HCL (pH 7.5), 1 mM EDTA (pH 8.0)
TAE buffer 50x
40mM Tris-acetate, 1mM EDTA (pH 8.0). For DNA electrophoresis; diluted to 1x with
distilled water.
2.3.2 Tissue fixation
Neutral buffered formalin (pH 7.0)
100ml full-strength formalin (37-40% formaldehyde), 6.5g Na2HPO4, 4g NaH2PO4 and 900ml
dH20.
Paraformaldehyde lysine periodate (PLP) fixative
Lysine stock solution: 0.2M lysine monohydrochloride (3.65g/100ml) and added to an equal
volume of 0.1M disodium hydrogen orthophosphate (1.41g/100ml for anhydrous). The
solution adjusted to pH 7.4 and stored at 4°C till use.
4% Paraformaldehyde: Paraformaldehyde was dissolved in dH20 at 4g/100ml with stirring at
60°C in a fume hood. The solution was cleared by adding a few drops of 1M NaOH and then
stored at 4°C.
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Immediately prior to use, 1 volume of 4% paraformaldehyde was added to 3 volumes of
lysine stock solution and sodium metaperiodate 0.214g/100ml (10mM) was added.
2.3.3 Immunohistochemistry
Phosphate buffered saline
137mM NaCl, 0.27mM KCL, 8.1mM Na2PO4, 1.5mM KH2PO4, adjust to pH 7.2
Tris buffered saline (TBS)
20mM tris(hydroxymethyl)aminomethane (TRIS), 150mM NaCl, adjust to pH 7.5
Acid alcohol
1% HCl, 70% ethanol
2.3.4 ELISA
Borate buffered saline (BBS) coating buffer
100mM boric acid, 25mM anhydrous sodium tetraborate, 75mM NaCl, pH8.3
Wash buffer
0.05% Tween 20 in PBS
Blocking buffer
1% BSA in PBS
Reagent diluent
0.1-1% BSA
Substrate solution
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1:1 mixture of Colour Reagent A (H2O2) and Colour Reagent B (Tetramethylbenzidine) (R&D
systems).
Stop solution
2N H2SO4
2.3.5 Tissue Culture
Mesangial cell medium
RPMI 1640 medium, 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin, 2mM L-
glutamine, 1% insulin/ selenium/transferrin growth supplement (ITS liquid), 20mM HEPES.
Endothelial cell medium
DMEM-glutamax 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin, 75µg/ml endothelial
cell growth supplement.
Macrophage cell medium
DMEM-glutamax, 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin, 25% L929
conditioned media
Human umbilical vein endothelial cell medium
Culture: M199 media, 20% FCS, 30µg/ml endothelial cell growth factor, 10U/ml heparin.
100U/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine
Experiments: M199 media, 10% FCS, 7.5µg/ml endothelial cell growth factor, 2.5U/ml
heparin, 100U/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine
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2.3.6 FACS solutions
Wash buffer and antibody diluents
Extracellular staining: 1% FCS diluted in PBS
Intracellular staining: 0.05% saponin diluted in PBS
Fixation solutions
4% and 2% paraformaldehyde
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Chapter 3 Investigation of S100A8/A9 in human ANCA associated
vasculitis
3.1 Introduction
Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) is characterized by
small vessel inflammation and immune reactivity against the neutrophil and monocyte
components proteinase 3 (PR3) and myeloperoxidase (MPO). ANCA have been
demonstrated to have a role in the pathogenesis of AAV by activation of neutrophils and
monocytes in vitro (Falk, Terrell et al. 1990), as well as by inducing disease in certain animal
models (Xiao, Heeringa et al. 2002),(Little, Smyth et al. 2005).
Patients have frequent monitoring of ANCA titres, although it is known that these titres are
not always a useful biomarker of disease activity or risk of relapse for many patients. A
recent meta-analysis has demonstrated that serial measurements are of limited use during
disease remission in guiding individualized patient treatment and do not strongly predict
future disease relapse (Tomasson, Grayson et al. 2011). Increasing ANCA titres are only
poorly predictive of disease relapse, therefore emphasising the need for a reliable clinical
biomarker of disease activity and of remission. AAV can often feature renal involvement
characterized by a focal necrotising and crescentic glomerulonephritis, which is pauci-
immune and characterized by infiltration of glomerular monocytes/macrophages and T cells
(Ruth, Kitching et al. 2006). A recent study which used cohorts of European Vasculitis study
group (EUVAS) trial-enrolled patients investigated the types of glomerular lesions and
correlated them with renal outcome, demonstrated that the extent of glomerular
inflammation on renal biopsy predicted renal outcome (Berden, Ferrario et al. 2010). The
more inflamed the glomeruli, with predominance (more than 50%) of crescents or focal
necrosis, the better the renal outcome compared to mixed or sclerotic lesions, suggesting
that crescentic and focal lesions respond the best to immunosuppressive therapy.
Phagocytes have been demonstrated to release S100A8/A9 after their interaction with
activated, inflamed endothelium (Frosch, Strey et al. 2000). Once secreted, the complex has
several pro-inflammatory effects following its binding to the endothelium, via heparan
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sulphate proteogylcans (Srikrishna, Panneerselvam et al. 2001; Robinson, Tessier et al.
2002). This includes increased secretion of IL-8, upregulation of ICAM-1, and further
recruitment of leucocytes. Additionally, this interaction results in impairment of the
endothelial monolayer integrity and induction of both caspase-dependant and caspase-
independent cell death mechanisms resulting in both endothelial cell (EC) apoptosis and
necrosis (Viemann, Strey et al. 2005; Viemann, Barczyk et al. 2007). These characteristics
make S100A8/A9 a potential candidate in the pathogenesis of AAV, in which endothelial
activation and vascular damage are prominent, and suggest a possible role for it as a
biomarker of disease activity. A previous study demonstrated formation of S100A8/A9
complexes on glomerular infiltrating macrophages in different forms of glomerulonephritis,
with expression correlating with the severity of disease, and most prominent staining being
found in proliferative forms of GN such as focal necrotizing or immune complex GN, as
opposed to conditions such as minimal change disease (Frosch, Vogl et al. 2004). In addition,
in renal vasculitis most activated glomerular macrophages express this complex and
produce TNFα and IL-1 (Rastaldi, Ferrario et al. 2000). Other systemic inflammatory
conditions have, in addition, been associated with elevated serum S100A8/S100A9 levels
including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), renal allograft
rejection, juvenile idiopathic arthritis and Kawasaki disease (Haga, Brun et al. 1993;
Burkhardt, Radespiel-Troger et al. 2001; De Rycke, Baeten et al. 2005; Hirono, Foell et al.
2006; Frosch, Ahlmann et al. 2009; Soyfoo, Roth et al. 2009), while increasing levels have
been associated with disease relapse in juvenile onset arthritis (Foell, Wulffraat et al. 2010)
and decreasing levels with improvements in joint swelling in RA (Andres Cerezo, Mann et al.
2011). The most elevated levels found in SLE have been seen in patients with both arthritis
and renal involvement, with a correlation between the serum concentration and disease
activity assessed by SLE disease activity index (SLEDAI) score, however no correlations were
found between S100A8/S100A9 cell surface and serum levels (Lood, Stenstrom et al. 2011).
Additionally, S100A8/S100A9 was used as a biomarker of disease progression in a recent
study measuring S100A8/S100A9 levels in patients with early osteoarthritis which
demonstrated significantly higher levels of S100A8/S100A9 in patients whose disease
progressed compared to those non-progressors (van Lent, Blom et al. 2011). A previous
study in patients with juvenile idiopathic arthritis treated with methotrexate, demonstrated
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that higher levels of serum S100A8/S100A9 were predictive of disease flares and reflected
underlying subclinical inflammation (Foell, Wulffraat et al. 2010).
3.2 Aims
The aims of this chapter were to investigate S100A8/A9 expression in tissues, cells and
serum from patients with AAV. Renal biopsies of patients with different classes of ANCA
associated glomerulonephritis (focal, crescentic, sclerotic and mixed) were assessed for both
macrophage and neutrophil infiltration (using CD68 and CD15 as cell markers respectively)
as well as S100A8/A9 expression by immunohistochemistry. Serum S100A8/S100A9 levels
were measured from AAV patients with both renal and non-renal involvement by ELISA and
then correlated with parameters of disease activity and outcome. Both monocyte and
neutrophil surface expression of S100A8/A9 was measured by flow cytometry (FACS) in
acute patients and those in disease remission and compared to healthy controls. The
intracellular expression of S100A8/A9 in CD14+ monocytes in response to purified MPO-
ANCA or PR3-ANCA IgG, and control IgG stimulation was investigated by incubating purified
CD14+ cells with IgG overnight before fixing the cells and staining them with a FITC-
conjugated antibody the following day then analysing them by flow cytometry.
3.3 Experimental design
Biopsies of patients with ANCA associated glomerulonephritis were collected from the
Hammersmith Hospital pathology department. Patients were classified into the following
classes of GN according to the recent Berden classification: focal (>50% normal glomeruli),
crescentic (>50% crescentic glomeruli), sclerotic (>50% sclerotic glomeruli) and mixed (not
fitting any of the above categories). The patients were classified by reading the formal
histopathology report. Patients whose biopsies contained less than 10 glomeruli were
excluded. Glomerular staining was assessed by quantification of positive glomerular staining
by observation, and grades from 0 (no staining) to 3 (extensive staining). The extent of
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S100A8/A9 staining was then compared across the GN classes to assess a correlation
between the staining pattern, class of GN and hence renal outcome.
Serum measurements were obtained by analysis of sera obtained from patients during
active and inactive disease at both Hammersmith and Royal Free Hospitals. Additionally, we
measured serum S100A8/S100A9 levels in a cohort of patients from the vasculitis clinic at
Addenbrooke’s hospital, Cambridge. All samples were obtained following informed consent
under local ethics committee approval from all 3 centres. Patient’s medication at the time of
venesection was recorded, as were details of organ involvement and other parameters of
disease activity and demographic data. An additional cohort of serum samples was obtained
from the NORAM (Nonrenal Wegener’s Granulomatosis Treated Alternatively with
Methotrexate [MTX]) trial (De Groot, Rasmussen et al. 2005) conducted by EUVAS. Serum
samples were obtained from 3 different time points, following one and six months of
treatment, and at 14 months, following withdrawal of medication. Unfortunately no pre-
treatment samples were available. This trial was characterised by high relapse rates
following medication withdrawal at 12 months, therefore correlation between the serum
levels of S100A8/A9 and relapse rate was assessed. Following optimisation of the ELISA,
S100A8/A9 levels were measured using a commercially available ELISA, and analysed with a
plate reader at 450nm. Results were expressed in ng/mL.
In addition, patients from the Royal Free Hospital with active and quiescent disease had
leukocyte cell surface levels of S100A8/A9 measured. Following venesection of anti-
coagulated blood, red cell lysis was performed. Surface expression of S100A8/A9 was
assessed by staining with a FITC-conjugated antibody, while additional CD14 and CD3
staining was performed to identify the monocyte and lymphocyte populations. Flow
cytometry analysis was performed within 24 hours following staining. Neutrophils were
identified by forward and side scatter characteristics, while monocytes and lymphocytes
were identified by forward and side scatter characteristics as well as by double
immunofluorescent staining. The percentage of positive cells gated as well as the mean
fluorescence index (MFI) was recorded and compared to the isotype antibody stained
samples.
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As well as quantifying the S100A8/9 expression on patients’ cells at different disease time
points, the effect of healthy control IgG, MPO-ANCA IgG and PR3-ANCA IgG on isolated
CD14+ monocyte S100A8/9 expression was also investigated. ANCA IgG was purified from
the samples of first or second plasma exchange fluid, obtained from AAV patients at either
the Royal Free or Hammersmith Hospitals during their acute presentation. Currently,
patients undergo plasma exchange as adjunctive therapy for severe acute AAV when there
is advanced renal involvement, with serum creatinine>500μmol/l or dialysis dependency or
features such as pulmonary haemorrhage or cerebral involvement. Plasma exchange fluid,
containing high levels of ANCA-IgG, or plasma isolated from healthy controls, were first
passed over a Protein A column to isolate IgG, and subsequently over a polymyxin column to
remove any lipopolysaccharide (LPS), since LPS is known to up-regulate S100A8/A9. PBMCs
were isolated from donor buffy coat using Lymphoprep density centrifugation, followed by
positive selection for CD14 cells using magnetic beads (Mylteni). These CD14+ cells were
then incubated with MPO-ANCA IgG, PR3-ANCA IgG or control IgG overnight then stained
for intracellular S100A8/A9 expression the following day and analysed by flow cytometry.
Lastly, to test whether endothelial cells could also be a source of S100A8/A9 found in the
serum, human umbilical vein endothelial cells (kind gift from Prof. Justin Mason, Imperial
College London) were stimulated with LPS, and S100A8/A9 cell surface- and intracellular-
expression (% positive cells gated and mean fluorescence intensity) were quantified by
FACS. CD14 positive cells were used in these experiments as positive controls.
GraphPad prism 4.0 (GraphPad Software, San Diego, California, USA) was used for statistical
analysis. To compare more than 2 groups, one way analysis of variance was used (ANOVA)
using non-parametric Kruskal-Wallis test and Dunn’s multiple comparison post test. To
compare 2 groups, the Mann-Whitney-U test was used. The non-parametric Spearman rank
correlation analysis was used to assess correlation. ROC (receiver operator curves) were
calculated for serum S100A8/A9 levels in relapsing and non relapsing patients from the
NORAM study. Results were significant when p<0.05.
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3.4 Results
3.4.1 Renal biopsy immunohistochemistry
Immunohistochemistry was performed on renal biopsies from patients either presenting
with newly diagnosed AAV, or patients known to have a diagnosis of AAV and presenting
with suspected disease relapse. Following review of the formal histopathological renal
biopsy report, it was possible to classify the patients according to the Berden classification
as follows: focal (n=4), crescentic (n=12), mixed (n=8) and sclerotic (n=4). In addition, there
were 4 patients with no active vasculitic lesions.
The staining of the renal biopsies is illustrated in figure 3.1. S100A8/A9 positivity was
localised to active glomerular lesions, found within crescents or in areas of endocapillary
proliferation (figure 3.1 (v) and (vi)). Sclerotic lesions were generally negative for S100A8/A9
expression, despite the presence of CD68+ macrophages on the renal biopsy in 75% (3 out
of 4) of the patients (Figure 3.1 (i) and (iv)). There was varying amounts of S100A8/A9
staining in the interstitium depending on the extent of active tubulointerstitial nephritis and
there was particularly prominent S100A8/A9 staining around active, necrotizing small
vessels (Figure 3.2). However, the staining pattern of S100A8/A9 was predominantly
glomerular and in a similar glomerular distribution to that of CD68 positive macrophages
[Figure 3.3 (i and iii)]. Neutrophils also abundantly express S100A8/A9, so to assess the
relative contribution of neutrophils to glomerular S100A8/A9 positivity; biopsies were also
stained for CD15, a neutrophil marker. Although some of the glomerular S100A8/A9 positive
cells were CD15 positive (ii), most of the cells were positive for macrophage CD68 (i). There
was a statistically significant difference between levels of expression in the crescentic
lesions compared with the sclerotic or inactive lesions (Figure 3.4) (p<0.01 one way ANOVA),
while there was a trend to lower levels of expression with decreasing degrees of
inflammation. The Berden histological classification of ANCA associated glomerulonephritis
has been shown to correlate with renal outcome. The best renal survival was found in
patients with a focal class of GN followed by the crescentic class, and the worst renal
outcome was found in the sclerotic class of biopsy. The immunohistochemistry data suggest
that glomerular S100A8/A9 expression within the renal biopsy effectively mirrors the
severity of the histological findings and impacts on the long term renal outcome, with the
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greatest staining in the crescentic lesions followed by focal lesions. By contrast, scarred
glomeruli lack calprotectin expression, but may still contain CD68 positive macrophages,
suggesting that those macrophages are of a different phenotype to those found in active
inflammatory lesions, and are associated with scarring and poorer long term renal survival.
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Figure 3-2 Prominent staining around an inflamed small vessel
Immunohistochemistry of a small vessel in the renal biopsy of a patient with active AAV
glomerulonephritis. There is very prominent S100A8/A9 positivity around the inflamed
vessel.
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Figure 3-4 Acute lesions demonstrate the most S100A8/A9 positivity
Graph to demonstrate the glomerular S100A8/A9 score of the renal biopsies according to
the Berden classification of ANCA associated GN classes: focal, crescentic, mixed and
sclerotic. Each biopsy is represented by the quantification of the amount of glomerular
staining (3= large amount, 2= moderate, 1= little, 0= none). Biopsies from patients with no
active disease were also included. There was a significant difference between crescentic and
sclerotic expression (p<0.01, one way ANOVA).
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3.4.2 Patients with AAV demonstrate high levels of S100A8/A9 during acute
disease, which decreases during remission but still remains abnormal.
Serum was obtained from patients during acute disease as well as disease remission. A total
of 57 patients were included- 32 patients from London (Hammersmith and Royal Free
Hospitals), 25 patients from Cambridge. 57 patients in disease remission were included as
well as 16 healthy controls. Out of these patients, 26 patients had samples taken and
S100A8/A9 levels measured during both acute disease and disease remission. Table 1
summarises the patient characteristics. The 16 healthy controls consisted of 7 females and 9
males with a mean age of 35 years.
Acute n=57 Remission n=57
(70 samples)
Age 61 (range 16-84) 61 (16-85)
Gender F 30, M 27 F 23, M 34
MPO-ANCA 21 33
PR3-ANCA 30 20
Both 2 0
ANCA negative 4 4
Median Creatinine 185 124
Organ involvement Renal and extra-
renal 42
Extra-renal 15
Renal and extra-renal
48
Extra-renal 9
Treatment at the
time of sample
taken
Nil 35
RTX, CYP, P 3
CYP, P 2
MMF 1
P/MP 10
P, MTX 3
P, AZA 1
P, CYP 2
Nil 5
P and Aza 31
P and CYP 10
MMF 2
Aza 4
P, RTX, CYP 1
P and MMF 5
P and MTX 3
P alone 2
RTX and P 4
RTX, P and Aza 2
RTX, P and MMF 1
Table 3 Clinical and demographic characteristics of the patients.
RTX=Rituximab, CYP=Cyclophosphamide, MMF=Mycophenolate Mofetil, P=Prednisolone,
MP=Methylprednisolone, AZA=Azathioprine, MTX=Methotrexate.
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The median serum levels and ranges of S100A8/A9 were for healthy controls 2,836 ng/ml
(range 1,058-6,175 ng/ml), acute AAV patients 13,453 ng/ml (4,769-40,000ng/ml) and
remission AAV patients 8,957 ng/ml (3860-25,083 ng/ml). There were significant differences
between healthy controls, and both acute and remission AAV sera as well as between acute
and remission samples (one way ANOVA p<0.001) (Figure 3-5 (i)). This is consistent with the
hypothesis that serum levels of S100A8/A9 reflect clinical inflammation, with patients with
active disease demonstrating very high circulating levels of the heterodimer. In addition,
there was a significant but weak correlation between serum calprotectin levels and total
neutrophil count (r=0.29)(p<0.05). There was no correlation with blood monocyte count or
serum creatinine. However, to confirm that abnormal renal function was not the cause of
the elevated serum calprotectin levels a cohort of 59 dialysis patients also had serum
S100A8/A9 levels measured. These patients, undergoing chronic haemodialysis,
demonstrated significantly lower levels of S100A8/A9 than those patients with either active
and inactive AAV (both p<0.001)(mean 5398ng/ml HD patients). Seventeen patients had
serum S100A8/A9 measured at more than 1 time point within the first year following
diagnosis (Figure 3-5 (iii)). One patient 19 weeks into treatment, demonstrated a large
increase in S100A8/A9 at the time of a clinical relapse and required an escalation in
immunosuppression. In the patients who entered remission, there was a decrease in serum
S100A8/A9 levels from presentation to 4-6 months during remission (p<0.05), but this didn’t
reach normal levels, while the ANCA titre decreased in all the patients (Figure 2 (iv)). There
was no difference in S100A8/A9 levels in those acute patients in whom prednisolone had
already been initiated in the previous week compared to those who were yet to commence
immunosuppression.
C-reactive protein (CRP) demonstrated a similar pattern to S100A8/A9 (figure 3-5 (ii)), with a
median level of 30mg/L (range 2-248) during active disease, decreasing to a median of
3mg/ml (0.6-138) during remission. The decrease between active disease and remission was
statistically significant (p<0.0001)(Mann-Whitney).
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3.4.3 Relapsing patients with limited systemic disease demonstrate higher
S100A8/A9 levels than the non-relapsers
The cohort of patients described above had predominantly renal involvement with a low
relapse rate. Therefore it was not possible to compare the serum level of S100A8/A9
between relapsers and non-relapsers. The European vasculitis study group (EUVAS) kindly
provided serum from patients who participated in the NORAM trial. This trial included
patients with early systemic involvement treated with either steroids and methotrexate or
steroids and cyclophosphamide. Patients were excluded from the trial if they had serum
creatinine >150µmol/l or evidence of glomerulonephritis. The trial was characterised by a
high relapse rate following termination of immunosuppression at 12 months. If any patients
relapsed before the 12 month time point when immunosuppression was being reduced,
then treatment was continued beyond 12 months. Additionally, if patients relapsed after
the 12 month time-point off treatment, then it was re-started.
Serum was not available at time 0, before patients started any treatment. However, from a
total of 100 patients recruited to the trial, serial samples from 27 patients were available for
analysis. The samples were taken at taken at 3 time points within 14 months of diagnosis:
the first sample was between time 0-2 months, then subsequently between 5-7 months of
therapy when treatment was with tapering doses of prednisolone from 60 to 25 mg/day,
and finally samples taken between 12-14 months, when immunosuppression had either
been withdrawn or was continued/re-started in those patients who had already relapsed.
Out of this group of 27 patients, 14 were relapsers, and 13 non-relapsers. The patients who
did not relapse had treatment stopped at 12 months. Five of the relapsing patients relapsed
before 12 months while still on immunosuppression, and 9 patients relapsed after 12
months and restarted immunosuppression. Six of the late relapsers had S100A8/A9
measured prior to the relapse and before re-introduction of immunosuppression.
In all the treated NORAM patients’ samples serum S100A8/A9 levels were significantly lower
than in those with generalized (renal) disease even during remission (median levels NORAM
samples at one month 418 ng/ml (range 71-2167) compared to generalized disease
remission 8,957 ng/ml (3860-25,083) (p<0.0001). However, there was a significant increase
in S100A8/A9 levels in NORAM subjects after 12 months (median level at 14 months 1689
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ng/ml (384-6245) vs 1 month 418 ng/ml (range 71-2167)(p<0.0001, Mann Whitney U test).
The 14 patients who went on to relapse during the study (at a median 13 months from
entry, range 6-18 months) had significantly higher levels of calprotectin at the first two time
points, compared with the 13 non-relapsing patients whilst on treatment at these time
points (both p<0.01)(Figure 3-6). At the final time point there was a trend to higher values in
the relapsers, but this did not reach statistical significance (p=0.055). Table 4 demonstrates
the serum levels in the relapsing and non-relapsing groups. These data suggest that failure
to sufficiently suppress S100A8/A9 levels, whilst on treatment, can predict subsequent
disease relapse. Receiver operating curves comparing relapsers to non-relapsers
demonstrated that at both one and six months there was a threshold which was associated
with a significant risk of relapse, at one month a S100A8/A9 level greater than 626 ng/ml
was associated with a sensitivity of 78.6% and specificity of 92.3% and a likelihood ratio of
10.3 (table 5), while at six months a level greater than 454 ng/ml was associated with a
sensitivity of 78.6% and specificity of 92.3% (table 6). The area under curve at one month
was 0.87, p=0.0009, while at six months it was 0.841, p=0.002 (Figure 3-6). This cohort of
patients, unlike those with renal involvement, consisted predominantly of PR3-ANCA
positive patients (25 PR3-ANCA positive, 1 MPO-ANCA and 1 ANCA negative) and the early
samples were taken at a time when patients were established on significant
immunotherapy.
Time 1-2 months Time 5-7 months Time 12 months
Relapsers Non-
relapsers
Relapsers Non-
relapsers
Relapsers Non-
relapsers
Median
ng/ml
1084 287 630 252 2066 957
Range
ng/ml
128-2167 71-980 180-2515 88-953 634-6245 384-5400
Table 4 Serum S100A8/A9 levels from 27 patients in the NORAM trial at different time
points.
The table demonstrates the median S100A8/A9 levels (and range) at the 3 time points when
patients in the NORAM study were sampled. The patients are divided into relapsers and the
non-relapsers.
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Table 5 Table to demonstrate sensitivities and specificities of serum S100A8/A9 at 1
month
The table above shows the sensitivities and specificities for predicting future disease relapse
in the patients from the NORAM trial. The S100A8/A9 level at 1 month following
commencement of treatment in bold illustrates the cut-off level which retained the greatest
sensitivity and specificity.
Cutoff ng/ml Sensitivity 95% CI Specificity 95% CI
> 80.00 1.000 0.7684 to 1.000 0.07692 0.001946 to 0.3603
> 108.0 1.000 0.7684 to 1.000 0.1538 0.01921 to 0.4545
> 127.5 1.000 0.7684 to 1.000 0.2308 0.05038 to 0.5381
> 129.0 0.9286 0.6613 to 0.9982 0.2308 0.05038 to 0.5381
> 142.0 0.9286 0.6613 to 0.9982 0.3077 0.09092 to 0.6143
> 157.0 0.9286 0.6613 to 0.9982 0.3846 0.1386 to 0.6842
> 185.5 0.9286 0.6613 to 0.9982 0.4615 0.1922 to 0.7487
> 249.0 0.8571 0.5719 to 0.9822 0.4615 0.1922 to 0.7487
> 299.5 0.8571 0.5719 to 0.9822 0.5385 0.2513 to 0.8078
> 318.0 0.8571 0.5719 to 0.9822 0.6154 0.3158 to 0.8614
> 355.0 0.8571 0.5719 to 0.9822 0.6923 0.3857 to 0.9091
> 390.5 0.8571 0.5719 to 0.9822 0.7692 0.4619 to 0.9496
> 406.5 0.7857 0.4920 to 0.9534 0.7692 0.4619 to 0.9496
> 494.0 0.7857 0.4920 to 0.9534 0.8462 0.5455 to 0.9808
> 626.5 0.7857 0.4920 to 0.9534 0.9231 0.6397 to 0.9981
> 712.5 0.7143 0.4190 to 0.9161 0.9231 0.6397 to 0.9981
> 790.0 0.6429 0.3514 to 0.8724 0.9231 0.6397 to 0.9981
> 909.0 0.5714 0.2886 to 0.8234 0.9231 0.6397 to 0.9981
> 985.0 0.5714 0.2886 to 0.8234 1.000 0.7529 to 1.000
> 1084 0.5000 0.2304 to 0.7696 1.000 0.7529 to 1.000
> 1314 0.4286 0.1766 to 0.7114 1.000 0.7529 to 1.000
> 1484 0.3571 0.1276 to 0.6486 1.000 0.7529 to 1.000
> 1563 0.2857 0.08389 to 0.5810 1.000 0.7529 to 1.000
> 1627 0.2143 0.04658 to 0.5080 1.000 0.7529 to 1.000
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Cutoff Sensitivity 95% CI Specificity 95% CI
> 156.0 1.000 0.7684 to 1.000 0.2308 0.05038 to 0.5381
> 189.0 0.9286 0.6613 to 0.9982 0.2308 0.05038 to 0.5381
> 205.0 0.9286 0.6613 to 0.9982 0.3077 0.09092 to 0.6143
> 215.0 0.9286 0.6613 to 0.9982 0.3846 0.1386 to 0.6842
> 221.0 0.9286 0.6613 to 0.9982 0.4615 0.1922 to 0.7487
> 238.0 0.8571 0.5719 to 0.9822 0.4615 0.1922 to 0.7487
> 256.0 0.8571 0.5719 to 0.9822 0.5385 0.2513 to 0.8078
> 286.0 0.8571 0.5719 to 0.9822 0.6154 0.3158 to 0.8614
> 317.0 0.8571 0.5719 to 0.9822 0.6923 0.3857 to 0.9091
> 357.5 0.7857 0.4920 to 0.9534 0.6923 0.3857 to 0.9091
> 406.0 0.7857 0.4920 to 0.9534 0.7692 0.4619 to 0.9496
> 422.0 0.7857 0.4920 to 0.9534 0.8462 0.5455 to 0.9808
> 454.0 0.7857 0.4920 to 0.9534 0.9231 0.6397 to 0.9981
> 487.5 0.7143 0.4190 to 0.9161 0.9231 0.6397 to 0.9981
> 524.5 0.6429 0.3514 to 0.8724 0.9231 0.6397 to 0.9981
> 590.0 0.5714 0.2886 to 0.8234 0.9231 0.6397 to 0.9981
> 630.0 0.5000 0.2304 to 0.7696 0.9231 0.6397 to 0.9981
> 711.3 0.4286 0.1766 to 0.7114 0.9231 0.6397 to 0.9981
> 825.8 0.3571 0.1276 to 0.6486 0.9231 0.6397 to 0.9981
> 880.0 0.2857 0.08389 to 0.5810 0.9231 0.6397 to 0.9981
> 923.5 0.2143 0.04658 to 0.5080 0.9231 0.6397 to 0.9981
> 965.5 0.2143 0.04658 to 0.5080 1.000 0.7529 to 1.000
> 1199 0.1429 0.01779 to 0.4281 1.000 0.7529 to 1.000
Table 6 Table to demonstrate sensitivities and specificities of serum S100A8/A9 at 6
months
The table above shows the sensitivities and specificities for predicting future disease relapse
in the patients from the NORAM trial. The S100A8/A9 level at 6 months following
commencement of treatment in bold illustrates the cutoff level which retained the greatest
sensitivity and specificity.
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3.4.4 Neutrophil and monocyte surface expression of S100A8/A9
Surface S100A8/A9 expression was investigated in a subset of healthy controls (n=7), active
AAV (n=10), and remission AAV (n=18) patients. Twenty three patients had renal disease,
while five had only extra-renal disease. Fifteen patients were MPO-ANCA positive and eight
PR3-ANCA positive, while five were ANCA negative. Monocyte gates were determined on
the flow cytometer by counterstaining with CD14, T lymphocyte gates were determined by a
CD3 counterstain, while neutrophil gates were identified by forward and side scatter
characteristics alone (Figure 3-7 (i)). Table 7 summarises the staining results. There was a
greater proportion (% of S100A8/A9 expressing gated cells compared to % of cells gated
with isotype control conjugated antibody) of both neutrophils and monocytes in AAV
patients during active disease and convalescence compared with healthy controls
(percentage neutrophils expressing S100A8/A9- median (range): healthy controls 0% (0-
3.6%), acute AAV 78.9% (14.7-98.1%), convalescent AAV 6.8% (0-98.8%), active AAV
compared to controls p<0.001 and active AAV compared to convalescent AAV p<0.05 (one
way ANOVA)(figure 3-8 (i)); percentage monocytes expressing S100A8/A9- median (range):
healthy controls 5.4% (0-16.9%), acute AAV 50.5% (0-91.6%), convalescent AAV 5.6% (1-
94.6%)(p=NS)(Figure 3-8 (ii)). We were unable to detect any surface S100A8/A9 expression
on CD3 positive cells. Among patients, the decrease in the proportion of monocytes
expressing cell surface S100A8/A9 between the acute and convalescent samples was large
but did not reach statistical significance (Figure 3-8 (ii)). There was a statistically significant
difference in S100A8/A9 mean fluorescent intensity (MFI) between acute patients and
healthy controls for both neutrophil (p<0.001)(Figure 3-8 (iii)) and monocyte (p<0.01)(Figure
3-8 (iv)) cell surface expression.
Table 7 Cell surface S100A8/A9 expression in controls and patients with active and
inactive disease
The table contains a summary of the results comparing controls, acute AAV and remission
AAV patients’ cells stained for surface calprotectin expression, according
The % of cells gated for S100A8/A9 surface expression and the mean fluorescent intensity
(MFI). The samples were subtracted from the % of cells gated and divided by the MFI of the
Isotype control antibody.
Figure 3-7 Shows the flow cytometry plot demonstrating the different cell populations and
their identification. Neutrophils identified by forward and side scatter. T
anti-CD3-PE antibody, and monocytes by ant
Characteristic
Number (n)
% calprotectin
positive neutrophils
% calprotectin
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3.4.5 Human IgG up-regulates intracellular S100A8/A9 in monocytes
The effect of MPO-ANCA IgG, PR3-ANCA IgG (isolated from plasma exchange fluid) and
healthy control IgG on human monocytes was investigated. To avoid the variability of donor
monocytes and the quantity of blood required from venesection, monocytes were purified
from leukocytes isolated from a buffy coat sample from NHS blood and transplant service.
All IgG samples were depleted of LPS using a polymyxin column with resultant undetectable
LPS as assessed by a limulus assay. Following PBMC isolation, CD14+ cells were purified
using CD14-magnetic beads and the resultant CD14 cell population was found to be 98%
pure. The CD14+ cells were stimulated with 250μg/mL of the different IgG preparations. Five
ANCA-IgG samples were used (2 PR3-ANCA, 3 MPO-ANCA) and healthy control IgG isolated
from 3 controls.
IgG from healthy controls and from patients with AAV was able to increase the proportion
of S100A8/A9 expressing cells. This corresponded to an increase in both percentage of
S100A8/A9 expressing cells and the mean fluorescent intensity (MFI) of the positive
population. Figure 3-9 demonstrates the increase in the percentage of calprotectin positive
cells, and the increase in MFI compared to unstimulated cells, suggesting an increase in the
number of cells expressing S100A8/A9 as well as the amount each cell expressed. The
results show that MPO-ANCA and PR3-ANCA IgG isolated from 5 different patients had a
similar effect on the calprotectin expression, without a significant increment when TNF
(10ng/mL) was added. IgG isolated from healthy controls had a more variable effect and
although there was a trend to lower level of S100A8/A9 expression compared to ANCA
containing IgG, the result was not significant (figure 3-9). Similarly, the mean fluorescent
intensity of CD14+ cells increased following stimulation with control IgG and was similar to
those obtained with MPO-ANCA and PR3-ANCA. Overall, these data demonstrate that IgG is
able to upregulate intracellular S100A8/A9 expression in CD14 expressing monocytes but
the effect is not specific to ANCA.
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Figure 3-11 IgG increases the proportion of CD14 cells expressing intracellular S100A8/A9
Graph above demonstrates the % increase in cells gated for S100A8/A9 compared to
unstimulated CD14 cells. IgG stimulation resulted in an increased proportion of cells with
detectable intracellular expression. There was no difference in expression compared to
ANCA-IgG and IgG isolated from healthy controls.
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3.4.6 Human umbilical vein endothelial cells do not express S100A8/A9
Human umbilical endothelial cells (HUVEC) were a kind gift from Professor Justin Mason,
Imperial College London, and were used at 300,000 cells per condition and stimulated to
investigate HUVEC S100A8/A9 expression. Healthy control PBMC were isolated, followed by
positive selection of CD14+ cells and used as a positive control (1x106 CD14+ cells per
condition). The cells were left unstimulated or stimulated with LPS (1-10µg/ml) in triplicate.
Following stimulation with LPS, cells were stained for intracellular and extracellular
calprotectin expression and assessed by flow cytometry.
CD14+ cells, as expected, had detectable surface expression of S100A8/A9 (mean %
S100A8/A9 expressing cells 34.3%%, increasing to 50% with 1 µg/ml LPS stimulation,
unpaired t-test p<0.05). The mean fluorescent intensity (MFI) also increased following
1µg/ml LPS (508.1 to 675, unpaired t-test p<0.005). The majority of CD14+ cells
demonstrated intracellular S100A8/A9 expressed and showed a non-significant increase in
expression following 1 µg/ml LPS (mean unstimulated 86.7% increasing to 94.6% with LPS),
with similar results with respect to change in MFI (unstimulated MFI 862.9 increasing to
986.8 following LPS). However, there was no HUVEC calprotectin expression detected either
on the cell surface or intracellularly in unstimulated cells or following LPS stimulation.
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3.5 Discussion
Glomerular lesions consisting of monocytes/macrophages, as well as neutrophil
degranulation are key features of pauci-immune glomerulonephritis secondary to AAV,
while circulating monocyte and neutrophil activation is found during active disease. This
chapter expands data from a previous study which reported glomerular macrophage
expression of S100A8/A9 in several different glomerular pathologies (Rastaldi, Ferrario et al.
2000), including a small subset of patients with AAV, who demonstrated prominent
expression in areas of necrotizing extracapillary damage. Those patients with more severe
glomerular pathologies demonstrated prominent S100A8/A9 expression unlike those
patients with less inflammatory glomerular lesions, such as minimal change nephropathy.
This work demonstrates glomerular infiltration of cells expressing S100A8/A9 in the renal
biopsies of patients with glomerulonephritis secondary to AAV. Prominent S100A8/A9
expression was seen within active crescents and in areas of focal necrosis, but was absent in
sclerotic or normal glomeruli. S100A8/A9 expression was greatest in the active histological
lesions that predict better long term renal outcome according to the recent Berden
classification. By contrast sclerotic glomeruli, did not contain S100A8/9 expressing
macrophages, demonstrating that inflammatory and sclerotic glomeruli contain
monocyte/macrophages of a different phenotype. Therefore, S100A8/A9 expressing
monocytes are associated with the most severely inflammed glomerular lesions and those
associated with better renal outcome following treatment, making it a potentially important
biomarker and potential therapeutic target.
In acute AAV, circulating monocytes and neutrophils are activated. Patients with AAV have
elevated levels of cell surface S100A8/A9 on both neutrophils and monocytes compared
with healthy controls, with levels greatest during active disease, to the extent that some
patients had almost 100% of their neutrophils and monocytes with detectable cell surface
S100A8/A9. Moreover, AAV patients expressed more S100A8/A9 on each cell, demonstrated
by increased mean fluorescent intensity, compared to healthy controls. Additionally, serum
levels of S100A8/A9 reflected these cellular findings, with significantly higher levels in active
disease compared to remission and those found in healthy controls. Interestingly, those
patients in clinical remission still had persistently elevated serum S100A8/A9 levels and
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leukocyte expression, suggesting that there is a degree of subclinical innate immune
activation. However, it is not possible from these experiments to conclude whether the
significant cellular surface expression of myeloid cells is due to intracellular production of
the heterodimer or whether circulating S100A8/A9 has become deposited on the cell
surface.
There are similar data illustrating persistent inflammation and cell activation in convalescent
AAV patients, such as persistent monocyte IL-12 and interferon gamma production
(Hruskova, Rihova et al. 2009), augmented indoleamine dioxygenase expression (an IFN-γ 
regulated enzyme) (Chavele, Shukla et al. 2010) as well as elevated monocyte TLR
expression (Tadema, Abdulahad et al. 2011). Importantly, levels of S100A8/A9 diminished
following immunomodulatory therapy, but achieved lower degrees of suppression in those
patients who went on to relapse. Additionally, analyzing the patients with severe systemic
disease and sequential levels of S100A8/A9 revealed one patient with a steep increase in
the serum S100A8/A9 level which corresponded to an increase in clinical disease activity in
the context of a decreasing MPO-ANCA IgG titre.
Analysis of ROC of the patients in the NORAM study, suggests that failure to suppress
S100A8/A9 at one or six months may be a useful predictor of future relapses, with a
likelihood ratio at one month of 10.3. This is significantly better than the predictive value of
a rising ANCA titre, which has recently been estimated in meta-analysis to provide a
likelihood ratio of 2.8 for disease relapse (Tomasson, Grayson et al. 2011). However, since
we did not have pre-treatment S100A8/A9 levels, there remains a possibility that relapsers
simply maintain higher levels of S100A8/A9. The levels at 1 month and 6 months were
measured when patients were receiving immunosuppression which may partially account
for the much lower levels compared to those patients with renal involvement. These results
are similar to those found in SLE (Haga, Brun et al. 1993; Soyfoo, Roth et al. 2009). The most
elevated S100A8/A9 levels in SLE have been seen in patients with arthritis and renal
involvement, and a correlation between the serum concentration and SLEDAI scores (Lood,
Stenstrom et al. 2011). Additionally, a recent study measuring S100A8/S100A9 levels in
patients with early osteoarthritis demonstrated significantly higher levels of S100A8/S100A9
in patients whose disease progressed compared to the group of non-progressors (van Lent,
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Blom et al. 2011). Patients with severe sepsis also demonstrate elevated levels of
calprotectin, although the levels are generally lower than those seen in vasculitis patients,
with no apparent correlation between serum levels and severity on the infection (van
Zoelen, Vogl et al. 2009).
With regards the source of serum S100A8/A9, I was not able to demonstrate intracellular or
surface expression of the heterodimer in human umbilical vein endothelial cells at rest or
following stimulation with LPS. By using CD14 cells as a positive control, both surface
expression and intracellular expression of S100A8/A9 could be demonstrated as could the
predicted increase following LPS stimulation. However, using the same techniques no
similar expression was detectable in HUVEC, suggesting that most serum S100A8/A9 in
patients with AAV is likely derived from circulating neutrophils and monocytes.
Both serum levels and cell surface S100A8/A9 expression are augmented during disease
activity, and in early systemic disease higher levels are associated with disease relapse.
These findings suggest that serum S100A8/A9 levels may help guide immunosuppression
treatment and may be of more clinical utility than CRP, an acute phase reactant, which is
generally within the normal range in patients during remission and does not provide
prognostic information. A previous study in patients with juvenile idiopathic arthritis treated
with methotrexate, demonstrated that higher levels of S100A8/A9 were predictive of flares,
and reflected underlying subclinical inflammation (Foell, Wulffraat et al. 2010).
S100A8/9 an example of a damage associated molecular pattern (DAMP) and a marker of
activation of innate immunity, has recently been demonstrated to play a role in
autoimmunity and induction of autoimmune T cells, exerting its action through TLR4 (Loser,
Vogl et al. 2010). TLR4 expression has been demonstrated in the kidney and has been shown
to contribute to renal injury in animal models (Brown, Lock et al. 2007). Furthermore, TLR4
expression on both bone marrow derived cells as well as glomerular endothelial cells has
been shown to have a role in neutrophil recruitment and renal injury in the experimental
myeloperoxidase glomerulonephritis model (Summers, van der Veen et al. 2010). In another
animal model, S100A8 was able to upregulate activatory FcγR in macrophages through 
binding TLR4 (van Lent, Grevers et al. 2010). Recently, it has been demonstrated that
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neutrophil extracellular traps (NETs) contain calprotectin (Urban, Ermert et al. 2009) and
that NETS are released by ANCA stimulated neutrophils. The formation of NETS may have a
role in triggering vasculitis and promoting the autoimmune response in patients with small
vessel vasculitis (Kessenbrock, Krumbholz et al. 2009).
This chapter demonstrates that S100A8/A9 is upregulated in patients with AAV and
represents a marker of cellular immune activation and disease activity. Alongside the
traditional markers of disease activity such as CRP and ANCA titre, measuring S100A8/A9
may have a role is aiding diagnosis but also in helping to predict those at risk of future
disease relapse. This may then help guide immunosuppression therapy. Clearly, replicating
these data in other cohorts, with renal involvement, is critical to understand the utility of
measuring calprotectin as a prognostic marker, and efforts are underway to measure
calprotectin in samples from other EUVAS studies.
Summary of results:
 Patients with focal and crescentic glomerulonephritis have a prominent infiltration of
S100A8/A9 positive cells linking the expression of S100A8/A9 with response to
therapy and disease outcome.
 Patients with AAV and renal involvement have elevated serum level of S100A8/A9,
which decreases but does not normalize during remission
 Patients with non-renal involvement who subsequently relapse have higher early
levels of S100A8/A9 than non-relapsers therefore S100A8/A9 may potentially be a
biomarker in this cohort of patients
 Patients have greatly elevated monocyte and neutrophil cell surface levels of
S100A8/A9.
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Chapter 4 The role of S100A8/A9 in nephrotoxic nephritis
4.1 Introduction
Nephrotoxic nephritis is a commonly used animal model of immune complex
glomerulonephritis. Sheep antibodies directed against the mouse glomerular basement
membrane act as a planted antigen, and focus the resulting immune response towards the
GBM. NTN is characterised by an early neutrophil influx at 2 hours after injection of
nephrotoxic serum, followed by glomerular injury induced by T cell and macrophage
infiltration. The pathology of this model is characterised by Th1 cell and macrophage
infiltration, and glomerular thrombosis with subsequent renal dysfunction. Although the
results can be variable, this model has been widely used to delineate crucial aspects of both
innate and adaptive immune systems to improve our understanding of immune-mediate
glomerulonephritis.
Macrophages have been shown to play an important role in both the initiation and
propagation of glomerulonephritis as discussed in the introduction. It has been increasingly
recognised that macrophages respond to the local cytokine milieu, and have an element of
plasticity in response to that local environment. S100A8/A9, which is present in neutrophils,
monocytes and some inflammatory macrophages, but absent is chronic lesions, has been
investigated in other animal models of inflammation and autoimmunity. Mrp14-/- mice, in
an antigen-induced arthritis model, are protected from joint erosions and destruction, with
S100A8/A9 having a role in the induction of matrix metalloproteinases (MMPs), which are
known to mediate joint destruction. S100A8 additionally has a role in the upregulation of
activatory FcγR (FcγRI, FcγRIV) receptors, as well as the upregulation of pro-inflammatory 
cytokines (van Lent, Grevers et al. 2008; van Lent, Grevers et al. 2010). This work is relevant
in the nephrotoxic nephritis animal model, in which the importance of Fc receptors on
infiltrating leucocytes has previously been investigated, with these receptors playing an
important role in the pathogenesis of disease (Tarzi, Davies et al. 2002). Additionally,
S100A8/A9 plays a role in the generation of autoreactive T cells (CD8+), linking the innate
immune system with the development of antigen-specific autoimmunity (Loser, Vogl et al.
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2010). The role of pattern-recognition receptors in the pathogenesis of autoimmunity and
inflammation is increasingly being recognised along with damage-associated molecular
patterns (DAMPs), which bind to these receptors. This mechanism may provide a link
between the innate and the adaptive immune system as well as providing a link between
infection and autoimmunity. This chapter explores S100A8/A9 in NTN, in both the
accelerated and non-accelerated models.
4.2 Aim
This chapter investigates the role of S100A8/A9 in nephrotoxic nephritis animal model by
comparing disease between WT and mrp14-/- mice. The experiments were repeated with
both low-dose and high-dose LPS to assess if disease protection, could be overcome. The
non-accelerated NTN model was also used to assess the early neutrophil infiltration in both
animal groups.
4.3 Experimental design
Macrophage phenotype in NTN was initially investigated using animals which had been
demonstrated in our lab to be protected from disease in NTN. These animal sections were
kindly provided by Dr. K. Chavele (mice deficient in mannose-receptor) and Dr. S. Hamour
(mice deficient in IL17). Sections were assessed for the presence of cells positive for
S100A8/A9 (antibody kindly provided by Dr. N. Hogg, Cancer Research UK). To investigate
the early cell influx of cells positive for S100A8/A9, WT mouse sections during the early
time-points in the nephrotoxic nephritis model were assessed for the presence of cells
positive for S100A8/A9.
Mrp14-/- mice were kindly provided by Prof. Fredrik Ivars, University of Lund, Sweden.
Animals were bred and housed according to guidelines at the Central Biological Services
department, Hammersmith Hospital Campus, Imperial College London. WT (C57BL/6) and
mrp14-/- were aged and sex matched. Females were used for all the experiments. Initial
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pilot experiments were performed to assess disease using varying concentrations of
nephrotoxic serum. Disease severity was assessed by the quantification of proteinuria,
measurement of serum urea to assess renal function, and histological assessment on PAS
and H+E sections to assess glomerular thrombosis. The humoral response was investigated
using an ELISA to measure mouse anti-sheep IgG, as well as immunofluorescence of kidney
sections to measure mouse and sheep IgG deposition on the glomerular basement
membrane. Cellular responses were investigated by CD68 and CD4 staining on kidney
sections to assess T cell and macrophage infiltration. A subset of animals had serum
S100A8/A9 measured by Professor T. Vogl, University of Muenster, Germany.
Statistical analysis was performed by GraphPad Prism. The Mann-Whitney test was used to
compare 2 groups of non-parametric data. To analyse more than 2 groups, 1-way analysis of
variance was used (ANOVA). Correlation data was assessed by using Spearman’s non-
parametric analysis.
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4.4 Results
4.4.1 Mice protected from NTN demonstrate few calprotectin (S100A8/A9)
expressing macrophages
Previous work done by Dr. K. Chavele had demonstrated that mice deficient in mannose
receptor (MR-/-) were protected from accelerated nephrotoxic nephritis. This protection
was explained by an alteration in the phenotype of MR-/- macrophages to a less
inflammatory phenotype, as well as impaired Fc mediated activity. Other work in our lab by
Dr. S. Hamour demonstrated that mice deficient in IL17-/- were also protected from renal
disease in NTN. In both these animal groups, the mice protected from disease had similar
CD68 macrophage infiltration as WT animals with disease. Using paraffin fixed formalin
embedded kidney sections from these previous experiments, the presence of macrophages
positive for S100A8/A9 was investigated.
WT (n=9), IL17-/- and MR-/- mice (n=4 of each) were tested. These animals had previously
been assessed for CD68 macrophage infiltration by immunohistochemistry on frozen
sections. In the IL17-experiments, WT mice demonstrated a median of 1.94 CD68
macrophages per glomerular cross section (range 1.68-2.72), while IL17-/- mice
demonstrated a median of 2.5 macrophages per glomerular cross section (range 1.72-3.28).
However, IL17-/- mice demonstrated significantly less S100A8/A9 positive cells (median 0.32
[range 0.08-0.36]) than WT mice (median 2.54 [range 0.68-3.28])(Mann-Whitney t-test
p<0.05).
Similarly, in the MR experiments; 5 WT mice and 4 MR-/- mice demonstrated a non-
significant difference in CD68 macrophage infiltration (median CD68 infiltration in WT mice
1.32 [range 0.24-1.6], MR-/- mice median 0.82 [range 0.64-1.28]). The MR-/- mice
demonstrated very few S100A8/A9 positive cells; median 0.14 [range 0.04-0.32]. When
comparing the ratios of S100A8/A9 positive cells/CD68 cells, IL17-/- and MR-/- cells
demonstrated similar ratios of 0.11 and 0.18 respectively, with WT mice demonstrating a
higher ratio of 1.1.
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4.4.2 WT mice demonstrate early infiltration of S100A8/A9 positive cells
Immunohistochemistry was performed to assess the early infiltration of cells positive for
S100A8/A9. During 2 separate nephrotoxic nephritis time course experiments in WT mice,
animals were sacrificed at 4 time points following the induction of disease; at 0 hours, 4
hours, 24 hours and 48 hours. Formalin fixed paraffin embedded sections were used to stain
for the presence of S100A8/A9 positive cells. 25 glomeruli were counted per section, and
then the average number of glomeruli calculated per animal.
At 0 hours, there was a mean of 0.06 S100A8/A9 positive cells. This increased to a mean of
2.48 cells/glomerular cross-section (gcs), but by 24 hours, this has decreased to a mean of
1.06 cells/gcs and decreased further by 48 hours to 0.66. This demonstrates that in NTN,
there is an early influx of S100A8/A9 positive cells, consistent with the known early
neutrophil infiltration in this model.
Figure 4-3 During NTN there is early infiltration of S100A8/A9 positive cells.
Graph demonstrates the number of S100A8/A9 positive cells analysed by
immunohistochemistry on WT kidney sections during 2 separate NTN time-course
experiments. There is an early infiltration of S100A8/A9 positive cells which has peaked by 4
hours.
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4.4.3 Genotyping of mrp14-/- mice
PCR analysis was used to confirm the genotype of mrp14-/- mice. Ear clippings were used as
a source of genomic DNA which was isolated and amplified as described in the methods. The
primer sequence for the WT and the mutant DNA was kindly provided by Prof. Ivars. WT
mice demonstrate a band of 540 base pairs while mutant mice demonstrate a smaller band
at 235 base pairs.
Figure
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4.4.4 Mrp14-/- mice are protected from nephrotoxic nephritis
The accelerated nephrotoxic nephritis animal model was used. Animals were pre-immunised
at day -5 with 200µl of a 1:1 dilution of complete Freund’s adjuvant (CFA) and 0.2mg sheep
IgG diluted in 0.9% sterile saline. At day 0, nephrotoxic serum (NTS) was injected by the tail
vein at a dilution of 1:1 with 0.9% sterile saline. Mice were placed in metabolic cages the
day prior to sacrifice and urine was collected. Mice were sacrificed between days 7-9.
A pilot study was initially performed as a new batch of NTS was used and there is known to
be batch to batch variation in NTS. 5 WT mice using a dilution of NTS 1:1, 5 WT mice using
NTS 1:4 and 3 mrp14-/- mice using a dilution 1:1 were included in the pilot study. The pilot
study demonstrated a non-significant trend to an improved renal function in the mrp14-/-
mice (WT 1:1 urea median 10.3mmol/l [range 7.8-17.5], WT 1:4 median 10.6mmol/l [range
6.6-79.1mmol/l], mrp14-/- median 8.2mmol/l [range 7.6-8.4]). There was a trend to less
thrombosis in the mrp14-/- group (median thrombosis score WT 1:1 0.36, WT 1:4 0.16 and
mrp14-/- 0.04). There was also a trend to less CD68 macrophage infiltration median WT 1:1
1.54 [range 1.25-1.72], WT 1:4 0.8 [range 0.2-2] and mrp14-/- 0.31 [range 0-0.68])(WT 1:1 v
mrp14-/- 1:1 p=0.057 Mann-Whitney t-test). The results lacking significance reflect the small
numbers of mrp14-/- animals used in this pilot study. Subsequent NTN experiments were
therefore performed using an NTS dilution of 1:1.
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NTN experiments were performed using NTS diluted 1:1 in 0.9% sterile saline. The mice
were monitored closely for 7-8 days before being place in metabolic cages and scarified the
following day.
Two nephrotoxic nephritis experiments were carried out using 9 WT and 9 mrp14-/- mice in
the first experiment and 9 WT and 8 mrp14-/- mice in the second experiment. The
experiments differed in that in experiment 1 the animals had milder disease, the
nephrotoxic serum was administered intra-peritoneally, and the mice were sacrificed on day
7. In the second experiment, the mice were administered with intravenous nephrotoxic
serum and sacrificed on day 9.
4.4.4.1 Renal histology
WT mice developed significant glomerular abnormalities with thrombosis and marked
tubular dilatation. Few crescents were seen. In experiment 1, WT mice demonstrated a
median thrombosis score of 0.2 (range 0-3.84). None of the mrp14-/- demonstrated any
thrombosis. The difference between these 2 groups was not significant. In experiment 2 the
median thrombosis score in WT mice was 0.52 (range 0-3.48), and in mrp14-/- mice the
median score was 0 (range 0-3.28). The difference between theses 2 groups was not
significant. A 2-way ANOVA determined there was no significant differences between these
2 experiments (p=0.14) allowing me to combine data from experiments 1 and 2. When
combined, the median thrombosis score in WT mice was 0.32 (0-3.84) and in mrp14-/- 0 (0-
3.28), with the 2-way ANOVA demonstrating a significant difference between WT and
mrp14-/- mice, (p<0.05).
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4.4.4.2 Proteinuria and renal function
Urine was collected in metabolic cages overnight. Proteinuria was measured using the
sulphosalicylic acid method. In experiment 1, there was very little proteinuria in the mrp14-
/- mice (median 0.33mg/24 hours [range 0-0.84] The WT mice demonstrated varying
amounts of proteinuria (median 0.37mg/24hours [range 0-22.75] and although the trend
was less proteinuria in the mrp14-/- mice, this difference was not significant. Similarly, in
experiment 2, mrp14-/- had less proteinuria (median 0.83mg/24hours [range 0.37-9.4] than
WT mice (median 6.54mg/24 hours [range 0.35-20.13] but was this trend was not
significant. 2-way ANOVA analysis showed there was no difference between the 2
experiments, therefore the animals from experiment 1 and 2 were combined. There was a
significant difference in the proteinuria between WT mice and mrp14-/- mice (p<0.05).
Figure 4-8 Mrp14-/- mice show a trend to less proteinuria than WT mice when induced
with NTN
(i) Graph demonstrates the amount of proteinuria (mg/24 hours) in experiment 1 and 2. The
difference between the 2 animal groups was not significant; however the trend is similar in
experiment 1 and experiment 2. (ii) The results were analysed with a 2-way ANOVA. There
was not a significant difference between the experiments (p=0.61), but there was a
significant difference between the animal groups (p=0.015). Graphs (i)-(ii) show the data
from each individual animal with a line representing the median.
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In experiment 1, disease in the WT mice was less severe than that in experiment 2. There
was no difference in the urea results in experiment 1 with WT mice having a median urea of
8.6mmol/l (range 6.6-42.5) and mrp14-/- mice a median urea of 7.6mmol/l (range 5-11.3).
In experiment 2, there was a significant difference between the 2 groups. WT mice had a
median urea of 14.1mmol/l (range 10.8-139). Mrp14-/- mice had a median urea of
7.45mmol/l (range 3.2-69.3)(Mann-Whitney p<0.05).
Serum creatinine is a poor marker of renal injury in mice, so was not used in the analysis.
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4.4.4.3 Leucocyte infiltration
Frozen sections of kidney were cut and stained for CD68 positive macrophages to
investigate macrophage infiltration into the glomerulus. 25 glomeruli per section were
included and the macrophages counted in each glomerulus before a mean was calculated. In
both experiment 1 and experiment 2 there were significantly more macrophages infiltrating
the glomeruli of WT animals compared to mrp14-/-.
In experiment 1; WT median number of macrophages per glomerulus was 1.2 (range 0-
1.72), compared to mrp14-/- median 0.08 (range 0-1)(p<0.05 Mann Whitney U test).
In experiment 2; WT median macrophages/gcs 3.64 (range 1.48-4.96) compared to mrp14-/-
median 1.32 (range 0.6-2.64)(p<0.001). A 2-way ANOVA demonstrated significant
differences between the experiments as well as the animal groups so the data was therefore
not combined.
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4.4.4.4 Systemic immune response4.4.4.4.1 Experiment 1
Mouse serum was isolated from blood, collected after the animals were sacrificed, to assess
the murine response to sheep IgG, by ELISA. Experiments 1 and 2 will be discussed
separately. Serum from a control mouse without NTN induction demonstrated very low
levels of total mouse anti-sheep IgG, which was not significantly above control ELISA level.
All the mice analysed had generated an appropriate immune response.
In experiment 1, there was no difference in the total IgG between WT and mrp14-/- mice,
WT median OD 0.88 (0.28-1.88) compared to 0.44 (0.01-1.34). Although the difference may
suggest that mrp14-/- mice generate lower antibody titres against total sheep IgG, this was
not statistically significant. Mouse antibodies against sheep IgG subclasses were also
investigated (IgG1, IgG2b, IgG2c, IgG3) by ELISA. Both animal groups had a similar IgG1, IgG3
and IgG2b responses to sheep IgG with a median OD for IgG1 WT 0.43 (range 0.002-0.66)
and a mrp14-/- median of 0.39 (range 0.05-0.57), IgG3 WT median OD of 0.042 (0-0.15) and
an mrp14-/- median OD 0.004 (range 0-2.4) and for IgG2b WT median 0.3 (0.06-0.78)
compared to mrp14-/- median OD 0.15 (0.02-0.5). However, WT mice generated a greater
IgG2c responses than mrp14-/- mice with a median IgG2c OD 0.095 (0-0.22) compared to a
mrp14 -/-median of 0 (0-0.02)(p<0.05, Mann Whitney U)
Overall, despite similarities in total the IgG response, WT mice demonstrated a significantly
higher IgG2c response than mrp14-/- mice.
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Figure 4-13 WT and mrp14-/- mice have a similar total IgG response but mrp14-/- mice
have a decreased IgG2c response to sheep IgG during NTN [experiment 1].
Graphs show the median (interquartile range) of total IgG(i), IgG1(ii), IgG2b(iii), IgG2c(iv) and
IgG3 (v) of the mice in experiment 1. The difference is not significant in the IgG subclasses
except IgG2c (p<0.05)(Mann-Whitney-U test)
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4.4.4.4.2 Experiment 2
Serum from experiment 2 was also analysed for the circulating mouse IgG response to
sheep IgG. Similar to experiment 1, ODs were measured by ELISA at 405nm. In this
experiment, there was no difference between WT and mrp14-/- mice with respect to total
IgG analysed, IgG3, IgG1, IgG2b, or IgG2c subclasses; WT vs mrp14-/- median OD total IgG
0.38 (range 0.04-0.89), vs 0.47 (range 0.29-1.67), IgG3 0.015 (range 0.007-0.09) vs 0.03
(range 0.005-0.07); IgG1 0.75 (range 0.40-1.28) vs 0.54 (range 0.31-1.09); IgG2b 0.05 (range
0.02-0.2) vs 0.13 (range 0.03-0.31); IgG2c 0.03 (range 0.02-0.12) vs 0.046 (range 0.007-
0.09).
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Figure 4-14 WT and mrp14-/- have a similar IgG response to sheep IgG during NTN
(experiment 2).
Graphs show the median (interquartile range) of total IgG(i), IgG1(ii), IgG2b(iii), IgG2c(iv) and
IgG3 (v) of the mice in experiment 2. The difference in OD of the IgG subclasses between WT
and mrp14-/- mice was not significant.
157
4.4.4.5 T cell responses
Splenocyte T cell proliferation was compared between WT and mrp14-/- mice during
nephrotoxic nephritis. Following experiment 2, spleens were harvested at termination. The
isolated splenocytes were subsequently stimulated with anti-CD28/CD3 or aggregated
sheep IgG (10µg/ml and 50µg/ml) and compared with unstimulated splenocytes. After 72
hours of incubation, 3H thymidine was added followed by assessment of T-cell proliferation
using a micro-beta counter (counts per minute c.p.m)
WT splenocytes demonstrated a lower proliferation rate than mrp14-/- splenocytes. Median
6976 c.p.m (4568-8758) for WT splenocytes; and 13422 c.p.m (range 10139-22949) for
mrp14-/- splenocytes. To calculate the proliferation in response to anti-CD3/CD28 and
sheep IgG, the proliferation rate unstimulated was subtracted from the conditions above.
There was no significant difference between the 2 animal groups in response to anti-
CD3/CD28, low dose sheep IgG (10µg/ml) and high dose sheep IgG (50µg/ml). Although
proliferation in the mrp14-/- splenocytes was less than WT splenocytes following higher-
dose aggregated sheep IgG (50µg/ml), it did not reach statistical significance.
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4.4.4.6 Not all WT macrophages are positive for S100A8/A9
Formalin fixed paraffin embedded sections from WT mice used in experiment 2 were
stained for S100A8/A9 following NTN and the mean number of cells positive for S100A8/A9
for each animal was calculated and compared to the number of CD68 macrophages in the
same sections. Only a subset of CD68 positive macrophages was positive for S100A8/A9.
This demonstrates that different macrophage subsets are present within the inflamed
glomerulus with only a proportion of infiltrating macrophages expressing S100A8/A9. There
was no correlation between glomerular thrombosis and the number of either S100A8/A9
positive or CD68 positive cells.
Figure 4-16 A subset of infiltrating glomerular macrophages express S100A8/A9
The graph demonstrates that in WT animals with nephrotoxic nephritis only a proportion of
infiltrating glomerular macrophages express S100A8/A9. The median number of CD68
macrophages per glomerulus was 3.64 (range 1.48-4.69). This decreased to a median of 1.48
(range 0.24-1.96) for S100A8/A9 positive cells. The ratio of S100A8/A9 positive cells/CD68
cells was 0.34. This is higher than the ratio of 0.11 and 0.18 for IL17-/- and MR-/- mice
respectively.
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Figure 4-17 Photomicrographs [(i) x400 and (ii)
expressing S100A8/A9 in NTN mouse glomeruli
A proportion of mouse glomeruli have infiltratin
during NTN.
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4.4.5 Mrp14-/- mice are protected from nephrotoxic nephritis using low dose
LPS- experiment 3.
Since experiments 1 and 2 demonstrated disease in WT mice that was attenuated in mrp14-
/- mice, it was interesting to test if disease protection could be overcome in mrp14-/- by
direct TLR4 stimulation. To stimulate TLR4 alone highly purified LPS was used at a low dose.
Highly purified LPS (from E.coli) has been demonstrated to stimulate TLR4 and not other TLR
receptors, such as TLR2, unlike other less purified LPS preparations. After several pilot
studies investigating varying doses of LPS, a dose was chosen which, when administered to
WT mice intravenously, in the absence of nephrotoxic serum, did not cause significant
histopathological changes (figure 4-18). However, the chosen dose, when used in
combination with NTS, results in a severe thrombotic glomerulonephritis.
WT (n=8) and mrp14-/- (n= 7) mice were pre-immunised with CFA and sheep IgG on day -5,
then on day 0, a dose of LPS (0.009 mcg) was given to each mouse at the same time as
nephrotoxic serum (diluted 1:1 with the above concentration of LPS). Mice were placed in
metabolic cages on day 7 to collect urine and were culled on day 8.Figure 4-18 LPS alone doesn’t cause a glom
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4.4.5.1 Renal histology
Kidney sections stained with H+E and PAS where assessed and scored for glomerular
thrombosis. The median glomerular thrombosis score in WT mice was 1.98 (range 0-4) and
in mrp14-/- mice the median score was 0 (range 0-2.88). The difference between these 2
groups was not significant at p=0.07. Combining this experiment with the thrombosis scores
in experiments 1 and 2 and analysing by a 2-way ANOVA demonstrates no difference
between the experiments (p=0.178). However, there is a significant difference between the
WT and mrp14-/- mice (p<0.005).
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Figure 4-20 Mrp14-/- mice demonstrate a trend to less glomerular thrombosis
Graph demonstrating the individual thrombosis score of the WT and mrp14-/- mice. There is
a trend to less thrombosis in the mrp14-/- mice, but this was not significant (p=0.07). Line
represents the median.
Figure 4-21 Mrp14-/- mice with NTN consistently develop less glomerular thrombosis than
WT counterparts.
Graph demonstrating the glomerular thrombosis score in WT and mrp14-/- mice in each of
the 3 experiments described. Each experiment when analysed separately shows a consistent
trend to less thrombosis in the mrp14-/- mice. A 2-way ANOVA demonstrated no significant
differences between the 3 experiments but did demonstrate a highly significant difference
between the 2 animal groups (**p<0.005). Graph demonstrating the median (interquartile
range) for each experiment.
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4.4.5.2 Proteinuria and renal function in experiment 3
There was proteinuria in both animal groups. WT animals had a median of 1.329 mg/24
hours (range 0-29.5), and mrp14-/- a median of 0.32mg/24 hours (range 0-2.9). The
difference between the 2 groups did not reach statistical significance. Using 2 way ANOVA
analysis, there was no difference between the 3 sets of experiments (p=0.87), but there was
a significant difference between the 2 animal groups (p<0.05).
Figure 4-22 Mrp14-/- mice with NTN demonstrate a trend to less proteinuria than WT
Graph demonstrating proteinuria (mg/24 hours) in WT and mrp14-/- animals. Line
represents the median
Figure 4-23 Mrp14-/- mice have consistently less proteinuria in the 3 sets of NTN
experiments described
Although the separate experiments did not reveal a statistical difference in proteinuria
between WT and mrp14-/- mice, combined they did show a difference (p<0.05). Graph
shows the median and interquartile range for proteinuria from the 3 NTN experiments
described.
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Mrp14-/- mice had a significantly lower serum urea than WT animals (median urea
6.6mmol/l (range 5.2-42.2) compared with 15.2mmol/l (range 6.9-128.8) respectively,
(p<0.05).
Figure 4-24 Mrp14-/- mice have better preserved renal function compared to WT mice.
Graph demonstrating the renal function (assessed by serum urea) in the 2 animal groups.
Mrp14-/- mice demonstrate preserved urea compared with WT animals (p<0.05). Each dot
represents a single animal with a line representing the median.
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4.4.5.3 Systemic immune response during NTN with low dose LPS
Mouse serum was isolated from blood collected at the time of sacrifice after nephrotoxic
nephritis. Serum was analysed by ELISA to assess the murine response to sheep IgG. Overall
the results demonstrate no difference in the humoral murine anti-sheep response between
WT and mrp14-/- mice, including no differences in total IgG response WT median OD 0.14
(range 0.03-1.3) vs mrp14-/- median 0.41 (0.01-1.1)(p=0.57); IgG1 WT median 0.15 (range
0.02-0.71) vs mrp14-/- median 0.23 (range 0.06-0.57)(p=0.35); IgG2b median WT 0.21
(0.008-0.55) and mrp14-/- median 0.26 (range 0.028-0.48)(p=0.46); IgG2c WT median 0.056
(range 0.006-0.717) vs mrp14-/- median 0.02 (0.015-0.048)(p=0.46); IgG3 WT median 0.14
(range 0.03-1.31) vs mrp14-/- median 0.42 (range 0.01-1.07)(p=0.57).
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Figure 4-25 Mrp14-/- mice have the same humoral response as WT animals following NTN.
Graphs show the median (interquartile range) of total IgG(i), IgG1(ii), IgG2b(iii), IgG2c(iv) and
IgG3 (v) in the sera of mice in experiment 3.
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Frozen kidney sections were stained for deposited sheep and mouse IgG by direct
immunofluorescence. For each mouse, 10 glomeruli were identified and photographed and
fluorescence measured by image analysis software.
With respect to mouse IgG deposition, there was similar fluorescence between WT and
mrp14-/- mice. The median WT score was 96.18 (range 65.35-140.2) and mrp14-/- median
123.1 (range 66.26-165)(p=ns)
With respect to glomerular sheep IgG, there was no difference between the 2 groups. The
median WT fluorescence was 25.96 (range 21.69-46.53) and Mrp14-/- median 38.76 (range
22.14-66.44).
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4.4.5.4 Leucocyte infiltration during NTN with low dose LPS
Frozen sections of mouse kidney were stained for CD68 and CD4 T cell infiltration. For each
animal, 25 glomeruli were counted and the mean number of cells per glomeruli calculated.
WT mice demonstrate significantly more glomerular CD68 infiltration than mrp14-/- mice.
Median WT number of CD68 cells per glomeruli was 1.7 (0.8-2.2) compared to mrp14-/-
mice with a median of 0.6 (range 0.44-2.1)(p<0.05).
Figure 4-28 Mrp14-/- mice have less glomerular CD68 infiltration than WT mice
Graph demonstrating the individual mouse values for CD68 infiltration in WT and mrp14-/-
animals. Line represents the median. There is a significant difference between the 2 groups
(p<0.05).
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There was no difference in the number of infiltrating glomerular CD4+ T cells demonstrated
by immunohistochemistry. The overall numbers were small with few T cells present. The
median number of T cells present in WT glomeruli was 0.12 (range 0-0.21), while in mrp14-
/- mice, the median was 0.12 (0-0.33). Although a difference was found in the previous NTN
experiment without low dose LPS, no difference was demonstrated in this experiment.
Figure 4-30 WT and mrp14-/- mice with NTN have a similar number of infiltrating CD4+ T-
cells.
Graph demonstrating similar glomerular T cell numbers. Line represents the median.
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4.4.5.5 Serum S100A8/A9 levels during NTN with low dose LPS
Serum S100A8/A9 levels were kindly measured by Dr T. Vogl, a collaborator at University of
Munster, Germany. WT mice (n=8) induced with NTN and low dose LPS had serum levels
measured following sacrifice on day 8 following administration of nephrotoxic serum. The
levels of S100A8/A9 were then analysed to detect any correlation with other parameters of
disease. The table below demonstrates the individual animal results.
Table 8 Table to demonstrate the serum S100A8/A9 levels (ng/ml) as measured by ELISA
in WT mice during NTN
Using Spearman’s correlation co-efficient for the 8 WT animals, there were significant
positive correlations between S100A8/A9 levels and serum urea (r=0.74)(p<0.05) as well as
glomerular thrombosis (r=0.9)(p<0.005). The mice with the most severe disease had the
highest levels of serum S100A8/A9, whereas those animals without much disease had much
lower levels, linking the serum levels of S100A8/A9 to disease severity.
Animal S100A8/A9
ng/ml
1 309
2 902
3 30363
4 3877
5 31428
6 776
7 11152
8 2020
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4.4.6 Mrp14-/- mice have a similar response to WT mice following
administration of high dose LPS after disease induction
The nephrotoxic nephritis model was altered slightly compared to the previous experiment
by increasing the dose and delaying the timing of additional LPS administration. Each mouse
received 1µg LPS intra-peritoneally at day 3 following the administration of nephrotoxic
serum. Day 7 the mice were placed in metabolic cages and were terminated on day 8.
4.4.6.1 Renal histology
The disease induced in the WT and the mrp14-/- animals was variable; however both the
animal groups had a similar response. Despite previous disease protection, mrp14-/- mice
now demonstrated similar disease severity as the WT mice, with no difference in the
thrombosis score; WT median thrombosis score was 1.36 (range 0.04-3.52) vs. mrp14-/-
mice median score of 0.92 (range 0-3.52)(p=ns).
4-32 Mrp14-/- and WT mice have similar thrombosis scores in NTN with high dose LPS.
Graph demonstrating the individual animals and their thrombosis scores. Line represents
the median. There is no difference between the 2 groups with both animal groups
demonstrating a variable degree of glomerular thrombosis.
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4.4.6.2 Proteinuria and renal function in NTN with high dose LPS after disease
induction
In line with the thrombosis score, there was a similar amount of proteinuria in the WT and
mrp14-/- groups. The median amount of proteinuria in the WT mice was 3.73mg/24 hours
(range 0.36-7.99). Mrp14-/- median was 4.19 (range 2.36-11.36). The difference was not
significant.
Figure 4-34 WT and mrp14-/- mice with NTN and additional LPS have similar proteinuria.
Graph above demonstrating each individual animal with the line representing the median.
There is no difference between the 2 animal groups.
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The renal function was also similar in both groups. Out of the 5 WT animals, all had an
abnormal urea median 13.3mmol/l [range 9.1-55.4]). In the mrp14-/- group, 3 of the
animals had preserved renal function, with the remaining 2 animals having severe renal
disease with a greatly deranged urea. The median urea in mrp14-/- mice was 7.4 (range 6.3-
81.6).
Figure 4-35 WT and mrp14-/- mice have similar renal dysfunction during NTN with LPS.
The graph above demonstrates the serum urea of each individual animal with the line
representing the median. There is no difference between the 2 animal groups.
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4.4.6.3 Leukocyte infiltration in NTN with high dose LPS after disease induction
Frozen sections of murine kidney were stained for macrophage (CD68) and CD4+ T cell
infiltration. 25 glomeruli were included and the mean number of macrophages per animal
calculated. Mrp14-/- mice demonstrated a trend to less CD68 macrophage infiltration
compared to WT mice, but this did not reach statistical significance. The median number of
macrophages infiltrating WT animals was 2.77 (range 1.57-6.8) and the mrp14-/- animals
median 1.84 (range 0.76-1.88)(p=0.056)
Figure 4-36 Mrp14/- mice demonstrate a trend to less CD68 infiltration during NTN with
LPS than WT mice.
Graph demonstrating macrophage infiltration. Mrp14-/- mice demonstrate a trend to less
CD68 glomerular infiltration following NTN compared with WT mice, but this is not
significant (p=0.056). Line represents the median.
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Both animal groups demonstrated a similar amount of glomerular CD4+ T-cell infiltration in
NTN; the results were not significantly different between the 2 groups. WT median 0.12
(range 0.04-0.44), mrp14-/- median 0.20 (range 0.16-0.24).
Figure 4-38 Mrp14-/- and WT mice display similar T cell infiltration during NTN with high
dose LPS
There was no difference between the number of infiltrating glomerular CD4+ T cells in WT
and Mrp14-/- mice with NTN and high dose LPS. Line represents the median.
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4.4.6.4 Systemic immune response in NTN with high dose LPS after disease
induction
Following sacrifice, mouse serum was collected and used to analyse the murine response to
sheep IgG. There were several differences in the response of the WT and mrp14-/- mice.
The total IgG response was similar between the 2 groups. WT mice had a median OD of 0.56
(range 0.1-1.9) and mrp14-/- mice a median of 0.27 (range 0.09-0.77). The difference was
not significant. The IgG3 response was also similar between groups WT median 0.56 (0.1-
1.9), mrp14-/- median OD 0.27 (0.09-0.77). However, mrp14-/- mice demonstrated
decreased IgG1, IgG2b and IgG2c responses; WT vs mrp14-/- : IgG1 median 0.25 (0.196-
0.75) vs 0.046 (0.03-0.156)(p<0.01); IgG2b median 0.25 (0.09-0.5) vs 0.067 (0.05-
0.08)(p<0.01); IgG2c 0.03 (0.014-0.25)vs 0.01 (0.009-0.015)(p<0.05).
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Figure 4-40 WT and mrp14-/- mice demonstrate different IgG responses during NTN with
high dose LPS
Graphs demonstrating the IgG and IgG subset responses of the mice to sheep IgG. Mrp14-/-
mice have a decreased IgG1 (p<0.01), IgG2b (p<0.01) and IgG2c (p<0.05) compared to WT
mice.
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1Direct immunofluorescence was used to analyse the deposition of sheep and mouse IgG on
the glomerular basement membrane. Although there was a difference in the systemic
response to sheep IgG; there was no difference between the animal groups with regard to
sheep or mouse antibody deposition on the glomerular basement membrane.
Immunofluorescence was quantified using arbitrary fluorescent units (AFU) and both groups
compared. There was no difference in the amount of mouse antibody deposition, median
WT AFU 113 (range 74-140) and mrp14-/- median 122 AFU (range 73-149).
Although there was a trend to greater amounts of sheep IgG deposition in the mrp14-/-
glomerulus, this was not significant. WT median 22 AFU (range 18-45) and mrp14-/- median
44 AFU (range 31-105)(p>0.05).
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4.4.7 The role of S100A8/A9 on circulating and intrinsic cells
To investigate the role of S100A8/A9 from haematopoietic cells and intrinsic cells, a bone
marrow transplant was performed. 8 WT to WT animals was used as a control. The other 2
groups consisted of 9 animals in each group; mrp14-/- to WT mice and WT to mrp14-/- mice.
Following bone marrow transplantation, the animals were left for 8 weeks to allow
haematopoietic reconstitution. NTN was then performed.
4.4.7.1 Reconstitution of bone marrow chimeras
At the end of the experiment, all mice were bled and the clotted blood used to assess for
bone marrow reconstitution. The intensity of the bands obtained was used to demonstrate
if reconstitution had occurred.
Figure 4-42 Genotyping of blood cells from bone marrow transplanted animals
demonstrating genetic reconstitution compared to WT or mrp14-/- mice
4.4.7.2 All animals were susceptible to renal disease
NTN was induced in the mice 8 weeks following bone marrow transplantation. The protocol
for inducing disease was similar to previous NTN experiments; mice were pre-immunised,
followed by intravenous injection of NTS (with low dose LPS) 5 days later. The mice were
sacrificed 8 days later. Disease was assessed by measurement of serum urea, proteinuria
and analysis of glomerular thrombosis. All groups were susceptible to disease.
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4.4.7.2.1 Renal function
All groups had severe renal disease. The median serum urea was 23mmol/l (range 4.6-53.2)
in the WT to WT group; in the mrp14-/- to WT the median was 37.5mmol/l (range 6.1-210)
and in the WT to mrp14-/- group the median was 38.9mmol/l (range 7.1-234). There was no
significant difference between the 3 groups (1-way ANOVA).
Figure 4-43 Renal function in bone marrow transplant recipients following NTN.
The graph above demonstrates the renal function (serum urea) in the 3 bone marrow
transplant groups- there was no significant difference between the groups. Line represents
the median.
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4.4.7.2.2 Proteinuria
Due to the limited capacity of the metabolic cages, 19 animals were placed in the cages
overnight and urine was collected for proteinuria. There was no significant difference
between the 3 transplanted groups. The median proteinuria (mg/24 hours) in the WT to WT
group was 9.83mg (2.7-16.86). In the mrp14-/- to WT group the median proteinuria was
8.95mg (0.45-32.8). WT to mrp14-/- group had median proteinuria of 2.73 (0.58-31.68).
Figure 4-44 Proteinuria in the bone marrow transplant recipients following NTN
There was no difference in the amount of proteinuria between the 3 groups. Line represents
the median.
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4.4.7.2.3 Glomerular thrombosis
Renal histology was assessed using the PAS stained paraffin sections. Consistent with the
other parameters of renal disease, there was no difference in the glomerular thrombosis
score between the 3 groups (1-way ANOVA). The median glomerular thrombosis score in
the WT to WT group was 1.72 (0-3.26); in the mrp14-/- to WT group was 1.58 (0-3.52) and in
the WT to mrp14-/- group the median was 2.08 (0.3.64).
Figure 4-45 Glomerular thrombosis score in bone marrow transplant recipients following
NTN
The graph demonstrates the thrombosis score in the 3 transplanted animal groups- there
was no statistical difference between the 3 groups (One-way ANOVA).
4.4.8 Mrp14-/- and WT mice have similar neutrophil infiltration using the non-
accelerated nephrotoxic nephritis model
The non-accelerated model of NTN was performed. This assesses the early neutrophil influx
at 2 hours. 9 animals in each group were included. Unlike the previous models of NTN, mice
were not pre-immunised. Instead, mice were administered with nephrotoxic serum via the
tail vein and then killed 2 hours later.
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at 2 hours in the WT mice was 0.6 (0.44-2) and in the mrp14-
neutrophils was 0.71 (0.56-1.2)(p=ns).
Killed 2 hours later
Figure 4-46 WT and mrp14-/- have similar early neutrophil influx in non-accelerated NTN
Graph demonstrating the individual animals and the calculated mean number of neutrophils
per animal. The line represents the median. The differences between the 2 animal groups
are not significant.
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4.5 Discussion
The experiments included in this chapter demonstrate that S100A8/A9 has a significant role
in nephrotoxic nephritis. Macrophage glomerular infiltration is a feature of the NTN model
and I found the presence of different macrophage phenotypes in mice during NTN with
respect to S100A8/A9. Two strains of knock-out mice (MR-/- and IL17-/-) protected from
NTN, demonstrate reductions in S100A8/A9 expression in their infiltrating macrophages-
linking disease associated macrophages with S100A8/A9.
Surprisingly, S100A8/A9 did not seem to play a role in mediating neutrophil influx in NTN.
Neutrophil influx occurs following interaction of the neutrophil with the endothelium
following the injection of heterologous antibodies to the glomerular basement membrane.
It is an important stage of glomerular injury and it has previously been demonstrated that
injury in the heterologous phase of NTN is dependent on neutrophils (Henson 1972). This
influx occurs at about 2 hours following NTS, and reaches a maximum at 2-4 hours (Unanue
and Dixon 1967). S100A8/A9 is abundantly expressed in neutrophils, and there is an early
influx of cells positive for S100A8/A9 which peaks at 4 hours following administration of
nephrotoxic serum. This demonstrates that cells positive in S100A8/A9 infiltrate the
glomerulus early on in NTN, but then decrease by 48 hours. The non-accelerated
heterologous experiment assessed whether mrp14-/- mice had the same amount of early
neutrophil influx as WT mice. This experiment demonstrates that S100A8/A9 is not required
for neutrophils to interact with the endothelium during NTN and infiltrate the glomerulus.
Therefore decreased neutrophil infiltration is not a mechanism by which mrp14-/- mice
have decreased disease during NTN. The neutrophils that are deficient in S100A8/A9 may
have different functional behaviour with respect to their pro-inflammatory profile, but this
was not investigated.
This chapter includes several NTN experiments. The nephrotoxic nephritis animal model can
have variable results of disease parameters, therefore when possible; results have been
combined to increase the number of animals in each group. Experiment 1 resulted in
generally milder disease with none of the mrp14-/- animals affected. Experiment 2 resulted
in a shift in disease severity with more WT animals affected and with a minority of mrp14-/-
being susceptible to disease. However, when combined the results demonstrate significantly
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less disease in the mrp14-/- mice. The results consistently demonstrate a decrease in
glomerular macrophage influx in the mrp14-/- mice. This is consistent with the hypothesis
that S100A8/A9 has a role in monocyte adhesion, for example by the upregulation of ICAM-
1, followed by transmigration through the endothelium to the site of local inflammation.
Mice therefore lacking this complex have a decreased macrophage ability to infiltrate the
glomerulus. Additionally, once the glomerulus has been infiltrated, as well as a greater
number of macrophages being present to participate in inflammation, the complex may
then have additional autocrine and paracrine effects to further amplify inflammation. It has
been described that it’s not just the presence of absence alone of macrophages which
contribute to the inflammatory response but also the macrophage function (Kluth, Erwig et
al. 2004).
NTN has been considered to be a Th1 model of disease, with T-cells playing a crucial role in
disease pathogenesis. This has been illustrated by mice deficient in IFN-γ having decreased 
renal injury in NTN with a reduction in effectors cells such as CD4 T cells and macrophages
(Kitching, Holdsworth et al. 1999). However, it is now increasingly recognised the role of
IL17 T-cells in the pathogenesis of autoimmunity, with disease protection in IL-23 p19-/-
mice during NTN (Paust, Turner et al. 2009), and protection in IL17-/- mice during NTN
(S.Hamour unpublished). In experiment 2, there was significantly less T-cell infiltration in
mrp14-/- mice as well as less macrophage infiltration. The decrease in CD4 T cells may then
also have contributed to decreased disease in the mrp14-/- mice due to the crucial role T
cells are known to play in NTN.
Experiment 1 and 2 had different results following detection of IgG subclasses. Different IgG
subclasses are associated with either a Th1 or a Th2 response. IgG2a isotype can fix
complement, and a reduction in this subtype has been associated with a reduction in renal
injury (Kitching, Holdsworth et al. 1999). The Th-1 cytokine, INF-γ, is able to induce IgG2a 
production, as well as inhibit IgG1, IgG3 and IgG2b. IgG2a has the ability to also induce
macrophage antibody-dependent cellular cytotoxity (Snapper and Paul 1987). During NTN,
treatment of mice with the Th2 cytokines (IL-10 or IL-4) has been shown not to result in a
change in the overall titres of anti-sheep antibodies, but instead changes the profile of the
IgG subclasses. IL-4 resulted in a decrease in the titres of IgG2a, IgG2b and IgG3, with a
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decrease in IgG2a and IgG3 following treatment with IL-10. The Th-2 associated IgG1 was
shown to be relatively spared in this model. Histologically, the mice treated with the Th-2
cytokines resulted in an attenuation of glomerular injury (Tipping, Kitching et al. 1997).
Experiment 1 was characterised by quite mild disease with no differences in renal function
between the 2 groups, despite a trend to less thrombosis and proteinuria with significantly
less macrophage infiltration. Mrp14-/- mice had significantly less IgG2a, with no significant
glomerular injury and no glomerular thrombosis in any of the mice. Although the disease
was quite mild in the WT mice, they did have a range of glomerular abnormalities.
Experiment 2 was unable to demonstrate a similar result. Generally, experiment 2 differed
from experiment 1 with respect to a greater proportion of both animal groups being
affected by disease, although the mrp14-/- mice had better preservation of renal function
and less macrophage and T cell infiltration than the WT group. Therefore, as disease
parameters may have increased in both groups in experiment 2, the difference in IgG2a
became less apparent.
Following experiment 2, the T-cell response during NTN was investigated. At rest, when
unstimulated, T cells isolated from mrp14-/- mice following NTN had a higher basal rate of
proliferation. The role of T-cells in mrp14-/- mice has been further explored in
transplantation models. MHC-class II allomismatched cardiac grafts transplanted into WT
and mrp14-/- mice resulted in a decreased survival in mrp14-/- mice, with an increase in
accumulation of macrophages and T-cells in the mrp14-/- mouse grafts. Additionally, there
were higher levels of INF-γ and IL-17 in infiltrating CD4+ T-cells (Shimizu, Libby et al. 2011). 
Although there are significant differences between this transplantation experiment and
NTN, the isolated splenocytes from mrp14-/- in the transplantation study also demonstrated
an increase in proliferation rate at rest compared to WT splenocytes, however, there was no
difference in either group following stimulation with CD3, consistent with the results that
we have obtained. In the transplantation model, the loss of mrp14-/- had a significant effect
on expression of co-stimulatory molecules and antigen presentation and T-cell priming.
During NTN, consistent with the above results, there is an increase in splenocyte
proliferation at rest, with no increase detected following anti-CD3/CD28 stimulation.
However, stimulation with sheep IgG resulted in a non-significant trend to less proliferation
in the mrp14-/- splenocytes.
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I tested the effect of LPS on NTN. Highly purified LPS is a TLR4 ligand. This experiment tested
the hypothesis whether direct stimulation of TLR4 by initially low dose then high dose LPS
would render the mrp14-/- mice susceptible to renal disease. In the endotoxic shock model,
mrp14-/- mice had an increased survival following LPS compared to WT mice (50µg/kg
I.P)(Vogl, Tenbrock et al. 2007). The NTN experiment used a lower dose of LPS to ensure
that the mice would survive till the end of the experiment 8 days later. It is recognised that
batches of nephrotoxic serum contain varying degrees of LPS contamination, with a
correlation between the degree of endotoxin contamination and the ability of the
nephrotoxic antibody to induce albuminuria in the rat (Karkar and Rees 1997). LPS has
previously been demonstrated to cause no glomerular abnormalities when administered
alone, however in a rat model of NTN using rabbit globulin the administration of LPS prior to
NTS results in an exacerbation of renal injury with increased proteinuria and increased
glomerular thrombi. LPS is known to result in increased neutrophil adhesion to the
endothelium as well as an increase in neutrophil influx (Tomosugi, Cashman et al. 1989).
In the low dose LPS experiment mrp14-/- mice showed a trend to less thrombosis and
significantly improved renal function. In this experiment, there was no difference in the
systemic antigen response with a non-significant decrease of the Th-1 associated
complement fixing IgG2c. There was no difference in the amount of T-cell infiltration which
may have been due to LPS resulting in an early increase in the neutrophil influx in both
groups with the resulting T cell infiltration which was equal in both animal groups. However,
CD68 macrophage infiltration was significantly less, consistent with the hypothesis that
S100A8/A9 has an important role in the adhesion of macrophages to the glomerular
endothelium and the resulting transmigration. This group of WT mice also had serum
S100A8/A9 levels measured, with very high serum levels in those mice with a severe
thrombotic GN. Therefore this links S100A8/A9 expression with disease parameters
suggesting that this complex is a biomarker of renal injury in NTN, as well as contributing to
disease pathogenesis. Considering that mrp14-/- has disease protection when LPS and NTS
are administered during NTN, the following experiment was designed to investigate if
disease could therefore be induced when a higher dose of LPS was used after the initiation
of disease. Previous studies administering LPS to exacerbate disease in NTN, have given LPS
as a pre-treatment prior to the administration of NTS aiming to increase disease primarily
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through the increase in the early neutrophil response. In the following experiment, LPS was
administered at a higher dose at day 3 after NTS. By day 3, the neutrophil influx has
disappeared and monocytes/macrophages are starting to infiltrate the glomerulus and play
an important role in disease pathogenesis. Despite similarities in the glomerular mouse and
sheep IgG deposition, there were differences in the systemic IgG response to sheep IgG.
Mrp14-/- mice had a similar total IgG response but there were differences in the IgG
subclasses. From this experiment, we can conclude that direct high-dose TLR4 stimulation
with LPS overwhelms the protection resulting from a lack of S100A8/A9, and therefore has
the ability to induce disease in mrp14-/- mice of a similar severity to WT mice.
The results of the bone marrow transplant experiment demonstrate that to have protection
from renal disease, total deficiency of S100A8/A9 is necessary, as all three animal groups
had the same severity of renal disease. This could have been confirmed if we had performed
mrp14-/- to mrp14-/- transplants, but these were not possible due to limited animal
numbers. This experiment illustrates that circulating haemopoietic cell and intrinsic
(radioresistant) cell production of S100A8/A9 are both important mediators of
inflammation. This is reminiscent of data from bone marrow chimeras used to investigate
the effect of S100A9 deficiency on the development of systemic atherosclerosis (Averill,
Barnhart et al. 2011). In that study, absence of haemopoietic S100A9 was not sufficient to
suppress systemic inflammation and atherosclerosis, (Croce, Gao et al. 2009). These
somewhat surprising results were attributed to S100A9 deficiency in dendritic cells, the
presumed main source of S100A8/A9 in atherosclerotic lesions, augmenting inflammation,
suggesting that under normal circumstances they may have an anti-inflammatory role in this
disease model (Averill, Barnhart et al. 2011)..
Additionally, it is recognised that under inflammatory conditions, non-myeloid cells may also
produce S100A8/A9. This is clearly illustrated by the production of S100A8/A9 in the renal
collecting ducts, which results in interstitial monocyte recruitment and their differentiation
into inflammatory M1-type macrophages causing renal epithelial cell injury and
inflammation in a murine ureteric obstruction model (Fujiu, Manabe et al. 2011). However,
the question remains unanswered as to which radioresistant cell in the kidney may also be
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producing S100A8 and S100A9 and possibly be contributing to glomerulonephritis. Future
work should focus on confirming S100A8/A9 expression in the NTN kidney.
The antigen induced arthritis model also supports the role of S100A8/A9 during
inflammation. Humoral immunity in WT and mrp14-/- mice was similar between the 2
groups, as was cellular T-cell responses. Similar to NTN, mrp14-/- mice had decreased joint
inflammation, with S100A8/A9 stimulation of macrophages having an important role in joint
destruction (van Lent, Grevers et al. 2008). Therefore, there is more than one animal model
of inflammatory disease demonstrating a role of S1008/A9 in the disease aetiology.
The following chapter therefore investigates the pro-inflammatory mechanism of
S100A8/A9 on different cell types known to play an important role in glomerulonephritis.
4.5.1 Summary
 Mrp14-/- mice in NTN have less disease than WT mice, which has not previously
been described before.
 Mrp14-/- mice administered LPS and NTS have preserved renal function compared to
WT mice.
 Disease can be induced in mrp14-/- mice after the administration of high dose LPS
on day 3 of NTN.
 Both myeloid and intrinsic renal production of S100A8/A9 contributes to disease as
demonstrated by the bone marrow transplant experiments.
 There is no difference in the early neutrophil influx in WT and mrp14-/- mice.
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Chapter 5 Mechanisms of disease protection and the pro-
inflammatory effects of S100A8/A9
5.1 Introduction
In the previous chapters, I have demonstrated that S100A8/A9 may have a role in human
disease and be a potential biomarker of disease activity. Additionally, the animal work
demonstrated that mice deficient in S100A8/A9 are protected from disease demonstrating
that the heterodimer may also have a role in disease pathogenesis. Mice deficient in
S100A8/A9 are protected in other murine models of autoimmunity, such as the antigen
induced arthritis model (van Lent, Grevers et al. 2008). In this model S100A9-/- mice are
protected from arthritis, with a significant reduction in osteoclasts within the knee joints
after 7 days. This study demonstrated that S100A8, S100A9 and S100A8/A9 had differential
effects on osteoclast formation and bone resorption. Both S100A8 and S100A9 are strongly
expressed in osteoclasts, although these proteins are not required for the normal
development of osteoclast precursors. In-vitro work demonstrated that S100A8 is the active
component of the heterodimeric complex, with S100A8 having the ability to upregulate
activatory Fc-gamma receptors and MMP more potently than either S100A8/A9 or S100A9.
S100A8 homodimers, as well as the heterodimer S100A8/A9, have been found within
inflammatory arthritis. This effect of S100A8 on macrophages was abrogated in TLR4-/-
deficient cells (van Lent, Grevers et al. 2010). Similarly, stimulation of osteoclasts with
S100A8 increased osteoclast numbers and bone resorption unlike stimulation with
S100A8/A9 or S100A9 and was dependent on TLR4 but not RAGE (Grevers, de Vries et al.
2011). Pro-inflammatory cytokine secretion by chondrocytes was also stimulated by the
individual S100 proteins, with an increase in the mRNA of IL-1β and IL-6 (not TNF-α). Again,
similar to previous studies, the effects of S100A8 and S100A9 were mediated through TLR4
with no change in the stimulation assays following blocking of RAGE, in agreement with
previous experiment data (Schelbergen, Blom et al. 2012).
In order to investigate the particular role of S100A8/A9 in autoimmune glomerular disease,
it is important to consider the cell types which may have a role in mediating disease. Within
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the glomerulus; the endothelial cell, the mesangial cell and the infiltrating
monocytes/macrophages may all potentially have a role in S100A8/A9-mediated
inflammation. TLR4 has already been shown to have a role in crescentic glomerulonephritis
with both intrinsic renal cell and infiltrating leukocyte TLR4 expression playing a role in
mediating disease (Brown, Lock et al. 2007). Potentially, S100A8/A9 may interact with TLR4
on the endothelium, as well as on novel carboxylated glycans and heparin sulphate
proteoglycans, or S100A8/A9 may act in an autocrine manner and once released bind to
TLR4 expressed macrophages/monocytes. Mesangial cells, a type of vascular pericyte,
provide structural support thus maintaining glomerular integrity, as well as regulating
glomerular filtration pressure and are known to express RAGE, through which S100A8/A9
may act, resulting in a proinflammatory effect. TLR4 may also be expressed on mesangial
cells, as demonstrated by in-situ hybridisation on kidney tissue and by PCR using primary
murine mesangial cell lines (Brown, Lock et al. 2007).
Cytokines, such as IL-8 and MCP-1, have important roles in glomerular inflammation
mediating chemotaxis and adhesion of neutrophils and monocytes. MCP-1 is produced by
several key cells found within an inflamed glomerulus such as macrophages, mesangial cells,
endothelial and smooth muscle cells. TNF-α primed mesangial cells results in an increase in
MCP-1 by the mesangial cells, and leads to a dose-dependent increase in monocyte
migration (Pai, Ha et al. 1996). Additionally, activated mesangial cells can also produce the
pro-inflammatory cytokine IL-12, which has diverse effects on NK cells, B cells and T-cells
and has been implicated as a key cytokine in autoimmunity (Bussolati, Mariano et al. 1999).
The interaction between mesangial cells and macrophages can be significant and may be
mediated by pattern-recognition receptors (PRR). Work done in our laboratory by Dr.
Chavele, has demonstrated that mice deficient in the mannose receptor (MR-/-) are
protected from crescentic glomerulonephritis using the nephrotoxic nephritis animal model.
MR-/- macrophages display a less inflammatory phenotype following their interaction with
apoptotic mesangial cells (Chavele, Martinez-Pomares et al. 2010). Further PRRs are the toll-
like receptors, which interact with danger associated molecular patterns (DAMPs), such as
S100A8/A9. These are generally proteins, released as a consequence of tissue injury, which
then promote the inflammatory response and may have a role in autoimmunity.
Experiments by Dr. Chavele and by Dr. Sally Hamour in our laboratory (unpublished)
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demonstrated that mice deficient in MR and IL-17 respectively, induced with NTN, result in a
similar number of glomerular macrophages as WT mice, despite the knockout animals
demonstrating significantly less disease, assessed by renal function, proteinuria and
glomerular histology. As shown in the previous chapter, the macrophages in both these
animal groups are different to the WT with respect to S100A8/A9 positivity, providing
further evidence that it is not only the presence or absence of macrophages, but their
phenotype which is associated with disease.
Previous work has demonstrated that one mechanism by which mrp14-/- mice were
protected in the endotoxic shock model was as a result of a decreased response to LPS.
Mrp14-/- bone marrow cells (BMC) had a decrease in TNF-α induction with reduced
activation of the transcription factor NF-κB (Vogl, Tenbrock et al. 2007). The secretion of 
TNF-α was restored following stimulation of bone marrow cells by S100A8 alone, while
S100A9 andS100A8/A9 had no effect when given alone, but did promote augmented TNF
secretion when co-cultured with LPS.
5.2 Aim
This chapter focuses on the mechanisms which account for the differences in renal disease
severity seen in WT and mrp14-/- mice described in the previous chapter. Experiments focus
on the differences between WT bone marrow derived macrophages (BMDMs) and BMDMs
isolated from mrp14-/- mice, with respect to their interaction with the endothelium, their
phagocytic ability and their response to exogenous S100A8/A9. I also explore the interaction
of S100A8/A9 on mesangial cells and assess whether TLR4 deficiency results in a limited
inflammatory response of mesangial cells following stimulation.
5.3 Experimental design
Mice from both the Hammersmith Hospital, Imperial College London, and from Royal Free
Hospital, University College London Central biological service were used for these
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experiments. All mouse species were bred on a background of C57BL/6. Kidneys and bone
marrow were harvested from WT, TLR4-/- (kind gift from Dr. Nathan Davis, UCL) and mrp14-
/- deficient mice. The bone marrow cells were grown and allowed to differentiate into
macrophages. The cells lines were grown in appropriate media. BMDMs, endothelial cells
and mesangial cells from the different mouse groups were subsequently stimulated with
S100A8 and S100A8/A9 (kind gift from Thomas Vogl) overnight. Supernatants were
collected and various cytokines were measured by ELISA. The response and cytokine
production between the cells groups were compared. Additionally, the phagocytic ability of
WT BMDMs and mrp14-/- BMDMs using opsonised beads was compared.
5.4 Results
5.4.1 Characterisation of kidney endothelial cells and mesangial cells
Kidney endothelial and mesangial cells were isolated as previously described. Both cell types
were characterised by immunofluorescence staining with antibodies directed against
myosin, pancytokeratin and CD31 (for endothelial cells). Both cells groups were
distinguished from fibroblasts by being negative for pancytokeratin and positive for myosin.
Additionally, endothelial cells were positive for CD31.
Figure 5-1 Characterisation of the isolated WT mesangial cells.
(i) Demonstrates positive immunofluorescence staining with anti-myosin antibody (green)
The cell nuclei are staining using DAPI (4’,6’ diamino-2-phenylindole)(blue). (ii) The cells are
negative for pancytokeratin by immunofluorescence. The cell nuclei are stained with DAPI
(blue). (iii) Negative control, anti-myosin antibody omitted, secondary FITC conjugated
antibody added and dapi.
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5.4.2 TLR4 expression is induced in kidney endothelial cells
It has previously been demonstrated that S100A8/A9 is able to have a proinflammatory
effect on the endothelium, mediated through binding to heparin sulphate proteoglycans
and novel carboxylated glycans or TLR4. I therefore assessed whether the endothelial cell
line that I had isolated and cultured was able to express TLR4. The expression of TLR4 was
assessed in unstimulated cells or following overnight stimulation with LPS (5µg/mL) or TNF
(25ng/mL). After RNA extraction, the RNA was reverse transcribed and DNA amplified. It
was possible to detect TLR4 expression by reverse-transcriptase PCR following stimulation of
the cells with LPS. No TLR4 was detected in the unstimulated cells or in the cells stimulated
with TNF-α
(i) (ii)
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5.4.3 S100A8/A9 exerts a pro-inflammatory effect on bone marrow
derived macrophages mediated through TLR4
To assess the role of S100A8 and S100A8/A9 on bone marrow derived macrophages
(BMDMs), the cytokine profile secretion was assessed by ELISA. Male mice were used in
these experiments. BMDMs were isolated as described from WT and TLR4 deficient mice.
The media was changed at day 3, and at day 7 the cells were plated out in 6 well plates for
stimulation overnight. In this experiment 9x105 BMDMs were used per condition, and
performed in triplicate. Following stimulation with S100A8 and S100A8/A9 at 1µg/mL,
supernatants were collected and cytokine analysis performed by ELISA. Both S100A8 and
S100A/9 had a proinflammatory effect on BMDMs which was abrogated in TLR4-/- BMDMs.
5.4.3.1 Comparing IL-8 secretion between WT and TLR4-/- BMDMs
Wild-type BMDMs produced a significant increase in IL-8 detected following stimulation
with TNF/S100A8, and a non-significant increase following stimulation with S100A8 or
S100A8/A9 alone. The median values for IL-8 secreted by unstimulated cells was 885pg/ml
(range 835.8-894.8pg/ml), following stimulation with S100A8 3929pg/ml [range 3767-8303])
and S100A8/TNF (median 9159pg/ml [range 3467-3760]), while stimulation with
S100A8/A9, produced 3667pg/ml (range 3467-3760pg/ml). This is in contrast to the results
obtained following the same experimental protocol with BMDMs isolated from male TLR4-/-
mice. The median value of IL-8 secreted from unstimulated cells was 714pg/ml, following
stimulation with S100A8 and S100A8/A9, there was no difference in IL-8 production, median
760.8pg/ml and 710.6pg/ml respectively. Figure 5.5 demonstrates the IL-8 secretion by WT
and TLR4-/- BMDMs under different conditions.
TLR4-/- BMDMs stimulated with LPS, do not produce a detectable increase in secreted
cytokines (IL-6 or MCP-1), with values similar to unstimulated TLR4-/- cells. This is in
contrast to TLR4-/- BMDMs stimulated with TNF-α, which results in significant cytokine
production. The TLR4-/- mice were genotyped by the supplier, confirming the mutant stain
(data from Yalda Sharifi).
Figure 5-
BMDMs.
Graphs to
triplicate
ANOVA).
abrogate
different
2
5
7
10
IL
-8
se
cr
et
io
n
pg
/m
l
2
5
7
10
se
cr
et
io
n
of
IL
-8
pg
/m
L(i)
WT nil TNF S100A8 TNF S100A8 S100A8/A9
0
500
000
500
000
p<0.05*205
5 S100A8 and S100A8/A9 promote IL-8 secretion from wild-type but not TLR4-/-
demonstrate the secretion of IL-8 from BMDM. Each condition was performed in
. (i) The addition of S100A8/TNF resulted in a significant increase in IL-8 (One-way
(ii) The increase in IL-8 secretion due to stimulation with S100A8 and S100A8/A9 is
d in TLR4-/- BMDM, with no difference in the amount of IL-8 detected in the
conditions. Line represents the median.
(ii)
TLR4 nil TNF S100A8 TNF S100A8 S100A8/A9
0
500
000
500
000
206
5.4.3.2 Comparing TNF-α secretion between WT and TLR4-/- BMDMs
Similar results were obtained when TNF-α secretion was assessed. Unstimulated wild-type
BMDMs had no detectable TNF-α. Following stimulation with S100A8 and S100A8/A9 there
was a significant increase in the amount of TNF-α detected by ELISA. The median amount of
TNF-α increased to 196.8pg/ml (range 194.8-202pg/ml) with S100A8 and to 97.51pg/ml
(range 96.54-117.3) with S100A8/A9. TLR4-/- BMDMs had undetectable TNF-α production
when unstimulated, and no increase in TNF-α was found following stimulation with S100A8
or S100A8/A9. Figure 5.6 shows the TNF-α production in BMDM.
Figure 5-6 TNF-α secretion by S100A8 and S100A8/A9 is mediated through TLR4.
There is significantly more TNF-α secretion following S100A8 or S100A8/A9 stimulation in
WT compared to TLR4-/- BMDM, p<0.0001 and p=0.0001 respectively (Unpaired t-test).
Each condition performed in triplicate. Line represents the median.
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5.4.4 BMDMs from mrp14-/- mice demonstrate a decreased pro-
inflammatory response
To assess whether BMDMs from mrp14-/- mice behave differently to wild-type mice,
BMDMs were isolated as previously described from male WT and mrp14-/- mice. At day 7,
the BMDMs were plated out into 6 well plates and stimulated overnight. In these
experiments, a total of 555,555 BMDMs were used per condition. The cells were stimulated
with TNF 10ng/ml, S100A8 1µg/ml, S100A8 and TNF, S100A8/A9 1µg/ml and S100A8/A9 and
TNF.
5.4.4.1 Mrp14-/- BMDMs produce less IL-8 than WT cells
The quantity of IL-8 produced from WT and mrp14-/- BMDM was compared. At baseline,
unstimulated WT cells produced a median of 493pg/ml (range 459.2-601pg/ml) of IL-8. With
S100A8 stimulation, this increased to 4787pg/ml (range 3678-5000pg/ml), and after
stimulation with S100A8/A9, 4267pg/ml (range 3716-5000pg/ml) both p<0.001 (all unpaired
t-test).
This increase in IL-8 secretion was conserved when mrp14-/- BMDM were stimulated with
S100A8, unstimulated median 977.8pg/ml [range 767.9pg/ml-1033]) increasing to
4278pg/ml [range 3673-4427] (p<0.0005). However this increase was diminished but still
significant in mrp14-/- cells stimulated with S100A8/A9, median IL-8 secretion 1585pg/ml
(range 1135-1718pg/ml) (p<0.046)(Unpaired t-test).
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Figure 5-7 WT cells produce significantly more IL-8 than mrp14-/- cells when stimulated
with S100A8/A9
The graph demonstrates the relative increase in IL-8 compared to unstimulated cells. The
difference in IL-8 secreted following the stimulation of WT and mrp14-/- BMDMs with
S100A8 is not significant. However, WT cells produce significantly more IL-8 when
stimulated with S100A8/A9 compared to mrp14-/- cells (p<0.005)(unpaired t-test). Each
condition performed in triplicate.
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5.4.4.2 Mrp14-/- BMDMs produce less TNF-α than WT
TNF-α secretion increased in WT cells following stimulation with S100A8 or S100A8/A9;
unstimulated WT BMDMs median TNF-α 53.5pg/ml (range 50.2-53.7pg/ml), S100A8
stimulated 321.5pg/ml (range 307.3-366.6pg/ml) and S100A8/A9 stimulated 324.6pg/ml
(range 255.1-362.4pg/ml).
Mrp14-/- BMDMs secreted TNF-α at a baseline value of 63.66pg/ml (range 52-73.2pg/ml)
increasing to 274.8pg/ml with S100A8 (range 238.3-291pg/ml) and to 96.32pg/ml with
S100A8/A9 stimulation (range 92.2-129.7). The increase in TNF-α secreted by WT and
mrp14-/- BMDMs following addition of S100A8 and S100A8/A9 was significant, (p<0.05 and
p<0.005 respectively)(unpaired t-test), but stimulated WT cells produced significantly more
TNF-α than mrp14-/- cells (P<0.005 for S100A8/A9 stimulated WT vs. Mrp14-/-; and p<0.05
for S100A8 stimulated WT vs. Mrp14-/-)(unpaired t-test).
Figure 5-8 WT cells produce significantly more TNF-α than mrp14-/- cells
The graph demonstrates the relative increase in TNF-α secretion compared to unstimulated
cells, following stimulation of WT and mrp14-/- cells with S100A8 or S100A8/A9. Conditions
performed in triplicate. Mrp14-/- produce significantly less TNF-α following stimulation with
both S100A8 and S100A8/A9 compared to WT cells (unpaired t-test). Line represents the
median.
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5.4.4.3 Mrp14-/- BMDMs produce less IL-6 than WT cells
WT BMDM produced an increase in IL-6 following stimulation with S100A8 and S100A8/A9.
There was no detectable IL-6 at baseline in unstimulated cells. Secretion increased to a
median of 106pg/ml following addition of S100A8 (range 101.8-113.9pg/ml), and to a
median of 96.45pg/ml with the addition of S100A8/A9 (range 58-106.4pg/ml). Unstimulated
mrp14-/- cells produced very small quantities of IL-6 at baseline, median 8.7pg/ml (range 0-
9.6pg/ml). This increased to 67.8pg/ml (range 61.6-84.6pg/ml) following S100A8 stimulation
and 18.23pg/ml following S100A8/A9 stimulation (range 17.6-22.2pg/ml).
Stimulated WT cells secreted significantly more IL-6 than mrp14-/- cells following S100A8
(p<0.01) and S100A8/A9 (p<0.0001).
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Figure 5-9 WT cells produce significantly more IL-6 than mrp14-/- cells following S100A8
and S100A8/A9 stimulation
Graph to demonstrate the increase in IL-6 secretion following stimulation with S100A8 and
S100A8/A9 in WT and mrp14-/- cells. The increase is compared to IL-6 production in
unstimulated WT or mrp14-/- cells. There is significantly more IL-6 produced by WT cells
after stimulation. Line represents the median.
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5.4.5 Th2 cytokines
There was no detectable secretion of either IL-4 or IL-10 by ELISA following the stimulation
of WT, TLR4-/- or mrp14-/- BMDMs with S100A8 or S100A8/A9.
5.4.6 BMDMs from mrp14-/- demonstrate decreased phagocytosis
To compare the phagocytic ability of mrp14-/- BMDMs with WT cells, BMDMs were isolated
from WT and mrp14-/- mice; plated onto a chamber slide at day 7 at a density of 100,000
cells per well and one day later the phagocytosis assay was performed in triplicate
5.4.6.1 Phagocytosis
The number of phagocytosed beads per 5 macrophages were counted, with 10 replicates
per well (a total of 3 wells for each condition was performed) for both WT and mrp14-/-
cells. WT BMDMs demonstrated significantly more phagocytosed beads than mrp14-/-
BMDMs (p<0.005 Mann-Whitney)
Figure 5-10 Mrp14-/- BMDMs demonstrated significantly less phagocytosis than WT cells
The graph demonstrates the median, interquartile range and range of phagocytosed beads
in WT and mrp14-/- BMDMs. A total of 50 BMDMs were counted for each cell type and
performed in triplicate.
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5.4.6.2 Assessing FcR in WT and mrp14-/- macrophages
To understand why there may be a difference in phagocytosis between WT and mrp14-/-
BMDM, unstimulated cells were assessed for expression of Fc receptors using an antibody
to CD16/32. This antibody recognises both FcγIII and FcγII expressed on BMDMs. The cells at 
day 7 were incubated with CD16/32 PE antibody or isotype control antibody followed by cell
fixation and analysis by flow cytometry. There were no differences between WT and mrp14-
/- BMDMs with regards the percentage of positive gated cells or the mean fluorescent
intensity (Mann-Whitney U-test). Each cell type was performed in triplicate.
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5.4.7 Co-culture of endothelial cells with WT but not mrp14-/- BMDMs
stimulates inflammatory cytokine production
Co-culture experiments were performed using murine wild-type endothelial cells (EC) and
either wild-type or mrp14-/- BMDMs. EC (3x105) were used in triplicate. The cells were left
in complete media for 2 days, followed by serum free media. Day 7 BMDMs were then
added to the EC, at a density of 1x106 cells per well. The cells were allowed to co-culture for
24 hours before the supernatants were collected and cytokine analysis performed by ELISA.
The following groups were cultured;
 EC alone
 EC+WT BMDMs
 EC+mrp14-/-BMDMs
 WT BMDMs alone
 Mrp14-/- BMDMs alone
5.4.7.1 Endothelial cells co-cultured with mrp14-/- BMDM secrete less MCP-1 than
endothelial cells co-cultured with WT BMDMs.
WT BMDMs and mrp14-/- BMDMs produced a small amount of MCP-1 (median values WT
843 pg/ml; mrp14-/- 942 pg/ml) when cultured alone with no significant differences
between the WT and mrp14-/- BMDMs. Endothelial cells alone produced an increased
amount of MCP-1, median 15340 pg/ml. This increased further with WT BMDMs co-culture
median value of 29990pg/ml. Following incubation of endothelial cells with mrp14-/-
BMDMs, the median amount of MCP-1 detected decreased to a similar value from
endothelial cells alone (median 11849pg/ml). Using a one-way ANOVA to compare all the
groups, there was a significant increase in MCP-1 following WT BMDMs co-culture with
endothelial cells compared to WT BMDMs alone (One-way ANOVA p<0.05).
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Figure 5-13 EC and WT BMDMs are pro-inflammatory unlike EC and mrp14-/- BMDMs
Graph to demonstrate MCP-1 production in EC-BMDM co-cultures (each condition is
performed in triplicate). At baseline, little MCP-1 is produced by BMDMs. Following co-
culture, mrp14-/- BMDM stimulate less increase in MCP-1 compared with WT BMDMs,
(p<0.05)(One-way ANOVA). Line represents the median.
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5.4.7.2 EC and mrp14-/- BMDM co-culture produce less IL-8 than EC and WT BMDM
Similar to the previous cytokine analysis, the unstimulated BMDM produced only small
quantities of IL-8, as did the EC. There was a significant increase in IL-8 when EC and WT
BMDMs were co-cultured (median 1000pg/ml [range 892.3-1000pg/ml) compared to cells
alone (p<0.05)(One-way ANOVA). However, while co-culture of EC and mrp14-/- BMDM
(median 445pg/ml [range 409-535.6]) was greater than the production by EC or mrp14-/-
BMDMs alone, it was 50% less than that produced by the co-culture of ECs and WT BMDMs.
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Figure 5-14 EC and WT BMDM co-cultures promote more IL-8 production than EC and
mrp14-/- BMDM co-cultures
Graph to demonstrate the IL-8 production in EC-BMDM co-culture. Each condition
performed in triplicate. Unstimulated WT and mrp14-/- BMDMs produce a small amount of
IL-8. Following co-culture with EC, mrp14-/- BMDM produce some IL-8, however this is also
almost half of that produced by WT BMDM-EC co-culture. Line represents the median.
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5.4.7.3 EC -mrp14-/- BMDM co-culture produce less IL-6 than EC- WT BMDMs co-
culture
The amount of IL-6 detected on ELISA was also investigated. Similar to MCP-1 and IL-8, the
greatest increase in IL-6 was following incubation of EC and WT BMDMs (median
870.8pg/ml [range 807.5-980.7]), while EC and mrp14-/- co-culture produced a similar
amount of IL-6 (median 181.8pg/ml {range 176.8-202.9pg/ml]) to the culture of mrp14-/-
BMDMs alone (113.3pg/ml [range 107-125.6]. A significant increase in IL-6 was observed
with incubation of EC and WT BMDMs (p<0.05)(1-way ANOVA) compared to endothelial
cells alone (median 28.7pg/ml [range 28.3-31.8pg/ml)
Figure 5-15 EC--WT BMDM co-culture produce increased amount of IL-6 compared to EC-
mrp14-/- BMDM co-culture.
Endothelial cells incubated alone produced small quantities of IL-6, with WT and mrp14-/-
BMDMs demonstrating a trend to increased IL-6 secretion (ns). There was a significant
increase in IL-6 following the co-culture of endothelial cells and WT BMDMs compared with
EC-mrp14-/- co-culture (p<0.05)(1-way ANOVA). Line represents the median. Each condition
performed in triplicate.
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5.4.8 S100A8/A9 has a pro-inflammatory effect on mesangial cells which is
not mediated through TLR4
Mesangial cells are known to play an important role in nephrotoxic nephritis and are a key
source of cytokine secretion. The effect of S100A8 and S100A8/A9 stimulation on mesangial
cells was explored using WT, TLR4-deficient and mrp14-deficient mesangial cells to
investigate whether TLR4 mediates the effect of S100 protein mediated stimulation.
Mesangial cells (MC) were stimulated with S100A8 and S100A8/A9 at a concentration of
1µg/ml. Each condition was performed in triplicate using 7.8x105 cells per condition.
Following incubation of the MC with S100A8 or S100A8/A9, the supernatants were
collected.
5.4.8.1 S100A8 and S100A8/A9 increase mesangial cell IL-8 secretion
Both S100A8 and S100A8/A9 had a pro-inflammatory effect on mesangial cells, but S100A8
had a greater effect than S100A8/A9. Using WT cells, compared to unstimulated MC, there
was an increase in IL-8 secretion following stimulation with S100A8 of 1472pg/ml (range
998-2182). However, in TLR4-/- MC, S100A8 provoked a significantly lesser increase in IL-8
compared to unstimulated cells; median 27.45pg/ml (range 16.57-212.1pg/ml).
By contrast, S100A8/A9 stimulation resulted in similar increases of MC IL-8 in WT and TLR4-
/- cells; WT median 376.3pg/ml (range 371.5-402.5pg/ml) and TLR4-/- median 254.3pg/ml
(range 169.3-350.3pg/ml), p=ns.
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S100A8. Each condition performed in triplicate.
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5.4.8.2 S100A8 increases MCP-1 secretion by MC and is mediated through TLR4
S100A8 had a significant effect on MCP-1 secretion by WT mesangial cells resulting in a
median increase (compared to unstimulated cells) of 1958pg/ml (range 1650-2629pg/ml),
however, this increase in MCP-1 was significantly attenuated when TLR4-/- MCs were used,
median 149pg/ml (range 0-239pg/ml). By contrast, the increase in MCP-1 was similar in WT
and TLR4-/- MC after S100A8/A9 stimulation, WT MC median 436.6pg/ml (range 412.8-
460pg/ml), and TLR4-/- MC median 400.3pg/ml (range 344.9-494.4pg/ml)(p=ns).
Figure 5-17 S100A8 induced-MCP-1 secretion by mesangial cells is mediated through TLR4.
The proinflammatory effect of S100A8/A9 was less than that of S100A8. S100A8 resulted in
significantly more MCP-1 when WT MC were stimulated compared to TLR4-/- (One-way
ANOVA p<0.05), while no difference was found between WT and TLR4-/- mesangial cells
stimulated with S100A8/A9. Line represents the median. Each condition performed in
triplicate.
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5.4.8.3 S100A8 stimulates IL-6 secretion in MC through TLR4 unlike S100A8/A9
Stimulation of WT MC with S100A8 resulted in a greater IL-6 secretion compared to
stimulation with S100A8/A9 (median 13.54pg/ml [range 12.97-14.69pg/ml] vs 6.135pg/ml
[range 5.113-7.95pg/ml] respectively). This effect was predominantly mediated through
TLR4 as TLR4-/- MCs produced significantly less IL-6 following S100A8 stimulation (0 pg/ml
[range 0-7.28pg/ml]), while there was no decrease in IL-6 following S100A8/A9 stimulation
of TLR4-/- MC (7.624pg/ml [range 0-9.45pg/ml]). The results show a similar trend to the
previous cytokines, although using One-way ANOVA, the results were not significant.
However, comparing IL6 secretion by WT and TLR4-/- cells following S100A8 stimulation, the
difference is significant (p<0.05)(Unpaired t-test).
Figure 5-18 WT mesangial cells produce IL-6 when stimulated by S100A8 and S100A8/A9
with the former mediated through TLR4
The graph demonstrates that MC stimulated by S100A8 and S100A8/A9 produce IL-6, which
for S100A8 stimulated MC is mediated though TLR4, unlike S100A8/A9. Line represents the
median. Each condition performed in triplicate. Differences between the groups were not
statistically significant.
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5.4.9 The response of mrp14-/- mesangial cells
Since mrp14-/- BMDMs had a significantly reduced pro-inflammatory response to
stimulation with S100A8/A9, the response of mrp14-/- mesangial cells was also analysed.
5.4.9.1 WT and mrp14-/- mesangial cells secrete IL-8 after stimulation with S100
proteins
In 2 separate experiments, the response of MC following stimulation was investigated.
3x105 WT mesangial cells per well were used per well in a 6 well plate. Each condition was
performed in triplicate. 8x105 mrp14-/- cells were used in separate experiments. Mesangial
cells were also stimulated with the pro-inflammatory cytokine, TNFα, which was used to
then compare the response to S100A8/A9. To enable a comparison between the WT and
mrp14-/- mesangial cells, the results were normalised to cytokine secretion per 1x105.
WT mesangial cells stimulated with TNFα (10ng/ml) produced IL-8 (compared to
unstimulated cells/per 1x105cells) with a median increase of 351.5pg/ml (range 325.5-
372.9), while following stimulation with S100A8/A9 the median increase was 267.8pg/ml
(range 230.5-288.1). Mrp14-/- mesangial cells (normalised to 100,000 cells) had a
significantly decreased response to TNF-α and S100A8/A9 stimulation, with a median
increase in IL-8 production of 137.6pg/ml (range 125.5-146.5) and 81.28pgml (range 67.62-
87.87pg/ml) respectively.
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Figure 5-19 Mrp14-/- mesangial cells produce less IL-8 in response to S100A8/A9 and TNF-
than WT mesangial cells
The graph demonstrates the increase in IL-8 secretion by WT and mrp14-/- mesangial cells
following stimulation with S100A8/A9 and TNF-α. Each condition was performed in
triplicate. There was a significant difference in the amount of IL-8 produced between WT
cells stimulated with TNF compared to mrp14-/- cells stimulated with TNF; as well as WT
cells stimulated with S100A8/A9 compared to mrp14-/- stimulated with S100A8/A9
(unpaired t-test).
WT
TN
F
WT
S1
00
A8
/A
9
mr
p1
4-/
- T
NF
mr
p1
4-/
- S
10
0A
8/A
9
0
100
200
300
400
***p<0.0001
***p<0.0005
In
cr
ea
se
in
IL
8p
g/
m
l
pe
r1
00
,0
00
ce
lls
224
5.4.9.2 Mrp14-/- mesangial cells produce less MCP-1 than WT mesangial cells after
S100A8/A9 stimulation
MCP-1 was also measured after stimulation of the mesangial cells with TNF-α and
S100A8/A9. Again, the results have been normalised to cytokine production per 1x105cells
to allow a comparison between WT and mrp14-/- mesangial cells. The median MCP-1
produced by WT mesangial cells in response to S100A8/A9 was median 403.7pg/ml (range
311.2-491.5pg/ml). Mrp14-/- MC secreted significantly less MCP-1 following stimulation
with S100A8/A9, median 103pg.ml (range 99.4-103.9)(p<0.005)(unpaired t-test).
Figure 5-20 Mrp14-/- mesangial cells produce less MCP-1 in response to S100A8/A9
stimulation than WT mesangial cells
The graph above demonstrates the pro-inflammatory effect of S100A8/A9 on mrp14-/- and
WT mesangial cells, with significantly less MCP-1 produced by mrp14-/- mesangial cells. Line
represents the median. Each condition performed in triplicate.
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5.4.9.3 Mrp14-/- mesangial cells secrete more IL-6 than WT mesangial cells
WT and mrp14-/- cells were analysed for the amount of IL-6 produced following stimulation
with TNF-α, S100A8/A9 and a combination of TNF-α and S100A8/A9. As different numbers
of WT and mrp14-/- mesangial cells were included, the results were again normalised to
1x105. Mrp14-/- mesangial cells, in contrast to mrp14-/- BMDMs, produced a greater
amount of IL-6 than WT mesangial cells. In response to TNF-α, WT cells produced a median
of 1.12pg/ml (range 0.26-2.1). In response to S100A8/A9, a similar amount of IL-6 was
detected, median of 0 (range 0-2.59). This increased following stimulation with TNF-α and
S100A8/A9 to a median of 14.78pg/ml (range 11.26-15.34).
Mrp14-/- mesangial cells produced a small amount of IL-6 following stimulation with TNF-α,
median 0pg/ml (range 0-1.53). This increased to 6.76pg/ml (range 6.7-14.29pg/ml) following
stimulation with S100A8/A9, and increased further to a median of 25.91pg/ml (range 24.26-
28.12) following stimulation with TNF-α and S100A8/A9. There was significantly more IL-6
secreted by mrp14-/- than by WT mesangial cells following stimulation with S100A8/A9
(p<0.05)(unpaired t-test), and significantly more IL-6 following stimulation of mrp14-/- cells
with TNF-α and S100A8/A9 than WT mesangial cells (p<0.005)(unpaired t-test).
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Figure 5-21 WT and mrp14-/- mesangial cells produce maximal IL-6 after stimulation with
TNF-α and S100A8/A9.
Demonstrates a small increase in IL-6 secretion following stimulation of WT mesangial cells
with TNF-α, with a further increase following stimulation with TNF-α/S100A8/A9. Mrp14-/-
mesangial cells produce very little IL-6 in response to TNF. However, mrp14-/- MC produce
significantly more IL-6 when stimulated with S100A8/A9 and TNF-α/S100A8A9 than WT
mesangial cells (p<0.05)(p<0.005)(unpaired t-test) respectively. Each condition performed in
triplicate.
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5.5 Discussion
In this chapter, I have investigated the in-vitro effects of S100A8 and S100A8/A9 on
different primary renal cell lines and on bone marrow derived macrophages. These cell lines
were isolated from murine kidney and murine bone marrow, and are known to play key
roles in nephrotoxic nephritis and glomerulonephritis.
In agreement with published work, the interaction between these S100 proteins and TLR4
on BMDMs seems to be critical. Incubation of TNF-α had the expected pro-inflammatory
effect on BMDMs, which was similar in WT BMDMs and TLR4-/- BMDMs with respect to IL-8
secretion. However, WT BMDMs had a significant increase in IL-8 secretion following
stimulation with S100A8 and S100A8/A9, an effect which was totally abrogated in TLR4-/-
BMDMs, demonstrating the critical requirement for this receptor on macrophages for the
S100 proteins to exert their autocrine proinflammatory effect. Although S100A8/A9 had a
less pronounced proinflammatory effect than S100A8 with regard to IL-8 secretion, there
was still a significant difference between the amount of IL-8 secreted when S100A8/A9 was
incubated with WT and TLR4-/- bone marrow cells. Analysis of TNF-α secretion by BMDMs
also elicited similar results, with no TNF-α being detectable following stimulation of TLR4-/-
bone marrow cells, and a significant increase when WT BMDMs were stimulated with
S100A8 and S100A8/A9. The experiments described above would be consistent with the
hypothesis that the S100 proteins, once bound to TLR4, induces activation of a signal
transduction cascade which results in the transcription of several important pro-
inflammatory cytokines including IL-8 and TNF-α.
Following the comparison between WT and TLR4-/- BMDMs, WT and mrp14-/- BMDMs
were subsequently compared. Mrp14-/- phagocytes have a slight abnormality of calcium
signalling compared to WT cells, but otherwise the myelopoietic potential of mrp14-/- bone
marrow is normal {McNeill, 2007 #5654}(Manitz, Horst et al. 2003). Previous studies have
shown crucial differences between mrp14-/- and WT BMDMs with respect to their
inflammatory response. Unstimulated, WT and mrp14-/- demonstrate no major differences
in global gene expression as assessed by an Affymetrix gene chip microarray. However,
following the administration of LPS, the expression of many genes involved in macrophage
activation was reduced in mrp14-/- bone marrow cells (BMCs) compared to WT BMCs (Vogl,
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Tenbrock et al. 2007). Extracellular S100A8/A9 added to mrp14-/- LPS-stimulated BMCs
resulted in a dose dependent increase in TNF-α, demonstrating that the addition of
S100A8/A9 was able to compensate for the blunted LPS response of mrp14-/- cells. This
study also demonstrated that the S100A8/A9 complex was active only with LPS, whereas
S100A8 was active alone on BMCs, and has the ability to induce the production of TNF-α
without the addition of LPS. These data suggest that the differences in S100A8 and the
heterodimer may be due to the binding of S100A8 to S100A9 preventing S100A8-dependent
stimulation of TLR4. Additionally, the S100A8/A9 complex appears to require a secondary
stimulus (such as LPS) to have a pro-inflammatory effect on BMCs (Vogl, Tenbrock et al.
2007). Some of the results in this chapter differ somewhat from these published findings. In
keeping with the published results S100A8 alone was able to have a pro-inflammatory effect
on BMDMs from WT mice. However, in this chapter, the administration of S100A8/A9 to WT
BMDMs was able to have a similar, although less pronounced effect compared to that of
S100A8, with respect to the secretion of TNF-α, IL-8 and IL-6. Additionally, I found that
there is a blunted pro-inflammatory response of mrp14-/- BMDM upon the addition of the
S100A8/A9 heterodimeric complex, while previous work demonstrated that addition of
S100A8/A9 to mrp14-/- BMCs was able to reverse the non-inflammatory phenotype. There
are a few differences in the methods used however between my work and the published
data. The paper by Vogl et al, used bone marrow cells which had been isolated from murine
femurs and tibias and following red cell lysis were cultured in media. By contrast, my
experiments used cells isolated following bone marrow cell extraction and grown in L929
(macrophage) conditioned media to allow the proliferation and differentiation of the
myeloid progenitor cells into macrophages. Also, TNF-α secretion following WT BMC
stimulation with LPS or S100A8 or S100A8/A9 was analysed following just 4 hours of
incubation by Vogl et al. The addition of extracellular S100A8/A9 on mrp14-/- cells was
followed by TNF-α analysis after 9 hours. In the experiments in this chapter, supernatants
were harvested following an overnight incubation period. It is possible that this could
account for some differences in the inflammatory response of the mrp14-/- or WT BMCs.
Importantly, the source of recombinant S100A8 and S100A8/A9 was similar, a kind gift from
T. Vogl, so this is also unlikely to be responsible for any differences in the response of cells
to the effects of these molecules.
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The BMDM experiments suggest that S100A8/A9 serves to amplify the inflammatory
response, as a lack of endogenous S100A8/A9 resulted in a decreased pro-inflammatory
response in macrophages, cells that usually secrete S100A8/A9 in response to pro-
inflammatory signals. This is supported by in-vivo murine experiments. Using an endotoxic
shock model, mrp14-/- mice have a significantly longer survival than WT mice, with
significantly less TNF-α and IL-6 production. After administration of S100A8/A9 this
protection was lost, with the resultant decrease in survival that was comparable to that of
WT mice (Vogl, Tenbrock et al. 2007).
Previous studies have investigated the pro-inflammatory effect of extracellular S100A8/A9
on the endothelium. Since endothelial cell-leukocyte interactions are crucial in both human
and experimental glomerulonephritis, the interaction between endothelial cells and WT and
mrp14-/- BMDMs was investigated. These experiments consistently demonstrated that
unstimulated BMDMs alone had little pro-inflammatory activity. Endothelial cells isolated
from the kidney secreted some cytokines at rest, however, the co-culture of WT BMDMs
and endothelial cells consistently resulted in significant cytokine production. The culture of
mrp14-/- BMDMs with endothelial cells also consistently resulted in less cytokine
production than WT BMDMs and ECs. This difference is consistent with the idea that
S100A8/A9 acts to amplify the inflammatory responses. Once macrophages have been
activated, the complex is released and is able to act in an autocrine manner on macrophages
and in a paracrine manner on endothelial cells resulting in a positive inflammatory loop with
the production and secretion of cytokines. Macrophages which lack S100A8/A9 are
therefore unable to contribute to this amplification loop and have less cytokine production
in co-culture experiments. This amplification loop could be further amplified in vivo within
the kidney by production of S100A8 and S100A9 by various other cell types including
fibroblasts and renal epithelial cells. A similar amplification loop to the one described above,
has been suggested to play a role in the pathogenesis of rheumatoid arthritis. S100A8 and
S100A9 released during synovial inflammation may then influence the function of
osteoclasts resulting in bony erosions and remodelling seen in inflammatory arthritis. This
hypothesis is further supported by the effect of a monoclonal antibody to S100A9 resulting
in decreased joint injury in the murine arthritis model as well as a decrease in local and
systemic cytokine release (Cesaro, Anceriz et al. 2012). As well as macrophage-derived
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S100A8/A9 having a role in mediating inflammation and joint destruction in the antigen
induced arthritis model, chondrocytes have been shown to express these proteins. Pro-
inflammatory cytokine stimulation of a murine chondrocyte cell line resulted in detectable
S100A8 and S100A9 mRNA as well as protein, therefore establishing a positive feedback
mechanism by which S100A8 proceeded to stimulate the secretion of pro-inflammatory
cytokines, such as IL-6, from the same chondrocyte cell line as well as the activation of the
transcription factor NF-κB. These pro-inflammatory effects were demonstrated to occur 
despite low expression of the known S100A8/A9 receptor TLR4, and in the presence of an
anti-RAGE antibody, implicating another unknown receptor in mediating the pro-
inflammatory effects of S100A8 (van Lent, Grevers et al. 2008).
Mesangial cells stimulated with S100A8 and S100A8/A9 resulted in the production of pro-
inflammatory cytokines. As described above, chondrocytes had detectable expression of IL-6
mRNA by RT-PCR when stimulated with S100A8, without detection of other pro-
inflammatory cytokines such as TNF-α and IL-1 (van Lent, Grevers et al. 2008). The
mesangial cells when stimulated with S100A8 and S100A8/A9 had a more pronounced pro-
inflammatory effect than that described for chondrocytes. IL-6 secretion was modest in the
mesangial cells, but greater amounts of MCP-1 and IL-8 were secreted. These cytokines are
involved in further macrophage and neutrophil recruitment to the glomerulus. S100A8
mediated its effects on mesangial cells through TLR4, supported by data demonstrating that
pro-inflammatory cytokine secretion was significantly attenuated in TLR4-/- mesangial cells.
S100A8/A9 had a more modest pro-inflammatory effect, but was still able to generate
cytokines in the absence of a secondary stimulus, with similar cytokine levels in WT and
TLR4-/- mesangial cells, suggesting that other receptors are involved in mediating this effect.
Possible candidates include RAGE, as well as other receptors containing carboxylated
glycans.
Macrophages containing S100A8/A9 are present in both human and experimental
glomerulonephritis, and these data suggest that once secreted, the heterodimer can exert a
stimulatory, proinflammatory effect on mesangial and endothelial cells while also having an
autocrine effect on macrophages.
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Similar to mrp14-/- BMDMs, mrp14-/- mesangial cells demonstrated significantly less pro-
inflammatory response to stimulation with S100A8 or S100A8/A9. Stimulation with S100A8
generally resulted in a profound inflammatory response, with the results often higher than
the highest standard of the ELISA standard curve, despite several attempts to optimise the
dilution (therefore results not included). A direct comparison between the responses of WT
and mrp14-/- mesangial cells was permitted by correcting the results to cytokine secretion
per 1x105 cells. The behaviour of mrp14-/- mesangial cells has not previously been
described. These results demonstrate that mrp14-/- MCs have the capacity to react to pro-
inflammatory stimuli such as S100A8/A9 and to produce pro-inflammatory cytokines, but to
a lesser amount than the WT mesangial cells- with the exception of IL-6. S100A8/A9 has a
role in glomerular inflammation as mesangial cells respond and secrete cytokines. These
results suggest S100A8/A9 stimulates mesangial cells through TLR4 dependent and
independent mechanisms.
Summary:
 S100A8 and S100A8/A9 induces the production and secretion of pro-inflammatory
cytokines by BMDMs which is mediated through TLR4.
 Mrp14-/- BMDMs produce significantly less pro-inflammatory cytokines than WT
BMDMs suggesting that endogenous S100A8/A9 production is necessary to amplify
the pro-inflammatory response.
 Mrp14-/- demonstrate less phagocytosis that WT BMDMs despite a similar
expression of activatory Fc-receptors.
 Endothelial cells co-cultured with WT BMDMs results in significantly higher levels of
pro-inflammatory cytokines than EC co-cultured with mrp14-/- demonstrating the
autocrine and paracrine effect of S100A8/A9 secreted by BMDMs.
 S100A8/A9 stimulates the production of pro-inflammatory cytokines by mesangial
cells in a TLR4 independent effect, unlike stimulation by S100A8, with mrp14-/-
mesangial cells secreting less cytokines in response to stimulation than WT
mesangial cells, except IL-6 secretion.
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Chapter 6 Discussion
6.1. Summary of results
Chapter 3 explored the role of S100A8/A9 in human glomerulonephritis. I demonstrated the
presence of S100A8/A9 expressing cells in the renal biopsies of patients with ANCA
associated glomerulonephritis, and that the presence of these cells correlates with acute,
inflammatory lesions while they are absent in the sclerotic predominant GN. Additionally,
there was a dense infiltrate of S100A8/A9 positive cells around inflamed blood vessels
within the kidney. Patients with active AAV had elevated serum levels of calprotectin, and
although levels decreased during disease remission, they did not normalise. Those patients
with non-renal involvement, from the NORAM trial, had lower levels than those with renal
involvement. The patients in this cohort who subsequently relapsed demonstrated
significantly higher levels during the early time-points after the initiation of
immunosuppressive therapy, suggesting that serum calprotectin may be a useful biomarker
for disease relapse in this cohort of patients with limited disease. Similar to the serum
calprotectin levels, patients with both active and inactive disease had detectable expression
of calprotectin on the cell surface of monocytes and neutrophils, which although was less
during disease remission, did not reach the same level as healthy controls. Human IgG,
isolated from healthy controls, as well as from patients with high titres of PR3-ANCA and
MPO-ANCA IgG, were able to upregulate monocyte expression of calprotectin, but this was
clearly not ANCA specific.
Chapter 4 investigated the role of S100A8/A9 during nephrotoxic nephritis. Mrp14-/- mice
demonstrated significantly less renal injury and less leukocyte infiltration than WT mice, an
effect which was reversed by the addition of high dose LPS during disease progression.
These effects occurred despite similar sheep and mouse IgG glomerular deposition and a
similar antigen-specific total IgG response. The non-accelerated model demonstrated that
WT and mrp14-/- mice have a similar early response in terms of glomerular neutrophil
infiltration, suggesting that differences in disease relate more to macrophage recruitment
and activation at later time points. The bone marrow transplant experiment illustrates that
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total deficiency of S100A8/A9 is necessary for protection from glomerulonephritis, although
I have not conclusively demonstrated which intrinsic (radioresistant) cell is required to
produce S100A8/A9 and maintain disease susceptibility. A control cohort of mrp14-/- to
mrp14-/- transplant mice would have been useful to compare the other three groups to and
confirm disease protection.
Chapter 5 explored the in-vitro pro-inflammatory effects of S100A8/A9 and S100A8 on
BMDMs and mesangial cells. The pro-inflammatory effect on BMDMs was mediated through
TLR4, however on mesangial cells the effect of S100A8/A9 was TLR4 independent, as
opposed to the effect of S100A8 which was predominantly mediated through TLR4. Mrp14-
/- BMDMs had a blunted response to the proinflammatory effects of S100A8/A9, with
significantly less secretion of cytokines known to play a role in renal inflammation. The co-
culture of WT endothelial cells and WT BMDMs resulted in the detection of significant
production of cytokines as opposed to that of WT endothelial cells and mrp14-/- BMDMs,
which was a significantly less inflammatory combination. Mrp14-/- macrophages also
demonstrate less phagocytic ability despite similar expression of Fc-γ receptors. Lastly, 
stimulation of mrp14-/- mesangial cells resulted in the production of less cytokines than WT
mesangial cells, similar to the response of mrp14-/- BMDMs. S100A8/A9 had a pro-
inflammatory effect on WT mesangial cells, although this effect was not mediated
exclusively thought TLR4. This suggests that intrinsic production of S100A8/A9 may have a
role in the generation of a mesangial cell inflammatory response.
6.2. Thesis limitations
6.2.1. Limitation of using mrp14-/- mice
Mice which either have a gene deleted, or over-expressed, have proven to be a very
valuable tool in the investigation of disease. The deletion of S100A8 (mrp 8) results in
embryonic death, a not uncommon occurrence in the generation of transgenic mice.
Therefore, using this approach it is not possible to investigate the role of S100A8 in
nephrotoxic nephritis independent to that of S100A9. However, deletion of mrp14-/-
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(S100A9) does result in complete absence of both proteins due to degradation of S100A8 in
the absence of its binding partner, S100A9. The mice were a kind gift from Professor Ivars,
who has provided the mice for many of the published work on S100A8/A9.
However, the deletion of genes may have some undesired effects. Mrp14-/- mice don’t have
an obvious phenotype, with normal growth and development occurring. However, the result
of gene deletion may have subtle developmental affects on the mouse and may affect their
response in NTN, independent of the gene deleted. Additionally, undefined salvage
pathways may exist which subsequently impact on disease susceptibility.
Mrp14-/- mice were generated using the embryonic stem cell line derived from 129/Ola
mice which were subsequently injected into the blastocysts of C57BL/6 mice (Manitz, Horst
et al. 2003). However, the 129/Ola is a different strain of mouse to the C57BL/6, and despite
backcrossing for several generations, the knock-out mice may not be completely genetically
similar to the wild-type control C57BL/6 mice used for experiments. Additionally, by deleting
the gene of interest, there may be an effect on genes that are nearby in the genome. The
strain of the mouse also has several effects, with NTN in the C57BL/6 being a Th1 driven
disease. It would have been more accurate to have used littermate mice that are the
offspring of mice heterozygous for the mrp14-/- deletion, therefore eliminating minor
genetic differences between totally unrelated C57BL/6 wild-type controls. This was not
done in this thesis due to difficulties obtaining mice homozygous for the mutation, as well as
generating wild-type mice from heterozygous parents with respect to the experiments
including mice of a similar age and sex.
6.2.2. Limitations of the animal model used
The model used in this thesis is the nephrotoxic nephritis animal model. This is not a
vasculitis model, but instead a model of immune-mediated glomerulonephritis
characterised by macrophage and T cell infiltration and glomerular thrombosis. There were
not many glomerular crescents in our experimental mice; instead the histology was
dominated by glomerular thrombosis, which is in contrast to human disease of AAV.
Additionally, NTN is characterised by variation within the animal groups. Relatively large
numbers of animals are needed to see an overall effect. This variation can partly be
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explained by several different steps required to induce disease which may have some inter-
mouse variability, for example the pre-immunisation and the injection of NTS may differ in
the amount administered by more than 1 operator. However, the mice were all housed
under the same conditions, and injected with the same batch of sheep IgG, CFA and NTS-
which was prepared at the same time, by the same single operator. Despite attempts to be
as accurate as possible, there still remains a difference in disease susceptibility within the
same experimental group. Therefore, when possible, the groups were combined to
investigate if there was an overall significant effect. This combination of animals and the
resultant increase in animal numbers, allowed analysis of various disease parameters, which
had previously been a trend when analysing smaller groups, to then became statistically
significant. However, this model is less labour-intensive than some of the vasculitis animal
models and is commonly used to investigate the pathogenesis of glomerulonephritis.
6.3. Hypothesis of the role of S100A8/A9 in human and experimental
glomerulonephritis
The data is this thesis suggests that S100A8/A9 has a role in both human and experimental
GN. I initially demonstrated that patients with focal and crescentic GN had an infiltrate of
S100A8/A9 positive cells within the glomeruli with active lesions and in the blood vessels.
The positive cells represent monocytes and infiltrating macrophages recruited from the
circulation. Previous work has demonstrated that the heterodimer is down-regulated and
absent from more chronic lesions, therefore it is not surprising that patients with a sclerotic
predominant GN have an absence of cells expressing S100A8/A9. This work has illustrated
that different phenotypes of macrophages exist, with S100A8/A9 representing the pro-
inflammatory infiltrating macrophage, the presence of which correlates with the response
to immunosuppressive therapy.
Patients with AAV had very high levels of serum S100A8/A9, with detectable surface
expression on a significant proportion of neutrophils and monocytes. The source of the
serum levels has presumed to be from monocytes and especially neutrophils due to the
abundant constitutive expression of S100A8/A9 in the myeloid cell. I was unable to
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demonstrate that human endothelial cells can be stimulated to produce the heterodimer. In
the environment of high levels of IgG, for example MPO-ANCA IgG or PR3-ANCA IgG,
S100A8/A9 intracellular expression can be increased. This effect is not specific to ANCA IgG,
as IgG isolated from the serum of healthy controls had a similar effect. However, increased
serum IgG may then contribute to inflammation by increasing the intracellular expression of
S100A8/A9 in monocytes. The human work demonstrated the presence of S100A8/A9
during disease, but it’s the animal work which has provided evidence for S100A8/A9 having
a role in the inflammatory response rather than just being a disease biomarker.
The nephrotoxic nephritis experiments demonstrated that mrp14-/- mice are protected
from severe renal disease. This work provided evidence that S100A8/A9 has an active role in
the pathogenesis of GN. This protection was overcome by the administration of high dose
LPS.
The pathological role of S100A8/A9 can be divided into the autocrine and paracrine actions
of this complex as well as the cells involved. The murine in-vitro work demonstrated that
BMDMs respond to S100A8/A9 through TLR4, resulting in the production and secretion of
TNF-α, IL-6 and IL-8. Additionally, the combination of macrophages and endothelial cells is
very pro-inflammatory in contrast to mrp14-/- BMDMs and endothelial cells, demonstrating
that S100A8/A9 secreted from BMDMs has an inflammatory effect on both cell types.
S100A8/A9 can then amplify the inflammatory response- this is supported by the resistance
of mrp14-/- BMDMs to the pro-inflammatory effects of S100A8/A9, which resulted in very
little cytokine secretion. A further protective effect of mrp14-/- could be due to the
decreased phagocytosis ability of mrp14-/- macrophages. Mesangial cells are also
responsive to the pro-inflammatory effects of S100A8/A9. The pro-inflammatory effects of
S100A8 are mediated through TLR4 on mesangial cells however; S100A8/A9 has a TLR4
independent effect on mesangial cells, resulting in the production of MCP-1, IL-8 and IL-6.
Within the inflammed glomerulus, S100A8/A9 may be secreted by macrophages, which then
stimulate the production of inflammatory cytokines by mesangial cells, endothelial cells and
also by macrophages, therefore demonstrating that both bone marrow derived cells and
intrinsic renal cells play a role in the amplification of S100A8/A9 secreted within an
inflammed glomerulus.
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The cytokines secreted following S100A8/A9 stimulation of intrinsic renal cells and
infiltrating leucocytes have several pathophysiological effects which are implicated in the
pathogenesis of AAV and glomerulonephritis. IL-6 is a cytokine with multiple effects. Soluble
IL-6R has the ability to stimulate mononuclear cell recruitment and to influence T-cell
differentiation towards pro-inflammatory T-cells. IL-6 can also induce B-cell differentiation
into B cells producing immunoglobulin. In combination with TGF-β, IL-6 is necessary for the
differentiation of CD4+ T cells into IL-17-secreting T-cells (Th17 cells). Additionally, IL-6 has
the ability to inhibit the formation of Tregs and to induce the production of cytotoxic T cells
by CD8+ cells. A monoclonal antibody against IL-6R has been used in the treatment of many
inflammatory diseases such as rheumatoid arthritis (Tanaka, Narazaki et al. 2012).
Additionally, there is a case report of the use of an IL-6R antibody in the treatment of MPO-
ANCA vasculitis (Sumida, Ubara et al. 2011).
IL-8 production by TNF-α stimulated endothelial cells has a significant role in neutrophil
migration, and recruitment of leukocytes to the site of inflammation (Smart and Casale
1994). Additionally, IL-8 acts with TNF-α to result in neutrophil degranulation, and the
resultant expression of PR3 on the neutrophil membrane, therefore demonstrating the
crucial role this cytokine has in the pathogenesis of AAV (Csernok, Ernst et al. 1994). PR3
also has the ability to enhance production of IL-8 by endothelial cells (Berger, Seelen et al.
1996). IL-8 mRNA has been demonstrated to be present in AAV glomerulonephritis within
both the inflammed glomerular and interstitial compartments. As well as IL-8 production by
endothelial cells; mesangial cells and proximal tubular cells can also produce this cytokine.
ANCA can also stimulate production of IL-8, therefore supporting the pathogenic role of IL-8
in AAV (Cockwell, Brooks et al. 1999).
MCP-1 is a monocyte and macrophage attractant. Patients with AAV GN have been
demonstrated to have elevated urinary levels of MCP-1, with increased glomerular and
interstitial expression. Both intrinsic renal cells, such as endothelial cells and mesangial cells,
and infiltrating macrophages can produce this cytokine, with elevated urinary levels
correlating with disease activity (Tam, Sanders et al. 2004).
TNF-α is a cytokine with numerous effects. TNF-α is not expressed in the kidney under
normal physiological conditions. Following stimulation, renal cells such as mesangial cells,
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tubular cells, endothelial cells and podocytes can produce this cytokine as can haemopoetic
cells which are the major source of TNF-α production. This cytokine has many effects, such
as localised endothelial cell activation and increased permeability with the upregulation and
expression of adhesion receptors on the endothelial cell, vasodilatation mediated through
nitric oxide release as well as the release of cytokines and the up-regulation of MHC class I
and class II molecules. TNF-α is also responsible for the priming of neutrophils and
monocytes, inducing the expression of PR3 and MPO on the cell surface which is a critical
step in the cross-binding of ANCAs (Ernandez and Mayadas 2009). Despite the numerous
roles of TNF-α in the pathogenesis of AAV, blockade of TNF-α by Etanercept (Wegener’s
Granulomatosis Etanercept Trial [WGET]) was characterised by a low response rate and a
high rate of complications, illustrating the complex role of cytokine blockade in
autoimmunity (2005).
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6.4. Unanswered questions relating to this work
Following the experimental work included in this thesis, a number of unanswered questions
remain.
S100A8/A9 neutrophil function
The non-accelerated NTN experiments demonstrate at 2 hours following injection of
nephrotoxic serum, WT and mrp14-/- mice had the same number of infiltrating neutrophils.
However, this thesis does not include any functional data comparing WT and mrp14-/-
neutrophils. Although there was the same number of neutrophils, it is unknown if both
groups of neutrophils have the same response in the inflammed glomerulus. The question
remains unanswered as to whether mrp14-/- neutrophils have a less pro-inflammatory
effect in response to the planted antigen of sheep anti-mouse GBM antibodies compared to
WT neutrophils. Neutrophils have a major role in human and experimental vasculitis. To
investigate the role of S00A8/A9 and neutrophils, I would initially investigate the in-vitro
secretion of S100A8/A9 following neutrophil degranulation in the presence of TNF-α and
ANCAs, as this would confirm that neutrophils are a major source of the high serum levels of
S100A8/A9 seen in patients with AAV. I would then repeat the experiments that I performed
with BMDMs, using murine granulocytes instead. These experiments would compare the
responses of mrp14-/- and WT granulocytes to stimulation with S100A8/A9 and S100A8
(with and without TNF-α) with respect to ROS production, nitric oxide synthesis and the
production of inflammatory cytokines. The use of TLR4-/- granulocytes would confirm the
importance of this receptor in mediating the pro-inflammatory effects.
Renal production of S100A8/A9
The BMDM experimental data in this thesis suggests that S100A8/A9 has a pro-
inflammatory amplification effect as demonstrated by the decreased inflammatory
response of mrp14-/- macrophages. Mrp14-/- mesangial cells had a similar response to WT
mesangial cells. Renal collecting duct epithelial cells have been shown to play a crucial role
in regulating inflammation and fibrosis, characterised by S100A8 and S100A9 production
(Fujiu, Manabe et al. 2011). Although immunohistochemistry demonstrated the presence of
241
S100A8/A9 positive macrophages in human and experimental glomerulonephritis, it is
possible that other cells in the kidney also produced these proteins. The antibodies used in
immunohistochemistry recognise an epitope present on the heterodimer. The individual
components of the heterodimer were not investigated, therefore it is possible that S100A8
and S100A9 were produced and secreted by other cell types within the kidney, for example
mesangial cells and podocytes, and may contribute to the inflammatory response. This is
supported by the bone marrow transplant data, which demonstrated that myeloid absence
of S100A8/A9 is not sufficient to protect against renal injury in NTN.
Vasculitis animal models and S100A8/A9
The in vivo experiments in this thesis utilise the nephrotoxic nephritis animal model, which
is a model of immune complex glomerulonephritis and is not a model of vasculitis. The next
logical step would be to repeat the work included in this thesis in a vasculitis model. The
murine model of MPO-ANCA disease (Xiao, Heeringa et al. 2002) has provided a
reproducible model of vasculitis and has improved understanding of the pathogenesis of
disease. To elucidate the role of mrp14-/- in experimental vasculitis, I would initially use this
animal model with mrp14-/- knock-out mice. Additionally, the rat model of MPO-ANCA
vasculitis could be utilised to demonstrate the efficacy of a molecule targeting S100A9
(Bjork, Bjork et al. 2009).
Receptor for advanced glycation end products (RAGE)
RAGE has been described to be present on cultured endothelial cells, mononuclear
phagocytes and mesangial cells, with AGE-RAGE interactions having a role in the progression
of diabetic nephropathy (Matsui, Yamagishi et al. 2009). S100A8/A9 was demonstrated in
this thesis to have a pro-inflammatory effect on mesangial cells, independent of TLR4.
However, the exact receptor to which S100A8/A9 binds to on mesangial cells remains
unanswered. Similarly, the critical receptor on endothelial cells to which S100A8/A9 binds to
remains uncertain. Heparan sulphate proteoglycans and novel carboxylated glycans have
been shown to bind to S100A8/A9 on endothelial cells. RAGE and TLR4 may also bind
S100A8/A9 on endothelial cells. In an investigation into the pathogenesis of atherosclerosis,
human umbilical vein endothelial cells pre-incubated with AGE-albumin resulted in
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upregulation of RAGE, and binding of S100A8/A9. This resulted in the increased secretion of
IL-6, MCP-1, ICAM-1 and VCAM-1 (Ehlermann, Eggers et al. 2006). Therefore, S100A8/A9
may also bind to glomerular endothelial cells through this mechanism resulting in the
upregulation of cytokines which have a role in glomerulonephritis and vasculitis.
S100A8/A9 as a therapeutic target
S100A9 has been described as the target of quinoline-3-carboxamides, which prevent the
binding of S100A9 to RAGE and TLR4, instead resulting in the binding of this compound to
S100A9 (Bjork, Bjork et al. 2009). A quinoline-3-carboxamide derivative has been used in the
MRL-lpr/lpr lupus-prone mouse model. These mice spontaneously develop severe disease
including an immune complex GN. The drug was added to murine drinking water and was
effective in preventing the development of disease, as well as being an effective treatment
(Bengtsson, Sturfelt et al. 2012). Survival in mice has been shown to be prolonged after the
initiation of the drug, even when the disease was clinically overt (Carlsten, Jonsson et al.
2004). This supports the immunomodulatory role of these compounds without significant
immunosuppressive activity.
However, more work needs to be done in this area to ensure that blockade of S100A8/A9
won’t significantly affect the host response to infections. This is illustrated by the
heterodimer having a key role in defence against Klebsiella pneumonia, whereby mrp14-/-
mice demonstrated increased bacterial dissemination, decreased macrophage ability to
phagocytose Klebsiella and reduced survival (Achouiti, Vogl et al. 2012).
The role of interstitial macrophages
The work in this thesis has concentrated on glomerular macrophages during NTN. However,
as previous work has demonstrated, the accumulation of interstitial macrophages plays a
crucial role in the development of chronic renal failure. The differences in interstitial
macrophages in the WT and mrp14-/- mice were not compared, and it is unknown whether
the macrophages in this compartment differed in the 2 animal groups.
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6.5. Concluding remarks
The work in this thesis suggests that S100A8/A9 may have a novel role in AAV and
glomerulonephritis. The human work describes S100A8/A9 as a potential biomarker in early
systemic AAV, and the presence of S100A8/A9 positive cells in the renal biopsy, link
S100A8/A9 with renal outcome. The animal work demonstrates a role for S100A8/A9 in the
pathogenesis of GN, with the in-vitro work illustrating the effect of S100A8/A9 and S100A8
on different cell types known to play a crucial role in renal inflammation.
S100A8/A9 has been described as an important factor in the pathogenesis of diseases such
as arthritis; therefore the work described in this thesis may therefore be relevant in the
study of other auto-immune diseases. The work described may also increase our
understanding of the inflammatory response as well as a possible link between infections,
LPS, TLR4 and the innate immune response.
This thesis is all original work. Where others have contributed it has been acknowledged.
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